Please select a day:
10.10.2012
11.10.2012
12.10.2012
13.10.2012
Search

Personal programme
Please enter your email address here in order to bring up your personal programme






Search result

Search Result: Session Chair

Wednesday, October 10, 2012

08:30 - 10:00 Auditorium Pasteur
Teaching Course 1: Meet the Professors: A case-based approach to diagnosis and management of MS
A. Miller (New York, US)
D. Bates (Newcastle, GB)
08:30 - 10:00 Salle Rhône 3
Teaching Course 2: Body fluid biomarkers
C. Teunissen (Amsterdam, NL)
J. Kuhle (Basel, CH)
08:30 - 10:00 Amphitheatre
Teaching Course 3: Disease-modifying therapy in MS - current and emerging treatment
H. Wiendl (Münster, DE)
C. Lubetzki (Paris, FR)
08:30 - 10:00 Forum 2 & 3
Teaching Course 4: Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS
W. Brück (Göttingen, DE)
C. Lucchinetti (Rochester, US)
08:30 - 10:00 Salon Pasteur
Teaching Course 5: Quantitating tissue and functional changes in MS
M. Filippi (Milan, IT)
A. Rovira (Barcelona, ES)
08:30 - 10:00 Auditorium Lumičre
Teaching Course 6: From dreams to reality: antigen-specific and stem cell therapy in MS?
K. Selmaj (Lodz, PL)
A. Uccelli (Genoa, IT)
08:30 - 10:00 Salle Rhône 2
Teaching Course 7: Molecular mechanisms of tissue injury in MS lesions
H. Lassmann (Vienna, AT)
J. van Horssen (Amsterdam, NL)
10:30 - 12:00 Auditorium Pasteur
Teaching Course 8: Issues in MS clinical trials: study design and results interpretation
M.P. Sormani (Genoa, IT)
F. Lublin (New York, US)
10:30 - 12:00 Forum 2 & 3
Teaching Course 9: Paediatric MS
B. Banwell (Toronto, CA)
C. Hemingway (London, GB)
10:30 - 12:00 Amphitheatre
Teaching Course 10: MRI in the diagnosis of MS and related disorders
N. De Stefano (Siena, IT)
M. Wattjes (Amsterdam, NL)
10:30 - 12:00 Auditorium Lumičre
Teaching Course 11: NMO: a practical approach
D. Wingerchuk (Scottsdale, US)
J. Palace (Oxford, GB)
10:30 - 12:00 Salon Pasteur
Teaching Course 12: Gender differences in MS
H. Harbo (Oslo, NO)
M. Tintoré (Barcelona, ES)
10:30 - 12:00 Salle Rhône 3
Teaching Course 13: Controversies in the natural history of multiple sclerosis
C. Confavreux (Lyon, FR)
A. Scalfari (London, GB)
12:30 - 14:00 Amphitheatre
Parallel Session 14: Late Breaking News I
T. Olsson (Stockholm, SE)
D. Laplaud (Nantes, FR)
14:00 - 15:30 Forum 2 & 3
Young Scientific Investigators’ Session I
P. Calabresi (Baltimore, US)
J. de Sčze (Strasbourg, FR)
16:00 - 17:15 Forum 2 & 3
Young Scientific Investigators’ Session II
J. Stadelmann (Göttingen, DE)
A. Siva (Istanbul, TR)
17:15 - 18:15 Amphitheatre
Satellite Symposium: Merck Serono S.A.: Get on track, stay on track: patient journeys in MS
D. Bates (Newcastle upon Tyne, GB)
P. Vermersch (Lille, FR)
N. Blanc (patients advocate) (Geneva, CH)
18:30 - 19:30 Amphitheatre
Satellite Symposium: Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS
J. Pelletier (Marseille, FR)
M. Duddy (Newcastle, GB)

Thursday, October 11, 2012

08:30 - 10:00 Amphitheatre
Plenary Session 1: Welcome Address and ECTRIMS Lecture
M. Clanet (Toulouse, FR)
C. Confavreux (Lyon, FR)
10:30 - 12:00 Amphitheatre
Parallel Session 1: From environment to MS
G. Ebers (Oxford, GB)
M. Debouverie (Nancy, FR)
10:30 - 12:00 Auditorium Lumičre
Parallel Session 3: Adaptative and innate immunity in MS
R. Gold (Bochum, DE)
R. Liblau (Toulouse, FR)
12:45 - 13:45 Amphitheatre
Satellite Symposium: Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment
C. Confavreux (Lyon, FR)
14:00 - 15:30 Forum 2 & 3
Parallel Session 4: Neurons and oligodendrocytes in MS
H. Lassmann (Vienna, AT)
P.-O. Couraud (Paris, FR)
14:00 - 15:30 Amphitheatre
Parallel Session 5: From inflammation to neurodegeneration
W. Brück (Göttingen, DE)
P. Giraudon (Lyon, FR)
14:00 - 15:30 Auditorium Lumičre
Parallel Session 6: Biology of recovery
N. Scolding (Bristol, GB)
S. Chandran (Edinburgh, GB)
15:30 - 17:00
Poster Session 1: Grey matter damage in MS
15:30 - 17:00
Poster Session 1: Economic burden
15:30 - 17:00
Poster Session 1: Pregnancy and MS
15:30 - 17:00
Poster Session 1: Databases and Pharmacoepidemiology
15:30 - 17:00
Poster Session 1: Epidemiology
15:30 - 17:00
Poster Session 1: Paediatric MS
15:30 - 17:00
Poster Session 1: Devic’s NMO spectrum
15:30 - 17:00
Poster Session 1: Diagnosis and differential diagnosis
15:30 - 17:00
Poster Session 1: MS and infections
15:30 - 17:00
Poster Session 1: Neuropsychology and fatigue
15:30 - 17:00
Poster Session 1: Immunomodulation
15:30 - 17:00
Poster Session 1: Risk management for disease modifying treatments
15:30 - 17:00
Poster Session 1: Tools for detecting therapeutic response
15:30 - 17:00
Poster Session 1: Adaptative and Innate immunology
15:30 - 17:00
Poster Session 1: Experimental models
15:30 - 17:00
Poster Session 1: Comprehensive care and rehabilitation
17:00 - 17:45 Auditorium Lumičre
Hot Topic 3: Temporal changes in MS epidemiology
P. De Jager (Boston, US)
M. Pugliatti (Sassari, IT)
17:00 - 17:45 Amphitheatre
Hot Topic 1: Devic's neuromyelitis optica spectrum
J. Palace (Oxford, GB)
D. Wingerchuk (Scottsdale, US)
17:00 - 17:45 Forum 2 & 3
Hot Topic 2: PML and IRIS
T. Weber (Hamburg, DE)
H. Wiendl (Münster, DE)
18:00 - 19:00 Auditorium Lumičre
Satellite Symposium: Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials
M. Trojano (Bari, IT)
19:15 - 20:15 Amphitheatre
Satellite Symposium: Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches
R. Gold (Bochum, DE)

Friday, October 12, 2012

09:15 - 10:15 Auditorium Lumičre
Free Communications III: Platform presentation of selected abstracts on fatigue and cognition
E. Havrdová (Prague, CZ)
D. Karussis (Jerusalem, IL)
09:15 - 10:15 Forum 2 & 3
Free Communications II: Platform presentation of selected abstracts on MS disease evolution
J. Hillert (Stockholm, SE)
M. Tintoré (Barcelona, ES)
09:15 - 10:15 Amphitheatre
Free Communications I: Platform presentation of selected abstracts on therapy and clinical trials
J. Wolinsky (Houston, US)
E. Wassmer (Birmingham, GB)
10:45 - 12:15 Auditorium Lumičre
Parallel Session 9: From databases and cohorts to pharmaco-epidemiology
M. Trojano (Bari, IT)
M. Clanet (Toulouse, FR)
10:45 - 12:15 Forum 2 & 3
Parallel Session 8: From natural to treated history
J. Rio (Barcelona, ES)
P. Soelberg Sorensen (Copenhagen, DK)
10:45 - 12:15 Amphitheatre
Parallel Session 7: Beyond clinical monitoring of progression in MS
C. Pozzilli (Rome, IT)
F. Cotton (Lyon, FR)
12:45 - 13:45 Forum 2 & 3
Satellite Symposium: Bayer HealthCare: Novel performance measures for early and long-term gains
P. Vermersch (Lille, FR)
14:00 - 15:30 Auditorium Lumičre
Parallel Session 10: Pregnancy
J. Nogales (Santiago, CL)
H. Tremlett (Vancouver, CA)
14:00 - 15:30 Amphitheatre
Parallel Session 12: Disease-modifying treatments
G. Comi (Milan, IT)
G. Edan (Rennes, FR)
15:30 - 17:00
Poster Session 2: Tools for detecting therapeutic response
15:30 - 17:00
Poster Session 2: Diagnosis and differential diagnosis
15:30 - 17:00
Poster Session 2: Devic’s NMO spectrum
15:30 - 17:00
Poster Session 2: Paediatric MS
15:30 - 17:00
Poster Session 2: Epidemiology
15:30 - 17:00
Poster Session 2: Databases and Pharmacoepidemiology
15:30 - 17:00
Poster Session 2: Pregnancy and MS
15:30 - 17:00
Poster Session 2: Economic burden
15:30 - 17:00
Poster Session 2: Grey matter damage in MS
15:30 - 17:00
Poster Session 2: Experimental models
15:30 - 17:00
Poster Session 2: Adaptative and Innate immunology
15:30 - 17:00
Poster Session 2: MS and infections
15:30 - 17:00
Poster Session 2: Neuropsychology and fatigue
15:30 - 17:00
Poster Session 2: Immunomodulation
15:30 - 17:00
Poster Session 2: Risk management for disease modifying treatments
15:30 - 17:00
Poster Session 2: Comprehensive care and rehabilitation
17:00 - 17:45 Amphitheatre
Hot Topic 6: Symptomatic treatments
B. Brochet (Bordeaux, FR)
A. Thompson (London, GB)
17:00 - 17:45 Forum 2 & 3
Hot Topic 5: Paediatric MS
M. Tardieu (Paris, FR)
A. Ghezzi (Gallarate, IT)
17:00 - 17:45 Auditorium Lumičre
Hot Topic 4: Imaging and cognition
A. Feinstein (Toronto, CA)
F. Fazekas (Graz, AT)
18:00 - 19:00 Amphitheatre
Satellite Symposium: Biogen Idec: Committed to MS
C. Confavreux (Lyon, FR)


Search Result: Abstracts

Wednesday, October 10, 2012

08:30 - 10:00 Meet the Professors: A case-based approach to diagnosis and management of MS (Auditorium Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
First-line therapies (ABCR drugs) 5
H. Wiendl (Münster, DE)
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Future use of biomarkers in daily clinical practice 4
F. Sellebjerg (Copenhagen, DK)
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Basic introduction on biomarkers in body fluids 2
C. Teunissen (Amsterdam, NL)
08:30 - 10:00 Meet the Professors: A case-based approach to diagnosis and management of MS (Auditorium Pasteur)
A case-based approach to diagnosis and management of MS 1
A. Miller, D. Bates (New York, US; Newcastle, GB)
08:30 - 10:00 Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS (Forum 2 & 3)
Inflammation and degeneration in MS 10
W. Brück (Göttingen, DE)
08:30 - 10:00 Quantitating tissue and functional changes in MS (Salon Pasteur)
Fibre tracts and functionality 12
O. Ciccarelli (London, GB)
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Antigen specific therapy of MS 14
K. Selmaj (Lodz, PL)
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Autologous haematopoetic stem cells for the treatment of MS 16
D. Karussis (Jerusalem, IL)
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Interplay of free radicals and mitochondrial dysfunction in MS 18
J. van Horssen (Amsterdam, NL)
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Amplification of oxidative damage in MS brain by iron 19
H. Lassmann (Vienna, AT)
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Monoclonal antibodies 6
C. Lubetzki (Paris, FR)
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Oral drugs 7
L. Kappos (Basel, CH)
08:30 - 10:00 Body fluid biomarkers (Salle Rhône 3)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Disease-modifying therapy in MS - current and emerging treatment (Amphitheatre)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Neuroinflammation, neurodegeneration, and tissue repair - in RRMS, SPMS, PPMS (Forum 2 & 3)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Molecular mechanisms of tissue injury in MS lesions (Salle Rhône 2)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 Quantitating tissue and functional changes in MS (Salon Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
08:30 - 10:00 From dreams to reality: antigen-specific and stem cell therapy in MS? (Auditorium Lumičre)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Age, prognosis and the MS disease course 36
H. Tremlett (Vancouver, CA)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Please download the Teaching Course Manuscript here by clicking on this link
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Statistical issues and results interpretation in MS clinical trials 20
M.P. Sormani (Genoa, IT)
10:30 - 12:00 Issues in MS clinical trials: study design and results interpretation (Auditorium Pasteur)
Surrogate outcomes for immunomodulation and neuroprotection 22
J. Wolinsky (Houston, US)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Environmental and genetic factors in paediatric MS 23
B. Banwell (Toronto, CA)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Relapse severity, recovery and progression in paediatric MS 24
E. Waubant (San Francisco, US)
10:30 - 12:00 Paediatric MS (Forum 2 & 3)
Acute disseminated encephalomyelitis in children and MS 25
C. Hemingway (London, GB)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Lesion characteristics in MS: brain and spinal cord 26
M. Wattjes (Amsterdam, NL)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
The ''Radiologically Isolated Syndrome'' 27
N. De Stefano (Siena, IT)
10:30 - 12:00 MRI in the diagnosis of MS and related disorders (Amphitheatre)
Pitfalls in diagnosing ''active MS'' 28
C. Enzinger (Graz, AT)
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
NMO diagnostic criteria: are they really so distinct in clincal practice? 30
D. Wingerchuk (Scottsdale, US)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Genetic aspects and gender differences in disease onset and progression 32
H. Harbo (Oslo, NO)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Effects of sex hormones, the menstrual cycle and pregnancy on MS 33
M. Tintoré (Barcelona, ES)
10:30 - 12:00 Gender differences in MS (Salon Pasteur)
Gender differences in the immune system and response to immunotherapy 34
R. Gold (Bochum, DE)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Relapses and long-term disability accumulation 35
A. Scalfari (London, GB)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Emerging concepts from natural history studies: an overview 37
C. Confavreux (Lyon, FR)
10:30 - 12:00 NMO: a practical approach (Auditorium Lumičre)
Pathogenesis of NMO 29
K. Fujihara (Sendai, JP)
10:30 - 12:00 Controversies in the natural history of multiple sclerosis (Salle Rhône 3)
Please download the Teaching Course Manuscript here by clicking on this link
12:30 - 12:45 Late Breaking News I (Amphitheatre)
The MS-STAT trial: high dose simvastatin demonstrates neuroprotection without immune-modulation in secondary progressive multiple sclerosis (SPMS) – a phase II trial 38a
J. Chataway, A. Alsanousi, D. Chan, D. MacManus, K. Hunter, J. Foster, C. Bangham, D. Wilkie, J. Nicholas, S. Clegg, C. Nielsen, N. Scheurer, V. Calder, J. Greenwood, C. Frost, R. Nicholas (London, Brighton, GB)
12:45 - 13:00 Late Breaking News I (Amphitheatre)
Induction of immune tolerance by autologous peptide-coupled cells – a phase I trial in relapsing-remitting and secondary-progressive multiple sclerosis patients 38b
A. Lutterotti, S. Yousef, A. Sputtek, K.H. Stürner, J.-P. Stellmann, P. Breiden, S. Reinhardt, C. Schulze, M. Bester, C. Heesen, S. Schippling, S. Miller, M. Sospedra, R. Martin (Innsbruck, AT; Hamburg, Hamburg-Eppendorf, DE; Zurich, CH; Chicago, US)
13:00 - 13:15 Late Breaking News I (Amphitheatre)
Defective sphingosine-1-phosphate receptor 1 (S1PR_1) internalization exacerbates autoimmune neuroinflammation by enhancing Stat3-mediated Th17 polarization 39a
C.S. Garris, S. Acharya, R. Axtell, D. Lewis, R.A. Sobel, L. Steinman, T. Hla, M.H. Han (Stanford, US)
13:15 - 13:30 Late Breaking News I (Amphitheatre)
A novel autoantigen in neuromyelitis optica spectrum disorders 39b
J.S. Tzartos, C. Stergiou, K. Kilintireas, P. Zisimopoulou, T. Thomaidis, S.J. Tzartos (Athens, Patras, GR)
13:30 - 13:45 Late Breaking News I (Amphitheatre)
Association of MRI metrics and clinical relapses to explain long-term disability changes in relapsing multiple sclerosis 40a
A. Giorgio, M.P. Sormani, M.L. Stromillo, M.L. Bartolozzi, F. Rossi, M. Battaglini, A. De Leucio, L. Guidi, P. Maritato, E. Portaccio, M.P. Amato, A. Federico, N. De Stefano (Siena, Genoa, Empoli, Florence, IT)
13:45 - 14:00 Late Breaking News I (Amphitheatre)
Gene expression profiling study in multiple sclerosis patients responders and non-responders to treatment with glatiramer acetate 40b
M. Comabella, N. Fissolo, R. Nurtdinov, J. Río, C. Tur, J. Sastre-Garriga, X. Montalban (Barcelona, ES)
14:00 - 14:15 Young Scientific Investigators’ Session I (Forum 2 & 3)
Multi-contrast MR imaging at 7T in multiple sclerosis: highest lesion detection in cortical grey matter with 3D fluid-attenuated inversion recovery 42
I.D. Kilsdonk, W.L. de Graaf, A. Lopez Soriano, J.J. Zwanenburg, F. Visser, J.P.A. Kuijer, J.J.G. Geurts, P.J.W. Pouwels, C.H. Polman, J.A. Castelijns, P.R. Luijten, F. Barkhof, M.P. Wattjes (Amsterdam, Utrecht, NL)
14:15 - 14:30 Young Scientific Investigators’ Session I (Forum 2 & 3)
Neuromyelitis optica spectrum disorder and multiple sclerosis can be distinguished on the basis of MRI brain lesion characteristics 43
L.A.E. Matthews, R. Marasco, M. Jenkinson, W. Kuker, M.I. Leite, A. Giorgio, N. De Stefano, S. Luppe, N. Robertson, H. Johansen-Berg, N. Evangelou, J. Palace (Oxford, GB)
14:30 - 14:45 Young Scientific Investigators’ Session I (Forum 2 & 3)
Rodent models of neuromyelitis optica based on pathogenicity of engineered anti-aquaporin-4 ‘NMO superantibodies’ with enhanced effector functions 44
J. Ratelade, N. Asavapanumas, P. W. Phuan, S. Wemlinger, A. Ritchie, J. L. Bennett, A. S. Verkman (San Francisco, Aurora, US)
14:45 - 15:00 Young Scientific Investigators’ Session I (Forum 2 & 3)
A novel retinal phenotype in multiple sclerosis is predictive of inflammatory disease activity and disability progression 45
S. Saidha, E. Sotirchos, M. Ibrahim, J. Gelfand, Y. Sepah, J. Ratchford, J. Oh, M. Seigo, S. Newsome, L. Balcer, E. Frohman, C. Crainiceanu, A. Green, Q. Nguyen, P. Calabresi (Baltimore, San Francisco, Philadelphia, Dallas, US)
15:00 - 15:15 Young Scientific Investigators’ Session I (Forum 2 & 3)
Impaired decision-making in MS and grey matter diffusion orientational complexity 46
N. Muhlert, V. Sethi, M. Ron, L. Cipolotti, G. Parker, H. Haroon, T.A. Yousry, C.A. Wheeler-Kingshott, D.H. Miller, D.T. Chard (London, Manchester, GB)
15:15 - 15:30 Young Scientific Investigators’ Session I (Forum 2 & 3)
Relation of cerebellar volume to performance in cognitive tests in patients with multiple sclerosis 47
K. Weier, I.K. Penner, S. Magon, M. Amann, Y. Naegelin, N. Mueller-Lenke, A. Beck, M. Andelova, T. Derfuss, E.-W. Radue, C. Stippich, L. Kappos, T. Sprenger (Basel, CH; Langenfeld, DE)
16:00 - 16:15 Young Scientific Investigators’ Session II (Forum 2 & 3)
Axonal damage in inflammatory demyelinating lesions of paediatric patients 48
S. Pfeifenbring, R.F. Bunyan, I. Metz, C.F. Lucchinetti, W. Brück (Göttingen, DE; Dammam, SA; Rochester, US)
16:15 - 16:30 Young Scientific Investigators’ Session II (Forum 2 & 3)
Analysis of HLA classical alleles and derived amino acids identifies independent effects in several DRB1 and non-DRB1 classical alleles 49
N.A. Patsopoulos, L. Barcellos, C. Schaefer, R.Q. Hintzen, P.L. De Jager, P.I.W. de Bakker on behalf of ANZgene, GeneMSA, IMSGC
16:30 - 16:45 Young Scientific Investigators’ Session II (Forum 2 & 3)
Role of the chemokine CCL2 in T-cell tolerance and protection from experimental autoimmune encephalomyelitis 50
O. Cédile, M. Lřbner, H. Toft-Hansen, T. Owens (Odense, DK)
16:45 - 17:00 Young Scientific Investigators’ Session II (Forum 2 & 3)
MCAM is expressed by IL-17-producing T-lymphocytes and regulates their entry in the CNS 51
C. Larochelle, J. Alvarez, H. Kebir, M.-A. Lécuyer, R. Cayrol, O. Saint-Laurent, J. Poirier, P. Duquette, N. Arbour, A. Prat (Montreal, CA)
17:00 - 17:15 Young Scientific Investigators’ Session II (Forum 2 & 3)
Endoplasmatic reticulum stress responses: mechanisms of oligodendrocyte stress in the cuprizone model for multiple sclerosis 52
J. Goldberg, M. Victor, B. Krauspe, S. Diederichs, S. Amor, P. van der Valk, T. Clarner, C. Beyer, M. Kipp (Aachen, DE; Amsterdam, NL)
17:20 - 17:35 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Starting on the right track 53
M.S. Freedman (Ottawa, CA)
17:35 - 17:55 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Staying the course: benefits of long-term therapy adherence 54
V. Devonshire (Vancouver, CA)
17:55 - 18:10 Merck Serono S.A.: Get on track, stay on track: patient journeys in MS (Amphitheatre)
Tracking outcomes: new imaging techniques 55
P. Gallo (Padua, IT)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
Growing evidence for the benefit–risk profile of treatment with fingolimod 57
H.-P. Hartung (Düsseldorf, DE)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
The evolving role of fingolimod in MS treatment 58
M. Duddy (Newcastle, GB)
18:30 - 19:30 Novartis Pharma AG: Growing global experience with once-daily oral fingolimod in MS (Amphitheatre)
Initiating treatment with fingolimod 56
B. Singer (St. Louis, US)

Thursday, October 11, 2012

08:30 - 09:00 Welcome Address and ECTRIMS Lecture (Amphitheatre)
Welcome 60
Welcome to Lyon
F.-N. Gilly, Lyon (FR)
President of Claude Bernard Lyon 1 University

Welcome to Lyon
C. Confavreux (Lyon, FR)

The ECTRIMS Society
M. Clanet (Toulouse, FR)

09:00 - 10:00 Welcome Address and ECTRIMS Lecture (Amphitheatre)
ECTRIMS Lecture
Biotherapies in MS: hopes and threats
61
H.-P. Hartung (Düsseldorf, DE)
10:30 - 10:50 Adaptative and innate immunity in MS (Auditorium Lumičre)
The effects of Vitamin D on the adaptive immune system (T and B cells) in relation to clinical manifestations in MS 72
R.M. Hupperts, J. Smolders, J. Damoiseaux (Sittard-Geleen, NL)
10:30 - 10:50 From genetics to MS (Forum 2 & 3)
From the genes to MS 67
J.S. Sawcer (Cambridge, GB)
10:30 - 10:50 From environment to MS (Amphitheatre)
From infections to MS 62
R. Du Pasquier (Lausanne, CH)
10:50 - 11:10 Adaptative and innate immunity in MS (Auditorium Lumičre)
Microglia and monocytes: kith or kin? 73
R.M. Ransohoff (Cleveland, US)
10:50 - 11:10 From genetics to MS (Forum 2 & 3)
Expectations from omics in MS 68
D. Brassat (Toulouse, FR)
10:50 - 11:10 From environment to MS (Amphitheatre)
From physico-chemical agents exposure to MS 63
S. Ramagopalan (London/Oxford, GB)
11:10 - 11:25 From environment to MS (Amphitheatre)
An age at exposure effect in the association between sun exposure and the risk of MS in Norway and Italy. The EnvIMS study 64
K. Bjřrnevik, T. Riise, K. Wesnes, E. Granieri, I. Casetta, J. Drulovic, K.M. Myhr, K. Lauer, M. Kampman, S. Magalhaes, T. Pekmezovic, T. Holmřy, A.M. Landtblom, C. Wolfson, M. Pugliatti (Bergen, NO; Ferrara, IT; Belgrade, RS; Griesheim, DE; Tromsř, NO; Montreal, CA; Oslo, NO; Linköping, SE; Sassari, IT)
11:10 - 11:25 From genetics to MS (Forum 2 & 3)
Genetic differences relating to oligoclonal band status in multiple sclerosis 69
I.-L. Mero, M. W. Gustavsen, H. Sćther, S. Flĺm, H.B. Sřndergaard, P.E.H. Jensen, T. Berge, A. Bjřlgerud, A. Muggerud, J.H. Aarset, K.-M. Myhr, E.G. Celius, F. Sellebjerg, J. Hillert, L. Alfredsson, T. Olsson, A.B. Oturai, I. Kockum, B.A. Lie, B. Kulle, H.F. Harbo (Oslo, NO; Copenhagen, DK; Bergen, NO; Stockholm, SE)
11:10 - 11:25 Adaptative and innate immunity in MS (Auditorium Lumičre)
The potassium channel KIR4.1 as an immune target in multiple sclerosis 74
R. Srivastava, M. Aslam, R Kalluri, L. Schirmer, D. Buck, B. Tackenberg, V. Rothhammer, A. Chan, R. Gold, A. Berthele, J. Bennett, T. Korn, B. Hemmer (Munich, Marburg, Bochum, DE; Denver, US)
11:25 - 11:40 From environment to MS (Amphitheatre)
Smoking is a potentially modifiable risk factor for all causes of mortality in patients with multiple sclerosis 65
A. Manouchehrinia, M. Weston, C. Constantinescu (Nottingham, GB)
11:25 - 11:40 Adaptative and innate immunity in MS (Auditorium Lumičre)
Immune reconstitution after autologous haematopoietic stem cell transplantation for aggressive relapsing-remitting MS 75
J. Burman, J. Fagius, T.H. Tötterman, M. Fransson, S.M. Mangsbo, A.S.I. Loskog (Uppsala, SE)
11:25 - 11:40 From genetics to MS (Forum 2 & 3)
ICAM3 expression level integrates the effects of six MS susceptibility alleles: dissecting a molecular cascade relevant to MS susceptibility 70
T. Raj, M. Kuchroo, B. Keenan, L. Ottoboni, X. Hu, S. Raychaudri, P. De Jager (Boston, US)
11:40 - 11:55 From genetics to MS (Forum 2 & 3)
A pharmacogenetic study on Italian, US and French MS patients reveals an SLC9A9 variant as a novel marker of response to interferon-beta 71
F. Esposito, E. Lim, M. Romeo, M. Rodegher, M. Sorosina, P. Brambilla, N.A. Patsopoulos, B. Keenan, V. Martinelli, D. Brassat, G. Comi, F. Martinelli Boneschi, P.L. De Jager (Milan, IT; Boston, US; Toulouse, FR)
11:40 - 11:55 Adaptative and innate immunity in MS (Auditorium Lumičre)
Encephalitogenic and non-encephalitogenic T-Cell epitopes of aquaporin-4 76
P. Nelson, M. Varrin-Doyer, C. Spencer, S. Sagan, R. Sobel, J. Bennett, S. Zamvil (San Francisco, Palo Alto, Denver, US)
11:40 - 11:55 From environment to MS (Amphitheatre)
Cytomegalovirus seropositivity is associated with lower multiple sclerosis risk 66
E. Sundqvist, T. Bergström, H. Daialhosein, P. Sundström, J. Hillert, L. Alfredsson, I. Kockum, T. Olsson (Stockholm, Gothenburg, Umeĺ, SE)
12:50 - 13:05 Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment (Amphitheatre)
Role of lymphocytes in the pathogenesis of MS 77
H. Wiendl (Münster, DE)
13:05 - 13:35 Genzyme, a Sanofi Company: MS pathophysiology and implications for treatment (Amphitheatre)
MS immunomodulation: experiences with B- & T-lymphocyte targeting agents 78
G. Comi, G. Giovannoni (Milan, IT; London, GB)
14:00 - 14:20 From inflammation to neurodegeneration (Amphitheatre)
From focal inflammation to neurodegeneration 84
F. Zipp (Mainz, DE)
14:00 - 14:20 Biology of recovery (Auditorium Lumičre)
Sodium channels in MS 89
M. Craner (Oxford, GB)
14:00 - 14:20 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Neurons in MS 79
D. Mahad (Edinburgh, GB)
14:20 - 14:40 Biology of recovery (Auditorium Lumičre)
Remyelination 90
C. Lubetzki (Paris, FR)
14:20 - 14:40 From inflammation to neurodegeneration (Amphitheatre)
From diffuse inflammation to neurodegeneration 85
D. Merkler (Geneva, CH)
14:20 - 14:40 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Oligodendrocytes in MS 80
T. Kuhlmann (Münster, DE)
14:40 - 14:55 From inflammation to neurodegeneration (Amphitheatre)
Periplaques form extensive lesions in multiple sclerosis spinal cords 86
A. Lhuillier, M. Chanal, G. Androdias, R. Reynolds, C. Confavreux, S. Nataf (Lyon, FR; London, GB)
14:40 - 14:55 Biology of recovery (Auditorium Lumičre)
Dosing regimen impacts in vitro effects of FTY720 on human astrocyte proliferation, IL1b-induced Ca2+ mobilisation, and miRNA-155 expression 91
C. Wu, C.S. Moore, S. Leong, T.A. Johnson, T.E. Kennedy, P. Séguéla, A. Bar-Or, J.P. Antel (Montreal, CA)
14:40 - 14:55 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Differential roles for the small heat shock protein Alpha B-Crystallin in cuprizone-induced de- & remyelination 81
H.F. Kuipers, J. Yoon, J. Vister, T.D. Palmer, L. Steinman (Stanford, US)
14:55 - 15:10 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Early disruption of astrocytic connexins in multiple sclerosis, Baló’s disease and neuromyelitis optica 82
K. Masaki, S.O. Suzuki, T. Matsushita, T. Matsuoka, M. Suzuki, T. Suenaga, T. Tabira, T. Iwaki, J. Kira (Fukuoka, Hamamatsu, Tenri, Tokyo, JP)
14:55 - 15:10 Biology of recovery (Auditorium Lumičre)
New enhancers of endogenous remyelination: an extensive in vitro and ex vivo screening 92
C. Eleuteri, C. Veroni, R. Umeton, V. Annibali, G. Ristori, M. Salvetti, C. Agresti (Rome, IT)
14:55 - 15:10 From inflammation to neurodegeneration (Amphitheatre)
Myelin debris regulates inflammatory responses in an experimental demyelination animal model and multiple sclerosis lesions 87
T. Clarner, F. Diederichs, K. Berger, B. Denecke, L. Gan, P. van der Valk, C. Beyer, S. Amor, M. Kipp (Aachen, DE; Amsterdam, NL)
15:10 - 15:25 From inflammation to neurodegeneration (Amphitheatre)
Preventing neurodegeneration in neuroinflammation – an in vivo two-photon imaging approach 88
V. Siffrin, R. Gollan, J. Birkenstock, M. Paterka, F. Zipp (Mainz, DE)
15:10 - 15:25 Neurons and oligodendrocytes in MS (Forum 2 & 3)
Heterogeneity of cortical remyelination in multiple sclerosis 83
E.M.M. Strijbis, E.J. Kooi, P. van der Valk, C.H. Polman, J.J.G. Geurts (Amsterdam, NL)
15:10 - 15:25 Biology of recovery (Auditorium Lumičre)
Krüppel-like factor-6 is required for oligodendrocyte maturation and CNS myelination 93
L. Asp, E. Kramer, Y.-M. Lee, J. Zhang, X. Pedre, A.T. Argaw, J. Liu, D. Dutta, E. Zaslavsky, D. Braun, T. Pham, G. Narla, C. Raine, P. Casaccia, S. Friedman, G. John (New York, Bronx, US)
15:30 - 17:00 Neuropsychology and fatigue
Assessment of different tests for tracking cognitive changes during MS relapses P 437
L. Vahter, L. Bachmann, T. Saarup, K. Rohulaid, K. Kannel, A. Reitsnik, U. Sorro, H. Maamägi, K. Gross-Paju (Tallinn, EE)
15:30 - 17:00 Environmental risk factors
Vitamin A and absence of systemic inflammation as risk factors for multiple sclerosis P 372
J. Salzer, G. Hallmans, M. Nyström, H. Stenlund, G. Wadell, P. Sundström (Umeĺ, SE)
15:30 - 17:00 Neuropsychology and fatigue
Language dysfunctions in multiple sclerosis P 441
F. Blanc, M.O. Kieffer, D. Baron, A. Michel, N. Cremel, B. Jung, J.B. Chanson, N. Collongues, J. de Seze (Strasbourg, FR)
15:30 - 17:00 Risk management for disease modifying treatments
Patient preferences for attributes of disease-modifying multiple sclerosis therapies: preliminary results of a conjoint analysis P 532
L. Wilson, A. Loucks, G. Gipson, E. Miller, L. Zhong, C. McCulloch, M. Azarraga, C. Gonzalez, M. Owen, E. Waubant (San Francisco, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Predictive factors for MS in patients with clinically isolated syndromes P 196
A. Ruet, G. Arrambide, B. Brochet, C. Auger, E. Simon, A. Rovira, X. Montalban, M. Tintore (Bordeaux, FR; Barcelona, ES)
15:30 - 17:00 Databases and Pharmacoepidemiology
Leveraging electronic health records for research in multiple sclerosis P 257
Z. Xia, R. Bove, T. Cai, S. Cheng, R. Perez, V. Gainer, S. Murphy, P. Chen, G. Savova, K. Liao, E. Karlson, S. Shaw, A. Ananthakrishnan, P. Szolovits, S. Churchill, I. Kohane, R. Plenge, P. De Jager (Boston, Charlestown, Cambridge, US)
15:30 - 17:00 Long-term treatment monitoring
Long-term safety and efficacy of natalizumab and assessment of 2-year freedom from clinical disease activity in patients with multiple sclerosis in the TYSABRI(R) observational programme P 519
F. Pellegrini, S. Belachew, H. Butzkueven, L. Kappos, M. Trojano, H. Wiendl, A. Zhang, R. Arnold (Chieti, IT; Ličge, BE; Melbourne, AU; Basel, CH; Bari, IT; Münster, DE; Weston, US)
15:30 - 17:00 Immunomodulation
Regulatory T-cell numbers in patients with RRMS were not associated with clinical or MRI outcomes in the SELECT study P 473
R. Gold, K. Selmaj, X. You, J. Sheridan, L. Amaravadi, J. Fontenot, J. Elkins (Bochum, DE; Lodz, PL; Cambridge, Redwood City, US)
15:30 - 17:00 Devic’s NMO spectrum
Aquaporin-4-specific T-cells in neuromyelitis optica exhibit a Th17 bias and recognise Clostridium ABC transporter P 202
M. Varrin-Doyer, C.M. Spencer, U. Schulze-Topphoff, P.A. Nelson, R.M. Stroud, B.A.C. Cree, S.S. Zamvil (San Francisco, US)
15:30 - 17:00 Treatment of specific symptoms
Evaluation of fampridine response by multivariate analysis of mobility in multiple sclerosis P 569
T. Schultheiß, R. Kempcke, K. Thomas, S. Sobek, T. Ziemssen (Dresden, DE)
15:30 - 17:00 Adaptative and Innate immunology
Liver X receptor activation alters the Teffector / Treg balance and enhances the suppressive capacity of Tregs derived from multiple sclerosis patients P 351
M. Herold, B. Grützke, S. Hucke, H. Wiendl, L. Klotz (Münster, DE)
15:30 - 17:00 Quality of life
Impact of electroacupuncture on quality of life for patients with relapsing-remitting multiple sclerosis under treatment with immunomodulators: a randomised study P 585
J.G. Quispe-Cabanillas, A. Damasceno, F. Von Glehn, C.O. Brandăo, B.P. Damasceno, W. Silveira, L.M.B. Santos (Campinas - SP, BR)
15:30 - 17:00 Neuroprotection
Lipoic acid prevents axonal spheroid formation and severing in adult neurons during oxidative stress P 506
A. Barsukova, M. Forte, D. Bourdette (Portland, US)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica spectrum disorder as a paraneoplastic disorder in a patient with breast cancer P 203
W. Vargas, S. Gauthier, N. Nealon, T. Vartanian, J. Perumal (New York, US)
15:30 - 17:00 Databases and Pharmacoepidemiology
Treatment patterns after lack of response to first-line disease-modifying therapy for relapsing-remitting multiple sclerosis P 258
B. Teter, N. Agashivala, R. Hashmonay, B. Weinstock-Guttman (Buffalo, East Hanover, US)
15:30 - 17:00 MS and infections
Neuropathological study of Epstein Barr-virus infection in the MS brain P 361
J.S. Tzartos, G. Khan, J. Middeldorp, G. Giovannoni, U.C. Meier (Athens, GR; Al Ain, AE; Amsterdam, NL; London, GB)
15:30 - 17:00 MS and infections
Relation of Helicobacter pylori infection and multiple sclerosis in Iranian patients P 360
N. Mohebi, M. Moghaddasi, M. Mamarabadi (Tehran, IR)
15:30 - 17:00 Devic’s NMO spectrum
Visual and motor disability in a cohort of patients with neuromyelitis optica in South Wales and the South West of England P 205
S. Luppe, K. Harding, T. Pickersgill, N. Robertson (Cardiff, GB)
15:30 - 17:00 Clinical assessment tools
Postural sway analysis as tool to assess balance impairments in individuals with multiple sclerosis P 299
E. Cocco, G. Coghe, J. Frau, C. Scalas, G. Fenu, L. Lorefice, M. Melis, M.G. Marrosu, M. Pau (Cagliari, IT)
15:30 - 17:00 Experimental models
Maternal neurofascin-specific autoantibodies have no long term effect on CNS development P 326
S. Hochmeister, T. Pekar, M. Kitic, M.K. Storch, F. Fazekas, C. Linington (Graz, Vienna, AT; Glasgow, GB)
15:30 - 17:00 Clinical assessment tools
Manovolumetric pattern in multiple sclerosis patients with anorectal dysfunctions P 294
M. Capobianco, S. Marola, A. Surace, E. Boero, A. Ferrarese, I. De Stefano, M. Scaglia, A. Di Sapio, M. Nano, A. Bertolotto (Orbassano, IT)
15:30 - 17:00 Imaging
Evaluation of microstructural brain white matter damage in patients with neuromyelitis optica and multiple sclerosis P 392
C. Pires, F. Rueda, T. Doring, G. Gutfilen, N. Ventura, S. Aves-Leon, E. Gasparetto (Rio de Janeiro, BR)
15:30 - 17:00 Imaging
Relationship between cognitive impairment and functional connectivity changes in multiple sclerosis patients during resting state P 397
A.J. Cruz-Gómez, N. Ventura Campos, A. Belenguer, C. Ávila, C. Forn (Castelló de la Plana, ES)
15:30 - 17:00 Quality of life
Subcutaneous interferon-beta-1a discontinuation rates are diminished for treatment-naive patients using RebiSmart P 591
K. Giles, J. Morin, G. Stoyanov, P. Moriarty (Cambridge, Mississauga, CA)
15:30 - 17:00 Neuroprotection
Fingolimod is neuroprotective after toxin-induced central nervous system demyelination P 511
A. Slowik, T. Schmidt, S. Amor, C. Beyer, M. Kipp (Aachen, DE; Amsterdam, NL)
15:30 - 17:00 Biomarkers
Insulin resistance and serum lipid profile are associated with disability in multiple sclerosis patients P 619
S.R. Oliveira, A.P. Kallaur, A.N.C. Simăo, D.R. Kaimen-Maciel, J. Lopes, R. Andrade, W. Pereira, H.K. Morimoto, E.M.V. Reiche (Londrina, BR)
15:30 - 17:00 Diagnosis and differential diagnosis
Anti-TNF alpha agents and CNS demyelination: further evidence of an association? P 194
K. O'Connell, C. McGuigan (Dublin, IE)
15:30 - 17:00 MS and infections
Unusual course and manifestation of natalizumab associated PML in a patient with multiple sclerosis P 365
T. Kümpfel, J. Havla, K. Lippmann, R. Hohlfeld (Munich, Neuburg, DE)
15:30 - 17:00 MS symptoms
Hidden symptoms of multiple sclerosis increase with patient age P 265
G.H. Kraft, D. Amtmann, K. Johnson, V. Weir, A. Verrall (Seattle, US)
15:30 - 17:00 Tools for detecting therapeutic response
Natalizumab treatment effects sustained decrease in serum levels of fibronectin and soluble adhesion molecules sVCAM-1 and sICAM-3 P 553
K. Oppermann, A. Harrer, G. Pilz, P. Wipfler, S. Afazel, E. Haschke-Becher, E. Trinka, J. Kraus (Salzburg, AT)
15:30 - 17:00 Clinical assessment tools
Employing fuzzy concept to MSFC as an alternative score for quantising the progression of MS disease P 298
J. Razjouyan, S. Gharibzadeh, A. Fallah, M. Raza, A.R. Azimi, M.A. Sahraian (Tehran, IR)
15:30 - 17:00 Tools for detecting therapeutic response
Longitudinal follow-up of MRI volumetry in routine clinical practice P 552
D. Horakova, T. Kalincik, M. Tyblova, J. Krasensky, M. Vaneckova, Z. Seidl, E. Havrdova (Prague, CZ)
15:30 - 17:00 Biomarkers
Expression of cytokines reflecting the Th17/Treg balance and MS disease activity. Effects of ivMP, IFN-beta and glatiramer Acetate P 608
V. van Pesch, H.A. Dang, N. Muls, C.J.M. Sindic (Brussels, BE)
15:30 - 17:00 Biomarkers
Cystatin C as a marker of the neurodegeneration in MS P 609
V. Sladkova, J. Mares, J. Langova, P. Kanovsky (Olomouc, CZ)
15:30 - 17:00 Genetics / transcriptomics
Role of HERV-K18 haplotypes in multiple sclerosis development (meta-analysis) P 344
B. de la Hera, M. García-Montojo, J. Varadé, A. de la Encarnación, M. Domínguez-Mozo, A. Arias-Leal, M. A. García-Martínez, V. de las Heras, R. Arroyo, E. Gómez de la Concha, R. Álvarez-Lafuente, E. Urcelay (Madrid, ES)
15:30 - 17:00 Imaging
Two-year progression of iron accumulation in subcortical nuclei in multiple sclerosis using high-field MRI P 420
A. Walsh, G. Blevins, A. Wilman (Edmonton, CA)
15:30 - 17:00 Adaptative and Innate immunology
CD6 expression on lymphocytes correlates with MRI gadolinium-enhancing lesions in multiple sclerosis patients P 358
A. Jurewicz, K. Zaleski, B. Szymanska, K. Wodz, M. Domowicz, H. Cwiklinska, K. Selmaj (Lodz, PL)
15:30 - 17:00 Immunomodulation
Autologous mesenchymal stem cell transplantation in multiple sclerosis: a randomised, double-blind, crossover with placebo phase II study P 462
M. Sepulveda, Y. Blanco, S. Llufriu, I. Gabilondo, P. Villoslada, P. Marín, J. Berenguer, M. Squarcia, B. Sánchez-Dalmau, S. Ortiz, N. Solŕ, F. Graus, A. Saiz (Barcelona, ES)
15:30 - 17:00 Grey matter damage in MS
Meningeal inflammation and cortical pathology play a prominent role in primary progressive multiple sclerosis P 315
R. Reynolds, O. Howell, S. Choi, D. Carassiti, R. Magliozzi, D. Gveric, P. Muraro, R. Nicholas, F. Roncaroli (London, GB; Rome, IT)
15:30 - 17:00 Epidemiology
Mutiple sclerosis in Hamburg, Germany – prevalence estimates for subgroups P 247
N. Erikli, S. Hadjilou, J. Poettgen, D. Kilian, J.P. Stellmann, C. Heesen (Hamburg, DE)
15:30 - 17:00 Quality of life
Measurement of quality of life in patients with relapsing forms of multiple sclerosis: the CoMPaRe study P 589
L. Lee, F. Moore, B. Vickrey, K. Fortin (Toronto, Montreal, CA; Los Angeles, US)
15:30 - 17:00 Immunomodulation
Maraviroc for treatment of immune reconstitution inflammatory syndrome following natalizumab-associated progressive multifocal leukoencephalopathy P 465
P.S. Giacomini, A. Rosenberg, D. Araujo, M.-N. Boivin, L. Poliquin-Lasnier, C. Xia, D. Tampieri, S. Narayanan, D. L. Arnold, N. Arbour, D. B. Clifford, A. Bar-Or (Montreal, CA; St. Louis, US)
15:30 - 17:00 Immunomodulation
Long-term immunological changes during fingolimod therapy in MS P 476
T. Sehr, U. Hainke, M. Zendzian-Piotrowska, R. Bucki, K. Thomas, M. Marggraf, T. Ziemssen (Dresden, DE; Bialystok, PL; Philadelphia, US)
15:30 - 17:00 Clinical assessment tools
Correlation of brain atrophy with cognitive evaluation and OCT results in multiple sclerosis P 296
S. Yurtogullari, O. Taskapilioglu, B. Hakyemez, B. Bilgic, B. Ozturk, A. Bayram, N. Turkes, D. Sigirli, O.F. Turan, M. Bakar (Bursa, Istanbul, TR)
15:30 - 17:00 Biomarkers
Multiparameter assay evaluation and quantification of inflammatory cytokines in cerebrospinal fluid and serum of multiple sclerosis patients P 622
A. Malekzadeh, N. Wijnstok, H. Twaalfhoven, B. van Oosten, V. de Groot, M. Blankenstein, C. Teunissen (Amsterdam, NL)
15:30 - 17:00 Immunomodulation
Does immunotherapy influence the vaccination response among patients with multiple sclerosis? P 461
H.K. Olberg, R.J. Cox, J.K. Nřstbakken, J.H. Aarseth, C.H. Vedeler, K.M. Myhr (Bergen, NO)
15:30 - 17:00 Clinical assessment tools
Speed of recovery after multiple sclerosis relapses P 282
K. Kannel, H. Maamägi, K. Taalfeld, M. Toots, M. Siiro, K. Kallaste, L. Vahter, T. Saarup, K. Rohulaid, I. Zopp, A. Aaso, A. Reitsnik, U. Sorro, K. Gross-Paju (Tallinn, EE)
15:30 - 17:00 Long-term treatment monitoring
Clinical and MRI outcomes following cessation of daclizumab therapy P 524
J. Rose, M. Rojas, A. Fjeldstad, N. Carlson (Salt Lake City, US)
15:30 - 17:00 Tools for detecting therapeutic response
Multiple sclerosis and gait impairment: moving from the subjective to the objective – Measurement as markers for disease progression P 555
M. Gudesblatt, E. Lamberg, R. McKenna, M. Zarif, C. Burke, B. Bumstead, M. Buhse, L. Fafard, L. Muratori (Patchogue, Stony Brook, US)
15:30 - 17:00 Pathology
Local T-cell infiltration is associated with subpial cortical demyelination and retinal ganglion cell activation in marmosets with experimental autoimmune encephalomyelitis P 310
C. Wegner, K. Neid, M. Ton, E. Fuchs, W. Brück (Göttingen, DE)
15:30 - 17:00 Neurophysiology
Altered functional connectivity in multiple sclerosis is related to thalamus atrophy, cognition and clinical status P 427
P. Tewarie, M.M. Schoonheim, C.J. Stam, M.L. van der Meer, B.W. van Dijk, F. Barkhof, C.H. Polman, A. Hillebrand (Amsterdam, NL)
15:30 - 17:00 Databases and Pharmacoepidemiology
The “Immunomodulation and Multiple Sclerosis Epidemiology” (IMSE II) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod (Gilenya®) P 261
N. Nordin, C. Holmen, J. Hillert, T. Olsson (Stockholm, SE)
15:30 - 17:00 Clinical assessment tools
Multiple sclerosis associated retrovirus proviral load is elevated in multiple sclerosis patients P 290
M. Garcia-Montojo, M.I. Dominguez-Mozo, A. Arias-Leal, M.A. Garcia-Martinez, V. De las Heras, I. Casanova, R. Faucard, N. Gehin, A. Madeira, R. Arroyo, F. Curtin, R. Alvarez-Lafuente, H. Perron (Madrid, ES)
15:30 - 17:00 Neuro-ophthalmology
Manual and automated segmentation of retinal layers in single transfoveal OCT scans of MS patients P 600
P. Albrecht, M. Ringelstein, A.K. Müller, N. Keser, J. Harmel, H.-P. Hartung, A. Methner, O. Aktas (Düsseldorf, DE)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica in Austria in 2011: to gap the bridge between neuroepidemiological research and practice in a study population of 8.4 Million people P 218
F. Aboul-Enein, M. Reindl, M. Storch, T. Berger, W. Kristoferitsch on behalf of the ARGE NMO Austria
15:30 - 17:00 Pathology
Megalin receptor: an important player in the pathogenesis of multiple sclerosis and blood-brain barrier abnormalities P 308
M.C. Ortega, D. Clemente, F. de Castro (Toledo, ES)
15:30 - 17:00 Neuro-ophthalmology
Comparison of two retinal nerve fibre layer segmentation algorithms for the Heidelberg Spectralis P 603
L. Balk, M. Mayer, B. Uitdehaag, A. Petzold (Amsterdam, NL; Erlangen, DE)
15:30 - 17:00 Comprehensive care and rehabilitation
Multiple sclerosis: intrathecal baclofen therapy provides measurable gains beyond spasticity reduction P 577
B. Bumstead, J. Megna, M. Zarif, J. Sylvia, C. Burke, S. Thotam, C. Rosenberg, L. Fafard, M. Buhse, L. Muratori, S. Bennett, M. Gudesblatt (Patchogue, Bay Shore, Stony Brook, Buffalo, US)
15:30 - 17:00 Imaging
No evidence for dynamic neuroplastic changes in cognitively stable multiple sclerosis patients over two years of follow-up P 415
C. Enzinger, M. Loitfelder, A. Pichler, K. Koschutnig, K. Petrovic, S. Fuchs, S. Ropele, M. Jehna, C. Langkammer, A. Mader, C. Neuper, F. Fazekas (Graz, AT)
15:30 - 17:00 Immunomodulation
Effects on heart rate of three different up-titration regimens of ponesimod, a selective S1P1 receptor modulator, and of re-initiation of treatment in healthy male and female subjects P 468
P. Brossard, D. D'ambrosio, M. Ipak, J. Dingemanse (Allschwil, CH; Berlin, DE)
15:30 - 17:00 Devic’s NMO spectrum
Efficacy of rituximab or mitoxantrone in patients with Devic's disease P 214
L. Molina, D. Sanchez, H. Juarez (Mexico City, MX)
15:30 - 17:00 Clinical assessment tools
Multiple Sclerosis Severity Scale: depression, fatigue and quality of life and perceived cognitive deficit correlates P 300
M. Gudesblatt, M. Zarif, O. Gorbatsevych, B. Bumstead, M. Buhse, L. Fafard, I. Topalli, G. Doniger (Patchogue, Stony Brook, Cambridge, Bellaire, US)
15:30 - 17:00 Neuropsychology and fatigue
Improvement of MS-related fatigue also significantly improves quality of life in patients treated with natalizumab: results from the TYNERGY trial P 445
I.K. Penner, E. Gulowsen Celius, K. Schreiber, S. Fuchs, E. Falk, S. Berkö, J. Sun, A. Svenningsson (Basel, CH; Oslo, NO; Copenhagen, DK; Graz, AT; Stockholm, SE; Weston, US; Umeĺ, SE)
15:30 - 17:00 MS symptoms
The burden of multiple sclerosis-related spasticity on indirect costs and requirement for non-professional care: results of a cross-sectional study in the USA P 263
R. Schapiro, D. Wynn, D. Lissin, A. AL-Sabbagh, E. Jones, J. Pike (Eagle, Northbrook, Santa Clara, US; Macclesfield, GB)
15:30 - 17:00 Neuropsychology and fatigue
Speed of presentation affects recall of medication and disease information in relapsing-remitting multiple sclerosis P 447
S. LLoyd, E. Silber, D. Langdon (London, GB)
15:30 - 17:00 Tools for detecting therapeutic response
Relation of disease activity-free status to visual function in the AFFIRM trial P 557
L.J. Balcer, S.L. Galetta, A. Zhang, R. Arnold (Philadelphia, Weston, US)
15:30 - 17:00 Imaging
Warmer outdoor temperature is associated with decreased cognitive efficiency in multiple sclerosis P 389
V. Leavitt, J. Sumowski, G. Wylie, N. Chiaravalloti, J. DeLuca (West Orange, US)
15:30 - 17:00 Imaging
Local functional connectivity is decreased across multiple cortical areas in multiple sclerosis P 384
E. Klawiter, S. Tobyne, S. Govindarajan, J. Sepulcre, E. Tinelli, R. Buckner, R.P. Kinkel, B. Rosen, C. Mainero (Boston, US; Rome, IT)
15:30 - 17:00 MS symptoms
Onset of multiple sclerosis-related spasticity and its impact on health-related quality of life as measured by EQ-5D and HAQUAMS P 264
D. Wynn, R. Schapiro, A. AL-Sabbagh, D. Lissin, E. Jones, J. Pike (Northbrook, Eagle, Santa Clara, US; Macclesfield, GB)
15:30 - 17:00 Environmental risk factors
Epstein-Barr virus shedding in children with multiple sclerosis P 374
C. Yea, C. Darrell, S. McGovern, S. Khan, M. McGowan, J. Pinto, S. McCorrister, G. Westmacott, D. Arnold, D. Sadovnick, R. Tellier, A. Bar-Or, B. Banwell on behalf of The Canadian Demyelinating Disease Network
15:30 - 17:00 MS and infections
An open-label observational pilot study to evaluate the safety and immunogenicity of the herpes zoster vaccine in patients with multiple sclerosis P 367
C. McGraw, M. Inglese, C. Hannigan, M. Petracca, A. Miller (New York, US)
15:30 - 17:00 Economic burden
Impact of the frequency of multiple sclerosis relapses on the direct and indirect cost burden of family caregivers P 303
H. Parisé, F. Laliberté, P. Lefebvre, M.S. Duh, E. Kim, N. Agashivala, S. Abouzaid, B. Weinstock-Guttman (Montréal, CA; Boston, East Hanover, Buffalo, US)
15:30 - 17:00 Biomarkers
BG-12 pharmacodynamic responses have distinct temporal profiles and are dose dependent P 615
M.N. Shackett, H. Patel, M.Y. Jung, S. Ryan, M. Lukashev, P. Bista, K.J. Rhodes, R.H. Scannevin (Weston, US)
15:30 - 17:00 Quality of life
The psychosocial impact of MS patients and their caregivers in the Turkish population P 592
D. Yandim Kuscu, G. Yilmaz Canturk, S. Tumen Oner, U. Dural Senoguz, B. Topcular, M.K. Kuscu (Istanbul, TR)
15:30 - 17:00 Clinical assessment tools
Taking therapeutic decisions in interferon-treated patients with multiple sclerosis: an evidence-based analysis based on clinical and magnetic resonance imaging activity P 293
M.P. Sormani, F. Baldinetti, P. Cornelisse, B. Stubinski, N. De Stefano (Genoa, IT; Geneva, CH; Siena, IT)
15:30 - 17:00 Immunomodulation
Clinical response to glatiramer acetate correlates with an increase in activated and memory CD45RA-Foxp3+CD4+ T-cells P 492
S. Dhib-Jalbut, S. Boppana, R. Valenzuela, O. Khan, K. Ito (New Brunswick, Detroit, US)
15:30 - 17:00 Risk management for disease modifying treatments
Asymptomatic non-tuberculous mycobacteriosis as an opportunistic infection in a subject treated with natalizumab for relapsing-remitting multiple sclerosis – case report P 535
P. Hradilek, I. Tudik, O. Zapletalova, I. Woznicova, D. Zeman (Ostrava, Jablunkov, CZ)
15:30 - 17:00 Pregnancy and MS
Post-marketing pregnancy outcomes in patients exposed to intramuscular interferon-beta-1a P 274
S. Tomczyk, B. Sperling (Weston, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Impaired cerebrovascular reactivity in multiple sclerosis measured with hypercapnia perfusion magnetic resonance imaging P 179
Y. Ge, Y. Zhou, H. Lu, F. Xu, I. Kister, H. Jaggi, J. Herbert, R. Grossman (New York City, Dallas, US)
15:30 - 17:00 Immunomodulation
Peripheral blood mononuclear cell phenotypes under treatment with fingolimod: a prospective study of a German cohort of patients with relapsing-remitting multiple sclerosis P 475
T. Dehmel, B. Opgenoorth, H.-P. Hartung, M. Diaz-Lorente, B.C. Kieseier (Düsseldorf, DE)
15:30 - 17:00 Neuropsychology and fatigue
Low-contrast visual acuity and near visual acuity is associated with cognitive and physical performance in relapsing-remitting and secondary-progressive multiple sclerosis P 434
T. Feaster (Wayne, US)
15:30 - 17:00 Immunomodulation
Endoglycosidase S converts neuromyelitis optica anti-aquaporin-4 immunoglobulin G from a pathogenic to a therapeutic antibody P 454
L. Tradtrantip, J. Ratelade, H. Zhang, A.S. Verkman (San Francisco, US)
15:30 - 17:00 MS and infections
Acute disseminated encephalomyelitis in two renal transplant patients: is there a role for EBV reactivation? P 368
N. Caucheteux, A. Maarouf, L. Daelman, O. Toupance, S. Lavaud, A. Tourbah (Reims, FR)
15:30 - 17:00 Adaptative and Innate immunology
Multiple sclerosis: high-throughput T-cell receptor sequencing reveals clonal expansions of Epstein-Barr virus specific T-cells in the cerebrospinal fluid P 347
A. Lossius, J. Johansen, F. Vartdal, H. Robins, T. Holmřy, J. Olweus (Oslo, NO; Seattle, US; Lřrenskog, NO)
15:30 - 17:00 Experimental models
Tertiary lymphoid organ development facilitates determinant spreading of the MP4-specific T-cell response P 335
S. Kuerten, C. Kerkloh, A. Schickel, K. Addicks, G. Fink, M. Schroeter, C. Kaiser (Cologne, DE)
15:30 - 17:00 Immunomodulation
Effect of daclizumab HYP treatment in highly active relapsing-remitting multiple sclerosis: results from the SELECT study P 463
G. Giovannoni, E.W. Radue, E. Havrdova, K. Riester, S. Greenberg, S. Glyman, J. Elkins (London, GB; Basel, CH; Prague, CZ; Cambridge, Redwood City, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Prediction of early conversion to multiple sclerosis in clinically isolated syndrome P 186
B. Piri Cinar, S. Ozakbas, E. Idiman (Izmir, TR)
15:30 - 17:00 Adaptative and Innate immunology
Auto-antibody biomarkers in childhood-acquired demyelinating syndromes: results from a national surveillance cohort P 355
Y. Hacohen, M. Absoud, L. Jacobson, M. Woodhall, P. Waters, W.K. Chong, C. Cummins, C. De Goede, K. Foster, R. Gunny, C. Hemingway, P.E. Jardine, R. Kneen, M. Likeman, K. Nischal, M.G. Pike, N. Sibtain, W. Whitehouse, E. Wassmer, A. Vincent, M. Lim on behalf of the UK & Ireland Childhood CNS Inflammatory Demyelination Working Group
15:30 - 17:00 MS symptoms
Gabapentin for spasticity in multiple sclerosis – lack of efficacy data using the Wartenburg’s Pendulum test P 267
B. Waddell, K. Grieve, P. Walker, J. O'Riordan (Dundee, GB)
15:30 - 17:00 Neuro-ophthalmology
Optical nerve diameter and echogenicity are impaired in demyelinating diseases P 601
J. Fernández-Domínguez, R. García-Rodríguez, V. Mateos (Latores Oviedo, ES)
15:30 - 17:00 Tools for detecting therapeutic response
The use of in vivo 1H - magnetic resonance spectroscopy for evaluating the efficacy of treatment of patients with relapsing-remitting multiple sclerosis with copaxone (glatiramer acetate) P 548
Z. Rozhkova, T. Kobys, O. Myalovitska, I. Lobanova (Kiev, UA)
15:30 - 17:00 Neuropsychology and fatigue
Long-term effects of cognitive rehabilitation in multiple sclerosis: 12-month follow-up P 440
A. Altinkaya, I. Guclu, E. Kurt, A. Bingol, A. Soysal, D. Yandim-Kuscu, D. Kirbas, B. Topcular (Istanbul, TR)
15:30 - 17:00 Risk management for disease modifying treatments
Fingolimod treatment initiation experience: cardiac and Holter electrocardiogram findings from three phase 3 studies P 530
J.P. DiMarco, P. O'Connor, J.A. Cohen, A.T. Reder, L. Zhang-Auberson, D. Tang, W. Collins, L. Kappos (Charlottesville, US; Toronto, CA; Cleveland, Chicago, US; Basel, CH; East Hanover, US)
15:30 - 17:00 Devic’s NMO spectrum
Autologous haematopoietic stem cell transplantation following high-dose immunosuppressive therapy in neuromyelitis optica P 201
J.D. Bowen, H. Hagglund, G.H. Kraft, A. Wundes, F. Piehl, R. Storb, G.E. Georges, K. Maravilla, R.A. Nash (Seattle, US; Stockholm, SE; Denver, US)
15:30 - 17:00 Long-term treatment monitoring
Phase III FREEDOMS study extension: long-term safety of fingolimod (FTY720) in relapsing-remitting multiple sclerosis P 523
P. O'Connor, C. Polman, R. Hohlfeld, K. Selmaj, T. Olsson, C. Agoropoulou, F. Holdbrook, L. Zhang-Auberson, P. von Rosenstiel, L. Kappos (Toronto, CA; Amsterdam, NL; Munich, DE; Lodz, PL; Stockholm, SE; Basel, CH)
15:30 - 17:00 Imaging
MR molecular Imaging of VCAM-1 in EAE mice treated by statin: a new perspective for diagnosis and therapeutic management P 422
R. Macrez, M. Gauberti, A. Montagne, D. Vivien, F. Docagne, G. Defer (Caen, FR)
15:30 - 17:00 Long-term treatment monitoring
Oral laquinimod in patients with relapsing-remitting multiple sclerosis: clinical effects at 36 months in the open-label extension phase of the ALLEGRO study P 516
G. Comi, D. Jeffery, L. Kappos, X. Montalban, A.N. Boyko, M.A. Rocca, M. Filippi on behalf of the ALLEGRO Study Group
15:30 - 17:00 Immunomodulation
The response to Toll-like receptor stimulation is impaired in plasmacytoid dendritic cells of multiple sclerosis patients undergoing interferon-b therapy P 479
M. Severa, F. Rizzo, E. Giacomini, R. Mechelli, V. Gafa, D. Vittori, G. Coarelli, M. Salvetti, E.M. Coccia (Rome, IT; Reims, FR)
15:30 - 17:00 Environmental risk factors
Low prevalence of cerebrospinal fluid oligoclonal IgG bands in Greek patients with multiple sclerosis P 376
E. Andreadou, S. Chatzipanagiotou, V.C. Constantinides, C. Kyriazi, A. Tsatsi, M.E. Evangelopoulos, M. Michalopoulou, F. Boufidou, C. Kilidireas, A. Rombos, C. Nicolaou, E. Stamboulis (Athens, GR)
15:30 - 17:00 Neuropsychology and fatigue
Detecting cognitive dysfunction in patients with multiple sclerosis: assessing the validity of a computerized battery P 431
H. Lapshin, P. O'Connor, K.L. Lanctôt, A. Feinstein (Toronto, CA)
15:30 - 17:00 Epidemiology
Polyautoimmunity in multiple sclerosis P 248
E. Koutlas, G. Deretzi, J. Rudolf, T. Tsironis, C. Zakestidis, P. Petrou, I. Tsiptsios (Thessaloniki, GR)
15:30 - 17:00 Paediatric MS
Report of 25 paediatric multiple sclerosis cases P 224
M. Alhyan, K. El Alaoui Taoussi, E.H. Ait Ben Haddou, W. Regragui, W. Ahid, R. Abouqal, A. Benomar, M. Yahyaoui (Rabat, MA)
15:30 - 17:00 Neuro-ophthalmology
Cholesterol affects retinal nerve fibre layer thickness in MS patients with optic neuritis P 598
A. Kardys, B. Weinstock-Guttman, M. Dillon, M. Masud, N. Weinstock, N. Mahfooz, J. Lang, A. Weinstock, N. Lincoff, R. Zivadinov, M. Ramanathan (Buffalo, US)
15:30 - 17:00 Long-term treatment monitoring
Adherence to disease-modifying treatments in Turkish cohort P 514
S. Yildiz, U. Uygunoglu, A. Bingol, E. Goksel, I. Aydin Canturk, N. Isik, N. Sutlas, D. Yandim Kuscu, B. Kocer, A. Kurne, B. Topcular, G. Demir Akman, O. Anlar, H. Efendi, A. Altintas, S. Saip, R. Karabudak, A. Siva (Istanbul, Ankara, Kocaeli, TR)
15:30 - 17:00 Clinical assessment tools
Detection and quantification of efficiency and quality of gait impairment in multiple sclerosis through foot path analysis P 295
R. Phan-Ba, S. Pierard, G. Moonen, M. Vandroogenbroeck, S. Belachew (Ličge, BE)
15:30 - 17:00 Epidemiology
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review P 252
E. Cristiano, J. Rojas, M. Romano, N. Frider, G. Machnicki, D. Callegaro, T. Corona, J. Flores, F. Gracia, M. Macias, D. Giunta, J. Correale (Buenos Aires, AR; Sao Paulo, BR; Mexico, MX; Panama, PA; Guadalajara, MX)
15:30 - 17:00 Neuro-ophthalmology
NMO, CRION or MS: what we say when we have recurrent optic neuritis P 604
A.B. Falcăo, D.B. Bichuetti, E.M.L. Oliveira, A.A. Gabbai (Săo Paulo, BR)
15:30 - 17:00 Quality of life
Unmet needs of adults with multiple sclerosis living in the northwest United States P 587
K. Johnson, D. Amtmann, A. Verrall, V. Weir (Seattle, US)
15:30 - 17:00 Biology of recovery
BLBP-expression in astrocytes is an important variable for endogenous remyelination P 381
M. Kipp, R. Bazinet, G. Eckert, S. Gingele (Aachen, DE; Toronto, CA; Frankfurt, DE)
15:30 - 17:00 Clinical assessment tools
The CogState Brief Battery (CBB): clinical advantages in detecting early cognitive impairment in patients with multiple sclerosis (preliminary data) P 289
L. de Meijer, E. Grobbee, D. Darby, J. Gale, P. Maruff, L. Kurczycki, J. Haartsen, H. Butzkueven, O. Skibina (Melbourne, AU)
15:30 - 17:00 Immunomodulation
Natalizumab (Tysabri) treatment outcome in terms of safety and efficacy in older patients and/or with longer disease duration – a Swedish nationwide long-term follow-up P 486
H. Matell, O. Sveinsson, C. Holmén, J. Hillert, T. Olsson, F. Piehl (Stockholm, SE)
15:30 - 17:00 Imaging
Early diffuse brain tissue injury predicts disability ten years later in RRMS patients P 423
A. Ruet, M. Deloire, J.C. Ouallet, V. Dousset, B. Brochet (Bordeaux, FR)
15:30 - 17:00 Neuropsychology and fatigue
Anxiety and depression in MS: short-term evolution and relationship with cognitive and clinical variables P 448
T. Olivares, Y. Pérez, M. Betancort, A. Nieto, J. Barroso, M. González-Platas, M.A. Hernández (La Laguna, ES)
15:30 - 17:00 Immunomodulation
Plasma exchange in acute central nervous system inflammatory demyelinating diseases P 495
J. Chateauraynaud, M. Deloire, A. Ruet, B. Brochet, J.C. Ouallet (Bordeaux, FR)
15:30 - 17:00 Epidemiology
Significant increase in prevalence of multiple sclerosis in Iran, review of literatures and report of new rates P 246
S. Izadi, A. Nikseresht, M. Sharifian Dorche, A. Rezaianzadeh (Shiraz, IR)
15:30 - 17:00 Comprehensive care and rehabilitation
Cerebellar-parietal dysfunctions in multiple sclerosis patients with cerebellar signs P 580
G. Mangone, A. Cerasa, P. Valentino, R. Nisticň, D. Pirritano, M.C. Gioia, C. Chiriaco, P. Perrotta, V. Vaiti, M. Trotta, T. Talarico, G. Bilotti, A. Quattrone (Catanzaro, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
The comparison of McDonald 2005, McDonald 2010 and Swanton criteria for prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis P 187
B. Piri Cinar, S. Ozakbas (Izmir, TR)
15:30 - 17:00 Comprehensive care and rehabilitation
ALLIANCE: evaluation of interruption to care in multiple sclerosis P 581
C. Donzé, L. Malapel, A. Kwiatkowski, B. Lenne, P. Louchard, V. Neuville, P. Hautecoeur (Lomme, Lille, Dunkerque, Maubeuge, FR)
15:30 - 17:00 Long-term treatment monitoring
Baseline predictors of mortality in patients with relapsing–remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study P 521
P. Cornelisse, L. Lehr, F. Baldinetti (Geneva, CH)
15:30 - 17:00 Imaging
Longitudinal absolute metabolite quantification and reproducibility in healthy controls and MS patients using CSI P 390
O.T. Wiebenga, A.M. Klauser, G.J.A. Nagtegaal, C.H. Polman, F. Barkhof, J.J.G. Geurts, P.J.W. Pouwels (Amsterdam, NL)
15:30 - 17:00 Neuro-ophthalmology
Bedside tested ocular movement disorders in multiple sclerosis patients P 597
G. Servillo, S. Bastide, D. Renard, P. Labauge, M. Zorzon, G. Castelnovo (Trieste, IT; Nimes, Montpellier, FR)
15:30 - 17:00 Long-term treatment monitoring
Study design and first interim results of a registry study to establish long-term safety and pharmaco-economic data on fingolimod (Gilenya®) in multiple sclerosis patients in Germany (PANGAEA) P 522
T. Ziemssen, M. Meergans, P. Vollmar, R. Kempcke, F. Tracik, T. van Lokven (Dresden, Nuremberg, DE)
15:30 - 17:00 Diagnosis and differential diagnosis
MRI parameters of cortical pathology identify patients at high risk of conversion to MS and increase the specificity of the new diagnostic criteria P 181
M. Calabrese, C. Romualdi, V. Poretto, D. Seppi, A. Favaretto, M. Puthenparampil, S. Alessio, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Biomarkers
Antiphospholipid antibodies in multiple sclerosis: a pathogenetic or epiphenomenal role? P 612
T. Koudriavtseva, P. Cordiali-Fei, G. D'Agosto, E. Onesti, E. Sbardella, E. Trento, F. Ensoli (Rome, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
Study of cerebrospinal fluid in neuromyelitis optica. Analysis and correlation with multiple sclerosis in a series of cases of Rio de Janeiro, Brazil P 192
V. Carvalho Neri, C.O. Brandao, M. Papais Alvarenga, C. Cristina Ferreira Vasconcelos, S. Camargo, E. Baptista, R.M. Papais Alvarenga (Rio de Janeiro, BR)
15:30 - 17:00 Grey matter damage in MS
Does white matter damage predict later grey matter changes in early primary-progressive MS? P 313
B. Bodini, D. Chard, D. Altmann, D. Tozer, D.H. Miller, A.J. Thompson, C. Wheeler-Kingshott, O. Ciccarelli (London, GB)
15:30 - 17:00 Long-term treatment monitoring
How do multiple sclerosis patients in the NARCOMS registry navigate their treatment options beyond first-line therapies? P 525
A. Salter, T. Tyry, S. Cofield, N. Agashivala, S. Ryu, R.A. Marrie, R. Fox, G. Cutter (Birmingham, Phoenix, East Hanover, US; Winnipeg, CA; Cleveland, US)
15:30 - 17:00 Adaptative and Innate immunology
Antibodies against native myelin oligodendrocyte glycoprotein in adult multiple sclerosis patients P 354
N. Sanderson, M. Ricklin, C. Pfaff, Y. Naegelin, P. de Jager, T. Sprenger, J. Kuhle, K. Dornmair, R.L.P. Lindberg, L. Kappos, T. Derfuss (Basel, CH; Boston, US; London, GB; Munich, DE)
15:30 - 17:00 Epidemiology
Patient reports of unmet needs in multiple sclerosis P 250
M. Ponzio, S. Traversa, V. Berio, M. Messmer Uccelli, M.A. Battaglia (Genoa, Siena, IT)
15:30 - 17:00 Quality of life
The impact of increasing disability on quality of life in multiple sclerosis P 584
E. Fogarty, C. Walsh, C. McGuigan, M. Barry, N. Tubridy (Dublin, IE)
15:30 - 17:00 Databases and Pharmacoepidemiology
Fingolimod (Gilenya®) compassionate use in patients with relapsing-remitting multiple sclerosis in France in 2011 - Population description P 259
K. Rerat, C. Gerbeau, F. Heintzmann, I. Bourdeix, M.-S. Behier on behalf of the fingolimod ATU GROUP FRANCE
15:30 - 17:00 Comprehensive care and rehabilitation
Improved autonomy and self-efficacy in people with multiple sclerosis after Can Do Training with Partners P 573
P. Jongen, R. Ruimschotel, M. Heerings, L. Duyverman, L. Visser, J. Vissers, H. Wolper, A. Hussaarts, M. van Droffelaar, G. Borm, A. Van der Zande (Nijmegen, Rotterdam, Maassluis, Tilburg, NL)
15:30 - 17:00 Biomarkers
Decreased circulating miRNAs in patients with multiple sclerosis P 614
C. Fenoglio, E. Ridolfi, C. Cantoni, M. De Riz, A. Pietroboni, M. Serpente, C. Villa, R. Bonsi, N. Bresolin, L. Piccio, A.H. Cross, D. Galimberti, E. Scarpini (Milan, IT; St. Louis, US)
15:30 - 17:00 Epidemiology
Relationship between body mass index and disease severity in an online multiple sclerosis population P 241
R. Bove, E. Secor, T. Vaughan, T. Chitnis, P. Wicks, P. De Jager (Boston, Cambridge, US)
15:30 - 17:00 Grey matter damage in MS
The grey matter basis of disability progression in multiple sclerosis P 319
M. Calabrese, V. Poretto, A. Favaretto, D. Seppi, S. Alessio, F. Rinaldi, P. Perini, P. Gallo (Padua, IT)
15:30 - 17:00 Comprehensive care and rehabilitation
Effects of 24 weeks progressive resistance training in comparison to core and stability training performed in groups on muscle performance, balance and spasticity in people with multiple sclerosis P 578
C. Jolk, R. Alcantara, L. Bernhardt, P. Platen, M. Marziniak, K. Weßling (Münster, Bochum, DE)
15:30 - 17:00 Immunomodulation
Interferon-beta induces hepatocyte growth factor in monocytes of multiple sclerosis patients P 469
N. Molnarfi, M. Benkhoucha, K. Bjarnadóttir, C. Juillard, P.H. Lalive (Geneva, CH)
15:30 - 17:00 Comprehensive care and rehabilitation
Preventive health care access in women with severe neurologic disability P 576
K. Dobos, B. Healy, M. Houtchens (Boston, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Are the clinically isolated syndrome days over? P 189
B. Canneti, I. Palmí, V. Meca Lallana, J. Vivancos (Madrid, ES)
15:30 - 17:00 Adaptative and Innate immunology
Epstein-Barr virus (EBV)-specific antibodies in multiple sclerosis patients, including targeted investigation of a candidate EBV nuclear antigen-1 (EBNA-1) B cell epitope P 349
K. Strautins, M. Tschochner, C. Berry, D. Nolan (Perth, AU)
15:30 - 17:00 Neuropsychology and fatigue
Multivariate analysis of clinical, behavioural and psychological influences on fatigue and cognition in patients with relapsing-remitting multiple sclerosis P 436
H. Schreiber, C. Lang, K. Kiltz, M. Lang, P. Flachenecker, H. Meissner, M. Freidel, H. Herbst, E. Scholz, W. Hofmann, E. Schlegel, W. Elias, K. Gehring, U. Eckhardt, A. Bergmann, G. Reifschneider, S. Ries, C. Ring, S. Schlegel on behalf of the NTD Study Group on Multiple Sclerosis
15:30 - 17:00 Long-term treatment monitoring
The switch from interferon-beta to natalizumab treatment is more effective in patients with relapsing forms of multiple sclerosis when administered early during the disease course P 515
A. Lourbopoulos, V. Giantzi, E. Chatzikyriakou, E. Liaptsi, N. Tascos, N. Grigoriadis (Thessaloniki, GR)
15:30 - 17:00 Biomarkers
The effects of intrathecal rituximab on biomarkers in MS P 617
J. Topping, E. Evdoshenko, R. Dobson, S. Lapin, A. Maslyanskiy, G. Giovannoni (London, GB; Saint-Petersburg, RU)
15:30 - 17:00 Quality of life
Health-related quality of life in elderly patients with MS P 590
M.B. Buhse, W.B. Banker, L.C. Clement (Stony Brook, Honeoye Falls, US)
15:30 - 17:00 Biomarkers
Extracellular Actin Scavenger system as a diagnostic/prognosis tool in multiple sclerosis P 613
S. Perga, A. Giuliano Albo, K. Lis, N. Minari, R. Reviglione, F. Marnetto, F. Gilli, M. Malentacchi, M. Capobianco, D. Corpillo, A. Bertolotto (Orbassano, Colleretto Giacosa, IT)
15:30 - 17:00 Immunomodulation
Siponimod (BAF312) treatment leads to early MRI benefits in relapsing-remitting multiple sclerosis patients: results from a phase 2 study P 494
D.K.B. Li, B. Hemmer, O. Stüve, H.-P. Hartung, M.S. Freedman, P. Rieckmann, X. Montalban, L. Zhang-Auberson, H. Pohlmann, E. Wallström, K. Selmaj, L. Kappos (Vancouver, CA; Munich, DE; Dallas, US; Düsseldorf, DE; Ottawa, CA; Bamberg, DE; Barcelona, ES; Basel, CH; Lodz, PL)
15:30 - 17:00 Epidemiology
Developing a tool-kit for measurement of risk factors and prospective harmonisation of paediatric MS case-control studies P 242
S. Magalhaes, I. Fortier, B. Banwell, A. Bar-Or, H. Hanwell, M. Pugliatti, C. Wolfson (Montreal, Toronto, CA; Sassari, IT)
15:30 - 17:00 Paediatric MS
Safety of adult doses of subcutaneous interferon-beta-1a in children and adolescents with multiple sclerosis: results of the REPLAY study P 220
A. Ghezzi, D. Pohl, B. Banwell, L.B. Krupp, A. Boyko, M. Meinel, L. Lehr, M. Stam Moraga, S. Tenembaum on behalf of the REPLAY Study Group
15:30 - 17:00 Tools for detecting therapeutic response
Cerebrospinal fluid biomarkers as outcome measures in clinical trials of MS: The significance of post lumbar puncture headaches P 550
A. Davis, R. Dobson, M. Espasandin, G. Giovannoni, K. Schmierer (London, GB)
15:30 - 17:00 Risk management for disease modifying treatments
Efficacy analysis of disease-modifying treatments in more than 9000 German patients with MS P 544
M. Mäurer, P. Knorn, G. Niemczyk, P. Schickmaier, K. Rehberg-Weber, C. Wernsdörfer, S. Schwab for the TYPIC Study
15:30 - 17:00 Risk management for disease modifying treatments
JCV antibodies seroconversion on natalizumab treatment and predictive factors: preliminary data P 539
R. Lanzillo, R. Liuzzi, A. Guacci, L. Amato, L. Vallefuoco, G. Vacca, G. Orefice, G. Portella, V. Brescia Morra (Naples, IT)
15:30 - 17:00 Genetics / transcriptomics
Association of genetic markers with the presence of cerebrospinal fluid oligoclonal bands in the Italian population P 342
N. Barrizzone, M.A. Leone, F. Esposito, A. Lucenti, H.F. Harbo, A. Goris, I. Kockum, A.B. Oturai, E.G. Celius, I.L. Mero, B. Dubois, T. Olsson, H.B. Sřndergaard, D. Cusi, S. Lupoli, F. Guerini, D. Galimberti, M. Salvetti, G. Liberatore, V. Martinelli, P. Naldi, K.-M. Myhr, R. Bergamaschi, G. Comi, F. Martinelli Boneschi, S. D'Alfonso (Novara, Milan, IT; Oslo, NO; Leuven, BE; Stockholm, SE; Copenhagen, DK; Rome, IT; Bergen, NO; Pavia, IT)
15:30 - 17:00 Treatment of specific symptoms
PR-fampridine and improvement of walking: it’s clinically meaningful in daily practice P 572
M. Prugger, T. Berger (Innsbruck, AT)
15:30 - 17:00 Diagnosis and differential diagnosis
Comparison of McDonald 2005 and 2010 criteria in a cohort of clinically isolated syndrome patients P 183
A. Enderle, H. Zephir, J. Salleron, O. Outteryck, A.S. Berteloot, M. Giroux, P. Vermersch (Lille, FR)
15:30 - 17:00 Immunomodulation
Efficacy, safety and tolerability of Atorvastatin in patients with Relapsing-remitting multiple sclerosis in treAtment with INterferoN-betA (ARIANNA): a multicentre, randomised, double-blind, placebo-controlled, parallel-group-study P 477
V. Brescia Morra, B. Alfano, R. Lanzillo, M. Quarantelli, M. Comerci, S. Marini, G. Vacca, M.P. Amato, M. Trojano, A. Brunetti, C. Pozzilli (Naples, Rome, Florence, Bari, IT)
15:30 - 17:00 Immunosuppression
Rituximab in secondary-progressive MS: a two-year retrospective analysis P 499
C. Ionete, C. Perrone, B. Barton, M. Diiulio, P. Riskind (Worcester, US)
15:30 - 17:00 Risk management for disease modifying treatments
Utilization of JC-virus antibody testing in clinical practice P 546
T. Berger on behalf of CETAB (Central European Tysabri Advisory Board)
15:30 - 17:00 Clinical assessment tools
Quick screening of cognitive function in MS patients using 5 min Montreal cognitive assessment subtests: a pilot study P 284
G. Kumar, D. Kaur, A.K. Singh (New Delhi, Patna, IN)
15:30 - 17:00 Epidemiology
The epidemiology of MS in Iceland, 1900 – 2000 P 251
S. Sveinbjornsdottir, H. Magnusson, J. Benedikz (Chelmsford, GB; Oslo, NO; Reykjavik, IS)
15:30 - 17:00 Treatment of specific symptoms
Effectiveness of Sativex® in multiple sclerosis spasticity. First data from a large observational study in Germany P 568
U. Zettl, T. Henze, C. Pfiffner, C. Vila Silvan, P. Flachenecker (Rostock, Nittenau, Munich, DE; Barcelona, ES; Bad Wildbad, DE)
15:30 - 17:00 Neuro-ophthalmology
Uveitis in patients with multiple sclerosis P 595
E. Shugaiv, M. Kurtuncu, M. Mutlu, G. Akman-Demir, I. Tugal-Tutkun, E. Tuzun, M. Eraksoy (Istanbul, TR)
15:30 - 17:00 Natural history
Does multiple sclerosis in Korea differ from that in the Caucasian populations? P 232
S.-H. Kim, W. Kim, S.-Y. Huh, S.J. Lee, A.-R. Joung, H. J. Kim (Goyangsi, KR)
15:30 - 17:00 Risk management for disease modifying treatments
Immunomodulatory treatment of relapsing-remitting multiple sclerosis – the ASSET (AVONEX Assessment in Multiple Sclerosis-Therapy)-study, an observational study in 1343 patients P 547
M. Marziniak, T. Graf, G. Niemczyk, K. Rehberg-Weber, C. Wernsdörfer for the ASSET Study Group
15:30 - 17:00 Devic’s NMO spectrum
The characteristics of Sjögren’s syndrome in patients with anti-aquaporin4-antibody positive neuromyelitis optica spectrum disorder P 210
D.K. Lee, J.H. Min, B.J. Kim, M.S. Park, S.J. Lee, J.H. Park, K.H. Lee (Seoul, KR)
15:30 - 17:00 Natural history
Male MS patients fare worse! P 230
K.A. Ribbons, P. McElduff, S. Vetere, C. Boz, M. Trojano, C. Zwanikken, A. Lugaresi, G. Izquierdo, P. Duquette, M. Girard, F. Grand'Maison, P. Grammond, C. Oreja-Guevara, R. Hupperts, T. Petersen, R. Bergamaschi, G. Guiliani, M. Barnett, V. Van Pesch, M.P. Amato, G. Iuliano, M. Fiol, M. Slee, F. Verheul, E. Cristiano, R. Fernandez-Bolanos, M.L. Saladino, M.E. Rio, W. Oleschko Arruda, J. Cabrera-Gomez, M. Paine, N. Vella, C. Shaw, F. Moore, S. Vucic, T. Petkovska-Boskova, H. Butzkueven, J.S. Lechner-Scott on behalf of the MS Base Group
15:30 - 17:00 Imaging
Multi-component relaxation reveals distinct patterns of white matter involvement in primary progressive multiple sclerosis and primary lateral sclerosis P 421
S. Kolind, A. Seddigh, N. Sibtain, S. Deoni, G.J. Barker, A. Traboulsee, S.C.R. Williams, M.R. Turner, P.A. Brex (Vancouver, CA; London, GB; Providence, US; Oxford, GB)
15:30 - 17:00 Imaging
Increased microglial activation in the brain of secondary progressive multiple sclerosis patients - a [11C]PK11195 PET study P 424
E. Rissanen, J. Tuisku, T. Paavilainen, S. Helin, R. Parkkola, J.O. Rinne, L. Airas (Turku, FI)
15:30 - 17:00 Adaptative and Innate immunology
The CD11b+ B1-cell subpopulation is diminished in relapsing-remitting multiple sclerosis patients P 357
C. Třrring, T. Petersen, P. Höllsberg (Arhus, DK)
15:30 - 17:00 Quality of life
Is it different what multiple sclerosis patients and their caregivers perceive as unmet needs? P 593
L. Lorefice, E. Cocco, G. Mura, G. Fenu, J. Frau, G. Coghe, G. Coni, C. Sardu, M.G. Marrosu (Cagliari, IT)
15:30 - 17:00 MS symptoms
Association of MS relapse symptoms with changes in cognition, fatigue, and work and usual activities P 271
H. Zwibel, B. Cohen, M. Tullman, T. Leist, P.K. Coyle, M. Lage on behalf of the TOP MS Study Steering Committee
15:30 - 17:00 Neuroprotection
Natalizumab improves MRI markers suggestive of irreversible tissue damage in RRMS P 513
C. Oreja-Guevara, A. Royo, S. Noval, L. Rodriguez de Antonio, B. Chamorro, J. Moreno, E. Diez-Tejedor, J. Alvarez-Linera (Madrid, ES)
15:30 - 17:00 Epidemiology
The low prevalence of multiple sclerosis in Maori is not responsible for the latitude gradient in New Zealand P 245
S. Alla, J. Pearson, G. Clarke, B. Taylor, D. Mason (Christchurch, NZ; Tasmania, AU)
15:30 - 17:00 Biology of recovery
Complement C3 in neural stem cell development P 382
Y. Song, J. Zhong, L. Weiner (Los Angeles, US)
15:30 - 17:00 Imaging
Spinal cord metabolic changes at onset of a relapse in relapsing-remitting multiple sclerosis P 395
K. Abdel-Aziz, B. Solanky, M.C. Yiannakas, C.A.M. Wheeler-Kingshott, A.J. Thompson, O. Ciccarelli (London, GB)
15:30 - 17:00 Risk management for disease modifying treatments
Cellular response to JC virus: a longitudinal study in a population of natalizumab-treated multiple sclerosis patients P 540
S. Masera, C. Costa, F. Dematteis, G. Superti, A. Romagnolo, A. Mattioda, L. Pinessi, L. Lopiano, R. Cavallo, P. Cavalla (Turin, IT)
15:30 - 17:00 Pregnancy and MS
Gene expression in the spinal cord in MBP-EAE in pregnant and post-partum rats: implications for the effects of MS in pregnancy P 277
H. Inglis, J. Greer, P. McCombe (Brisbane, AU)
15:30 - 17:00 Treatment of specific symptoms
FTY720 attenuates experimental neuropathic pain through mechanisms independent of its immunosuppressive properties P 563
J. Zhang, J.P. Zhou, X.Q. Shi, Y.C. Wu, H. Huang, S.H. Lee, J. Antel (Montreal, CA)
15:30 - 17:00 Grey matter damage in MS
Classification by location of cortical grey matter lesions studied using phase sensitive inversion recovery P 314
V Sethi, T. Yousry, N. Muhlert, M. Ron, X. Golay, C. Wheeler-Kingshott, D. Miller, D. Chard (London, GB)
15:30 - 17:00 Pregnancy and MS
Preliminary evaluation of pregnancy outcomes from the TYSABRI® (natalizumab) Pregnancy Exposure Registry P 275
L.M. Cristiano, C. Bozic, G. Bloomgren, S. Friend, Y.-J. Liu (Weston, US)
15:30 - 17:00 Immunomodulation
Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor agonist, in healthy adult volunteers P 457
J. Hartung, R. Peach, M. Boehm, H. Rosen, H. Smith, C. Pan, J. Brooks, G. Timony, S. Gujrathi (San Diego, US)
15:30 - 17:00 Epidemiology
A new method to identify multiple sclerosis patients with a high risk for secondary progression P 254
H. Tedeholm, B. Skoog, B. Runmarker, A. Oden, O. Andersen (Gothenburg, SE)
15:30 - 17:00 Diagnosis and differential diagnosis
Diagnostic uncertainty during the transition to secondary progressive multiple sclerosis P 178
I. Katz Sand, S. Krieger, C. Farrell, A. Miller (New York, US)
15:30 - 17:00 Neuropsychology and fatigue
Brief International Cognitive Assessment for MS (BICAMS): reliability and identifying statistically reliable change P 433
R.H.B. Benedict, M.P. Amato, J. Boringa, B. Brochet, F. Foley, S. Fredrikson, P. Hämäläinen, H.-P. Hartung, L. Krupp, I.K. Penner, A. Reder, D. Langdon (Buffalo, US; Florence, IT; Amersfoort, NL; Bordeaux, FR; New York, US; Stockholm, SE; Masku, FI; Düsseldorf, DE; Basel, CH; Chicago, US; London, GB)
15:30 - 17:00 Grey matter damage in MS
Molecular basis of memory dysfunction in MS patients P 316
R. Dutta, A. Chang, A. Chomyk, S. Deckhard, M. Ribaudo, K. Doud, R. Fox, B. Trapp (Cleveland, US)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Comparison of intravascular ultrasound to gold standard catheter venography for detection of extra-cranial venous abnormalities indicative of CCSVI: results of the PREMiSe (Prospective Randomized Endovascular therapy in Multiple Sclerosis) study P 632
Y. Karmon, R. Zivadinov, B. Weinstock-Guttman, K. Dolic, C. Kennedy, K. Marr, V. Valnarov, A. Siddiqui (Buffalo, US)
15:30 - 17:00 Risk management for disease modifying treatments
Experience with nataluzimab use, JCV antibody testing and treatment decisions P 533
E. Williamson, L. Buchbinder, K. Plascencia, M. Bravo, J. Aparicio, M. Burnett (Los Angeles, US)
15:30 - 17:00 Devic’s NMO spectrum
Neurology Mosaic 17: a reliable test for NMO and NMO-related disorders diagnosis. P 209
L. Granieri, F. Marnetto, P. Valentino, M. Capobianco, A. Bertolotto (Orbassano, IT)
15:30 - 17:00 Imaging
Spinal cord 18flourodeoxyglucose positron emission tomography discriminates neoplastic from inflammatory myelopathic aetiologies P 387
E.P. Flanagan, C. Hunt, V. Lowe, J. Mandrekar, S. Pittock, B. O'Neill, M. Keegan (Rochester, US)
15:30 - 17:00 Pregnancy and MS
The impact of menopause on multiple sclerosis P 276
S Rubin, J. Bernard (Chicago, US)
15:30 - 17:00 MS and infections
Preliminary search for a Japanese macaque rhadinovirus-like virus in multiple sclerosis subjects P 369
D. Bourdette, S. Wong (Portland, US)
15:30 - 17:00 Risk management for disease modifying treatments
Attitude of Italian neurologists about neutralising antibodies to interferon-beta P 541
F. Marnetto, M. Caldano, A. Sala, S. Malucchi, F. Sperli, P. Valentino, C. Carcione, F. Gilli, M. Zaffaroni, R. Bergamaschi, P. Borrelli, A. Bertolotto (Orbassano, Gallarate, Pavia, IT)
15:30 - 17:00 Devic’s NMO spectrum
Diagnostic dilemma of Japanese patients with AQP4 antibody P 213
I. Kawachi, K. Yanagawa, E. Saji, M. Arakawa, A. Yokoseki, M. Hokari, M. Nishizawa (Niigata, JP)
15:30 - 17:00 Imaging
Six-year follow-up of a case-series with non-communicating syringomyelia in multiple sclerosis P 417
K. Weier, Y. Naegelin, M. Amann, S. Magon, M. Andelova, N. Mueller-Lenke, E.W. Radue, L. Kappos, C. Stippich, A. Gass, T. Sprenger (Basel, CH)
15:30 - 17:00 Natural history
Age-related white matter microstructural changes in multiple sclerosis P 234
M. Ivkovic, K. Fujimoto, G. Passiatore, J. Perumal, N. Nealon, T. Vartanian, S. Gauthier (New York, US)
15:30 - 17:00 Clinical assessment tools
Walking distances comparison between one and six minutes in multiple sclerosis patients P 283
C.T. Guerreiro, D.G. Brum, A.A. Barreira (Săo Paulo, BR)
15:30 - 17:00 Immunomodulation
Multicentre clinical trial phase I/II randomised, placebo-controlled study to evaluate safety and feasibility of therapy with two different doses of autologous mesenchymal stem cells in patients with SPMS who do not respond to treatment P 493
O. Fernandez, G. Izquierdo, M. Guerrero, G. Navarro, A. Leon, M.J. Pinto-Medel, M.D. Paramo, D. Pozo, L. Leyva, P. Galvez (Malaga, Sevilla, ES)
15:30 - 17:00 Genetics / transcriptomics
MicroRNA expression dynamics during interferon-beta treatment in peripheral blood of multiple sclerosis patients P 346
M. Hecker, M. Thamilarasan, C. Angerstein, B.K. Paap, D. Koczan, H.-J. Thiesen, U.K. Zettl (Rostock, DE)
15:30 - 17:00 Experimental models
Astrocyte-derived VEGF-A drives blood-brain barrier disruption in CNS inflammatory disease P 329
A.T. Argaw, L. Asp, J. Zhang, K. Navrazhina, T. Pham, J. Mariani, S. Mahase, D. Dutta, J. Seto, E. Kramer, N. Ferrara, M. Sofroniew, G. John (New York, South San Francisco, Los Angeles, US)
15:30 - 17:00 Neuropsychology and fatigue
Alexithymia in multiple sclerosis is associated with callosal atrophy P 444
F. Reuter, N. Moll, W. Zaaraoui, A. Rico, I. Malikova, P. Cozzone, J.P. Ranjeva, B. Audoin, J. Pelletier (Marseille, FR)
15:30 - 17:00 Genetics / transcriptomics
Polymorphisms in TRAIL and TRAIL receptor genes and response to IFN-beta P 345
C. Lopez-Gomez, A. Pino-Angeles, J.A. García-León, M.J. Pinto-Medel, B. Oliver-Martos, J. Ortega-Pinazo, M. Suardíaz, L. García-Trujillo, C. Marín-Bańasco, T. Órpez-Zafra, R. Maldonado-Sánchez, C. Guijarro-Castro, J. Varadé, E. Urcelay, Ó. Fernández, L. Leyva (Málaga, Madrid, ES)
15:30 - 17:00 Imaging
Influence of T2 lesion load on cognitive impairment at the early phase of MS P 411
N. Moll, F. Reuter, W. Zaaraoui, A. Rico, I. Malikova, L. Crespy, A. Faivre, A. Loundou, P. Auquier, P. Cozzone, J.P. Ranjeva, B. Audoin, J. Pelletier (Marseille, FR)
15:30 - 17:00 Neurobiology
Neurodegeneration in the retina precedes manifest experimental optic neuritis P 377
R. Fairless, S.K. Williams, D.B. Hoffmann, A. Stojic, S. Hochmeister, F. Schmitz, M.K. Storch, R. Diem (Heidelberg, Homburg/Saar, DE; Graz, AT)
15:30 - 17:00 Neuropsychology and fatigue
Benign multiple sclerosis in a cohort of Brazilian patients: cognitive outcomes P 438
G. Santos, C.C. Ferreira Vasconcelos, S. Gomes Camargo, F. Hampshire Araujo, J. Calvet Kallembach, R. Alves Paes, D.-N. Rodrigues Cerqueira, T.C. Monteiro, L.C. Santos Thuler, R. Papais Alvarenga (Rio de Janeiro, BR)
15:30 - 17:00 Imaging
R2* based iron mapping in multiple sclerosis: a multicentre study P 416
S. Ropele, M. Wattjes, I.D. Kilsdonk, W. de Graaf, C. Langkammer, J.L. Frederiksen, D. Fuglř, O. Ciccarelli, M. Khalil, M.A. Rocca, T. Sprenger, L. Kappos, M. Filippi, A. Rovira, D. Miller, F. Barkhof, F. Fazekas (Graz, AT; Amsterdam, NL; Copenhagen, DK; London, GB; Milan, IT; Basel, CH; Barcelona, ES)
15:30 - 17:00 Immunomodulation
Natalizumab exerts direct signalling capacity and supports a pro-inflammatory phenotype in some patients with multiple sclerosis P 474
T.F. Benkert, L. Dietz, E.M. Hartmann, E. Leich, A. Rosenwald, E. Serfling, M. Buttmann, F. Berberich-Siebelt (Würzburg, DE)
15:30 - 17:00 MS and infections
qPCR versus two-step ELISA to detect JC virus in natalizumab-treated patients P 364
M.I. Domínguez-Mozo, M. García-Montojo, V. De las Heras, M.A. García-Martínez, A. Arias-Leal, I. Casanova, R. Arroyo, R. Álvarez-Lafuente (Madrid, ES)
15:30 - 17:00 Paediatric MS
Antibody response against EBV antigens and myelin oligodendrocyte glycoprotein in paediatric patients with demyelinating CNS diseases P 228
F. Di Pauli, S. Mader, K. Rostasy, K. Schanda, B. Bajer-Kornek, B. Kuenz, R. Ehling, M. Reindl, T. Berger (Innsbruck, AT)
15:30 - 17:00 Neuro-ophthalmology
Quantification of retinal vessels in multiple sclerosis P 602
E.M. Kadas, F. Bilger, L. Ludin, T. Oberwahrenbrock, A.U. Brandt, F. Paul (Berlin, DE)
15:30 - 17:00 Pathology
Lesion formation in multiple sclerosis and spontaneous experimental autoimmune encephalomyelitis is associated with early disturbances in the blood-brain barrier P 312
J. Alvarez, S. Terouz, A. Godschalk, O. Saint-Laurent, A. Prat (Montreal, CA)
15:30 - 17:00 Risk management for disease modifying treatments
Progressive desensitization of the heart prevents first dose effects: guinea pig study with ponesimod, a selective S1P1 receptor modulator P 543
B. Steiner, M. Rey, P. Hess (Allschwil, CH)
15:30 - 17:00 Devic’s NMO spectrum
Differences in optic neuritis related retinal damage between patients with neuromyelitis optica and multiple sclerosis P 207
E. Schneider, H. Zimmermann, T. Oberwahrenbrock, A.U. Brandt, B. Wildemann, F. Paul (Berlin, Heidelberg, DE)
15:30 - 17:00 Neuropsychology and fatigue
Italian version of Minimal Assessment of Cognitive Function in Multiple Sclerosis: a pilot study P 446
S. Migliore, A. Ghazaryan, D. Landi, P. Pasqualetti, F. Moffa, M.M. Filippi, F. Vernieri (Rome, IT)
15:30 - 17:00 Environmental risk factors
Prognostic factors in clinically isolated syndromes: the role of vitamin D P 373
V. Martinelli, G. Dalla Costa, B. Colombo, D. Dalla Libera, L. Leocani, R. Furlan, A. Rubinacci, M. Filippi, G. Comi (Milan, IT)
15:30 - 17:00 Experimental models
ONO-4641, a potent and selective sphingosine 1-phosphate receptor-1 and -5 agonist, reverses chronic and progressive neurological deficits in preclinical models of multiple sclerosis P 340
A. Savinainen, F. Bernard, T. Crandall, S. Nock, R. Chang, N. Martinier, T. Seabrook, P. Smith, H. Kurata, H. Habashita, S. Nakade, U. Boschert, T. Dellovade (Billerica, US; Geneva, CH; Osaka, JP)
15:30 - 17:00 Treatment of specific symptoms
Cannabis as a symptomatic treatment for MS: clinically meaningful MUSEC to the stiffness and walking problems of people with MS P 571
J.C. Hobart, J.P. Zajicek (Plymouth, GB)
15:30 - 17:00 MS symptoms
Spasticity in MS patients: prevalence and demographics in Australia P 270
C. Taylor, D. Silva, C. Skulina, H. Butzkueven on behalf of the MS Base Australian Investigators
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
British Columbia CCSVI Registry: preliminary survey results P 626
I. Yee, A. Traboulsee, A. Sadovnick, L. Machan (Vancouver, CA)
15:30 - 17:00 Paediatric MS
Increased body mass index in paediatric onset multiple sclerosis P 226
A. Musallam, N. Baruch, S. Messina, R. Bove, B. Healy, T. Chitnis (Boston, US)
15:30 - 17:00 Long-term treatment monitoring
Disease reactivation after fingolimod discontinuation in two multiple sclerosis patients P 518
D. Baroncini, A. Ghezzi, M. A. Rocca, P.O. Annovazzi, A. Bianchi, G. Minonzio, M. Zaffaroni, M. Filippi, G. Comi (Gallarate, Milan, Milan-Gallarate, IT)
15:30 - 17:00 Devic’s NMO spectrum
Diagnostic biopsy of spinal tumours: need for prior aquaporin-4 antibody testing P 208
M. Ringelstein, I. Metz, K. Ruprecht, A. Koch, J. Rappold, J. Harmel, C. Mathys, S. Jarius, W. Brück, H.-P. Hartung, F. Paul, O. Aktas (Düsseldorf, Göttingen, Berlin, Hochegg, Heidelberg, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
The prevalence of incidental findings in multiple sclerosis patients and control subjects evaluated for possible chronic cerebrospinal venous insufficiency: Do multiple sclerosis researchers report incidental findings? P 625
J. Trufyn, J. Scott, J. Modi, M. Goyal, D. Lautner, D. Bhayana, J. Davenport, J. Mah, J.M. Burton, M.D. Hill, F. Costello (Calgary, CA)
15:30 - 17:00 Epidemiology
Seasonal variation of relapse rate and ultraviolet radiation levels are sinusoidal and their phase-shifted relationship is latitude-dependent P 237
T. Spelman, O. Gray, M. Trojano, A. Lugaresi, G. Izquierdo, C. Zwanikken, P. Duquette, F. Grand'Maison, V. Shaygannejad, P. Grammond, C. Oreja-Guevara, R. Hupperts, C. Boz, G. Giuliani, T. Petersen, R. Bergamaschi, G. Iuliano, E. van Munster, J. Lechner-Scott, R. Alroughani, M. Barnett, H. Butzkueven on behalf of the MSBase Investigators
15:30 - 17:00 Long-term treatment monitoring
Long-term comparison of fingolimod with interferon-beta-1a: results of 4.5-year follow-up from the extension phase III TRANSFORMS study P 517
X. Montalban, F. Barkhof, G. Comi, H.-P. Hartung, L. Kappos, B. Khatri, J. Pelletier, K. Tiel-Wilck, F. Holdbrook, E. Kornyeyeva, T. Stites, P. von Rosenstiel, J. Cohen (Barcelona, ES; Amsterdam, NL; Milan, IT; Düsseldorf, DE; Basel, CH; Milwaukee, US; Marseille, FR; Berlin, DE; East Hanover, US; Cleveland, US)
15:30 - 17:00 Diagnosis and differential diagnosis
The optic nerve head component of the multifocal electroretinogram: a novel signature for dissecting pathophysiologic mechanisms in MS P 177
D. Graves, T. Frohman, Z. Schnurman, D. Conger, A. Conger, B. Greenberg, S. Beh, S. Saidha, J. Ratchford, S. Galetta, P. Calabresi, L. Balcer, A. Green, E. Frohman (Dallas, Baltimore, Philadelphia, San Francisco, US)
15:30 - 17:00 Immunomodulation
Early effect of fingolimod on clinical and MRI related outcomes in relapsing multiple sclerosis P 459
P.S. Chin, P.A. Calabresi, Y. Zhang, P. von Rosenstiel, L. Kappos (East Hanover, Baltimore, US; Basel, CH)
15:30 - 17:00 Imaging
Improving the detection of spinal cord atrophy in multiple sclerosis: evaluation of methodologies at six-month follow-up P 394
H. Kearney, M.C. Yiannakas, K. Abdel-Aziz, C.A.M. Wheeler-Kingshott, O. Ciccarelli, D.H. Miller (London, GB)
15:30 - 17:00 Genetics / transcriptomics
Gene expression analysis of relapsing-remitting, primary progressive and secondary progressive multiple sclerosis P 343
R. Ratzer, H.B. Sřndergaard, P.S. Sřrensen, J.C. Christensen, F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Devic’s NMO spectrum
Absence of reactivity against myelin oligodendrocyte glycoprotein in neuromyelitis optica P 206
J.B. Chanson, G. Pacini, N. Collongues, G. Rudolf, E. Trifilieff, P. Rovero, J. De Seze, A.M. Papini (Strasbourg, FR; Florence, IT)
15:30 - 17:00 Immunomodulation
Daclizumab HYP monotherapy reduces black holes and T2 burden of disease in relapsing-remitting multiple sclerosis: results of the SELECT trial P 471
E.W. Radue, R. Gold, G. Giovannoni, D. Stefoski, N. Mueller-Lenke, S. Glyman, K. Riester, J. Elkins (Basel, CH; Bochum, DE; London, GB; Chicago, US; Cambridge, US)
15:30 - 17:00 Devic’s NMO spectrum
The differential diagnoses of patients presenting with longitudinally extensive transverse myelitis: analysis of 76 cases P 204
J. Kitley, M.I. Leite, J. Palace (Oxford, GB)
15:30 - 17:00 Neurophysiology
Measuring axonal loss in multiple sclerosis P 429
V. Fernandez, M.J. Postigo, P. Urbaneja, A. León, A. Alonso, M Guerrero, O. Fernández (Málaga, ES)
15:30 - 17:00 Paediatric MS
Adolescent-parent relationships in paediatric MS patients P 225
E.A. Boyko, O.V. Bykova, I.A. Nankina, T.T. Batysheva, A.N. Boyko (Moscow, RU)
15:30 - 17:00 Neuropsychology and fatigue
The relationship between emotion processing deficits and moral judgment in patients with multiple sclerosis P 450
V. Sinay, F. Manes, E. Gleichgerrcht (Buenos Aires, AR)
15:30 - 17:00 Experimental models
Marginal zone/B220+CD21hiCD23low B-cells is associated with autoimmune pathology in an animal model of multiple-sclerosis: immunomodulatory effect of glatiramer acetate P 330
S. Begum-Haque, M. Christy, Y. Wang, K. Telesford, A. Haque, L.H. Kasper (Lebanon, US)
15:30 - 17:00 Neuroprotection
Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study P 502
M. Mohyeddin Bonab, M.A. Sahraian, A. Aghsaie, S. Ahmadi Karvigh, S.M. Hosseinian, B. Nikbin, J. Lotfi, S. Khorramnia, M.R. Motamed, M. Togha, M.H. Harirchian, N. Beladi Moghadam, K. Alikhani, S. Yadegari, S. Jafarian, M.R. Gheini (Tehran, IR; Calgary, CA)
15:30 - 17:00 Biomarkers
Biomarkers of blood-brain barrier in the progression of multiple sclerosis P 605
A. Valado, T. Proença, J. Sargento-Freitas, S. Batista, L. Sousa, C.R. Oliveira, I. Baldeiras (Coimbra, PT)
15:30 - 17:00 Paediatric MS
Age of menarche and MS risk in paediatric patients with acute demyelination P 222
J. O'Mahony, C. Phan, H. Hanwell, A.D. Sadovnick, R.A. Marrie, B. Banwell on behalf of the Canadian Paediatric Demyelinating Disease Network
15:30 - 17:00 Natural history
Similarities in disability profiles in North American Research Committee on Multiple Sclerosis (NARCOMS) registry and Genetic Analysis of Multiple Sclerosis in Europeans (GAMES) dataset P 235
I. Kister, E. Chamot, G. Cutter, A. Salter, T.E. Bacon, J. Herbert (New York, Birmingham, US)
15:30 - 17:00 Grey matter damage in MS
Heterogeneity of cortical lesions in multiple sclerosis: clinical and pathological implications P 323
E. Kooi, E.M.M Strijbis, P. van der Valk, J.J.G. Geurts (Amsterdam, NL)
15:30 - 17:00 Imaging
The development of cognitive impairment correlates with the metabolic alterations in different brain structures in patients with relapsing-remitting and progressive multiple sclerosis P 412
G. Shkilnyuk, A. Ilves, G. Katayeva, L. Prakhova, T. Reznikova, I. Stolyarov (St-Petersburg, RU)
15:30 - 17:00 MS and infections
Human herpesvirus in multiple sclerosis patients P 363
R.B. Thomaz, G.S. Olival, C.P. Tilbery, J.V. Bermudez, L.H.S. Nali, C.M. Romano, L. Moraes, D. Callegaro, V. Cavenaghi, J.S. Casseb, A.C. Penalva de Oliveira, C. Fink, L.S. Sumita (Săo Paulo, BR)
15:30 - 17:00 Neuro-ophthalmology
Microcystic macular oedema in neuromyelitis optica P 599
J.M. Gelfand, B.A. Cree, P. Calabresi, E. Frohman, L. Balcer, R. Nolan, A.J. Green (San Francisco, Baltimore, Dallas, Philadelphia, US)
15:30 - 17:00 Adaptative and Innate immunology
High secreted levels of EGF from immune cells of patients with RR-MS may be related to the impaired neuronal repair P 359
A. Karni, K. Mausner-Fainberg, Y. Amir-Levy (Tel Aviv, IL)
15:30 - 17:00 Neuropsychology and fatigue
Measuring cognitive fatigue in multiple sclerosis P 432
S.A. Morrow (London, CA)
15:30 - 17:00 Comprehensive care and rehabilitation
Which pain indicators are most associated with walking capacity in individuals with multiple sclerosis? P 575
S. Shahrbanian, P. Duquette, A. Kuspinar, S. Teng, N. Mayo (Montreal, CA)
15:30 - 17:00 Risk management for disease modifying treatments
Thyroid function and autoimmunity during long-term disease-modifying therapy in patient with multiple sclerosis, data from every-day practice P 534
A. Boyko, L. Petrova, E. Gusev (Moscow, RU)
15:30 - 17:00 Quality of life
The quality of life assessment in patients with multiple sclerosis using MusiQoL questionnaire: results of the nationwide multicentre study in Russia P 582
A. Boyko, O. Boyko, A. Khitry, O. Rozenson on behalf of the investigators in the EMR200077-510 project
15:30 - 17:00 MS Variants
Distinct HLA polymorphisms among atopic myelitis, multiple sclerosis and neuromyelitis optica patients in Japan P 197
S. Sato, N. Isobe, S. Yoshimura, Y. Kanamori, K. Masaki, T. Matsushita, J.-I. Kira (Fukuoka, JP)
15:30 - 17:00 Imaging
Can anti-TNFa therapy cause clinically silent MS-like white matter lesions? An MRI study and case analysis P 393
S.Y. Lim, C.R. Tench, D.P. Auer, I. Pande, M. Abaei, C.S. Constantinescu (Nottingham, GB)
15:30 - 17:00 Others
Osteoporosis and fracture risk in multiple sclerosis P 562
R. Dobson, S. Ramagopalan, G. Giovannoni (London, GB)
15:30 - 17:00 Quality of life
Evaluation of the effect of dalfampridine-ER on the EQ-5D based on an MSWS-12 to EQ-5D mapping equation derived in North American patients P 588
M. Sidovar, B. Limone, J. Gaebler, S. Lee, C. Coleman (Hawthorne, Hartford, Weston, US)
15:30 - 17:00 Paediatric MS
Detecting cognitive and psychoaffective deficits in children and juveniles with multiple sclerosis: The MUSICADO study P 229
P. Calabrese, K. Storm van`s Gravesande, A. Blaschek, F. Heinen, P. Hupke, V. Mall (Basel, CH; Vienna, AT; Munich, Göttingen, Freiburg, DE)
15:30 - 17:00 Long-term treatment monitoring
Five-year safety and efficacy data of natalizumab from the STRATA study P 520
L. Kappos, A. Goodman, F. Lublin, P. O'Connor, C. Polman, L.M. Cristiano, F. Forrestal, P. Duda (Basel, CH; Rochester, New York, US; Toronto, CA; Amsterdam, NL; Cambridge, US)
15:30 - 17:00 Paediatric MS
Vitamin D deficiency as the enviromental risk factor for child multiple sclerosis P 219
M. Bilska, K. Kotulska-Józwiak (Warsaw, PL)
15:30 - 17:00 Neuroprotection
The inhibition of oxidative stress by a xanthine oxidase inhibitor ameliorates EAE P 503
J.A. Honorat, M. Kinoshita, T. Okuno, K. Takata, T. Kohda, S. Tada, H. Mochizuki, S. Sakoda, Y. Nakatsuji (Suita, Toyonaka, JP)
15:30 - 17:00 Epidemiology
Incidence of life-threatening immune thrombocytopenia in a multiple sclerosis clinic cohort P 238
D. Barone, K. Barone (Westampton, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Hamburg isolated clinical syndrome (HIS) cohort – sensitivity of diagnostic criteria P 185
B. Kaulen, A. Neuhaus, L. Reitz, S. Siemonsen, K. Radelfahr, J.P. Stellmann, M. Daumer, C. Heesen (Hamburg, Munich, DE)
15:30 - 17:00 Imaging
Characterisation of enhancing and non-enhancing MS lesions with susceptibility-weighted imaging P 407
P. Eisele, M. Griebe, K. Szabo, M. Wolf, M.G. Hennerici, A. Gass (Mannheim, DE)
15:30 - 17:00 Environmental risk factors
Smoking and disease progression in patients with multiple sclerosis: UK cohort study P 375
A. Manouchehrinia, C. Tench, J. Maxted, R. Bibani, J. Britton, C. Constantinescu (Nottingham, GB)
15:30 - 17:00 Clinical assessment tools
A practical definition of aggressive onset multiple sclerosis P 285
J. Perumal, S. Gauthier, N. Nealon, T. Vartanian (New York, US)
15:30 - 17:00 Diagnosis and differential diagnosis
Multiple sclerosis and chronic inflammatory demyelinating polyradiculoneuropathy with hypertrophic cranial and spinal neuroradiculopathy mimicking neurofibromatosis: report of a case series P 180
D. De Feo, M. Maria Josč, M. Rodegher, B. Colombo, D. Dalla Libera, S. Gerevini, A. Quattrini, U. Del Carro, G. Comi, V. Martinelli (Milan, IT)
15:30 - 17:00 Long-term treatment monitoring
Natalizumab results in sustained freedom from disease activity in highly active relapsing-remitting MS patients: a four-year follow-up P 526
S.B. Kelly, M. Duggan, L. Buckley, K. Kinsella, M. Hutchinson, N. Tubridy, C. McGuigan (Dublin, IE)
15:30 - 17:00 Diagnosis and differential diagnosis
Nf-H CSF levels in patients with clinically isolated syndromes P 190
M. Tintoré, J. Kuhle, G. Arrambide, M. Limberg, C. Espejo, E. Simón, M. Comabella, C. Auger, A. Rovira, X. Montalban (Barcelona, ES; Basel, CH)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Multiple stenosis or multiple sclerosis? P 624
G. Panczel, C. Rozsa, K. Kovacs, I. Szikora, Z. Berentei, I. Gubucz, M. Marosfoi, A. Rozsa (Budapest, HU)
15:30 - 17:00 Diagnosis and differential diagnosis
Metabolic profiling of patient's sera by HRMAS-NMR spectroscopy: a new analytical tool for distinguishing neuromyelitis optica from multiple sclerosis? P 182
F.M. Moussallieh, K. Elbayed, J.B. Chanson, G. Rudolf, M. Piotto, J. de Sčze, I.J. Namer (Strasbourg, Wissembourg, FR)
15:30 - 17:00 Immunomodulation
Non-inferiority of azathioprine versus beta interferons for relapsing-remitting multiple sclerosis: a multicentre randomised trial P 460
L. Massacesi, I. Tramacere, M.D. Benedetti, G. Filippini, L. La Mantia, A. Solari, C. Milanese on behalf of the MAIN trial Study group
15:30 - 17:00 Immunomodulation
Oral treatment with laquinimod augments regulatory T-cells and brain-derived neurotrophic factor expression and reduces injury in the CNS of mice with experimental autoimmune encephalomyelitis P 489
R. Aharoni, R. Saada, R. Eilam, L. Hayardeny, M. Sela, R. Arnon (Rehovot, Natanya, IL)
15:30 - 17:00 Immunosuppression
Mitoxantrone therapy for multiple sclerosis: the Nova Scotia experience P 500
N. Parks, J. Wadhawan, T. Campbell, V. Bhan (Halifax, CA)
15:30 - 17:00 Experimental models
Astrocyte-targeted production of interleukin-17A is not sufficient to induce severe inflammatory CNS disease but promotes accumulation of activated microglia/macrophages in different models of brain inflammation P 332
J. Zimmermann, M. Emrich, M. Krauthausen, M. Hofer, I.L. Campbell, M. Müller (Bonn, Marburg, DE; Sydney, AU)
15:30 - 17:00 Devic’s NMO spectrum
Altered topological organisation of white matter structural networks in patients with neuromyelitis optica P 212
Y. Liu, Y. Duan, N. Shu, H. Butzkueven, K. Li (Beijing, CN; Melbourne, AU)
15:30 - 17:00 Quality of life
Information provision for persons with multiple sclerosis (Cochrane Review) P 583
S. Köpke, A. Solari, F. Khan, C. Heesen, A. Giordano (Lübeck, DE; Milan, IT; Melbourne, AU; Hamburg, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Hydration status may confound CCSVI ultrasound assessment P 627
C. Diaconu, R. Fox, M. Lu, A. Grattan, A. Rae-Grant, H. Gornik, S. Kim (Cleveland, US)
15:30 - 17:00 Imaging
Multiple sclerosis impairs regional functional connectivity in the cerebellum P 414
A.-M. Dogonowski, K. Winther Jřrgensen, K.H. Madsen, P. Soelberg Sřrensen, O.B. Paulson, M. Blinkenberg, H.R. Siebner (Hvidovre, Copenhagen, DK)
15:30 - 17:00 Epidemiology
Relationship between hours of daylight, date of birth and risk of multiple sclerosis P 249
A. Antiguedad, C. Llarena, M. Mendibe (Bilbao, ES)
15:30 - 17:00 Immunomodulation
A comparison of the efficacy of interferon-beta and glatiramer acetate in relapse-rate reduction: a prospective randomisation study P 497
C. Crentsil, N. Scolding, A. Wilkins, J. Burrow, L. Bennetto, K. Ingles, D. Cottrell (Bristol, GB)
15:30 - 17:00 Experimental models
The role of TIM-3 in the development of Theiler's Murine encephalomyelitis virus-induced dymyelinating disease P 331
T. Kaneyama, H. Tomiki, S. Tsugane, M. Ichikawa, H. Yagita, B. Kim, C.S. Koh (Matsumoto, Tokyo, JP; Chicago, US)
15:30 - 17:00 Epidemiology
Age-specific sex ratio of multiple sclerosis in Sweden P 255
I. Boström, A.M. Landtblom (Kristinehamn, Linköping, SE)
15:30 - 17:00 Diagnosis and differential diagnosis
Time gain using the 2010 McDonald criteria for the diagnosis of multiple sclerosis after a clinically isolated syndrome P 184
E. Thouvenot, M.-L. Inghilleri, B. Clarivet, M. Charif, B. Carlander, W. Camu, G. Mercier (Nîmes, Montpellier, FR)
15:30 - 17:00 Neuroprotection
ACTH 1-39 protects oligodendroglial progenitor cells from excitotoxic and inflammation-related damage and promotes their proliferation and differentiation P 507
J. Benjamins, L. Nedelkoska, B. Bealmear, R. Lisak (Detroit, US)
15:30 - 17:00 Imaging
Biological origin of MR phase contrast in white matter lesions at 7T P 383
P. Maggi, P. Sati, S. Macri, E. Leibovitch, M. Absinta, L. Massacesi, S. Westmoreland, S. Jacobson, A. Silva, D.S. Reich (Bethesda, Boston, US)
15:30 - 17:00 Epidemiology
Do patient-reported symptom changes indicate increased risk for a future relapse in multiple sclerosis? P 240
A. Salter, T. Tyry, S. Cofield, D. Belletti, R.A. Marrie, R. Fox, G. Cutter (Birmingham, Phoenix, East Hanover, US; Winnipeg, CA; Cleveland, US)
15:30 - 17:00 Clinical assessment tools
Displaying the motor components of the MSFC as an interval score on a IPhone / IPad app with sagas20/10 P 297
S. Vaney, S. Bayard, C. Kuonen, M. Zeiter, S. Rapillard, T. Rapillard (Crans Montana, Vétroz, CH)
15:30 - 17:00 Immunomodulation
Effect of teriflunomide on the pharmacodynamic and pharmacokinetic profiles of warfarin in healthy male subjects P 453
S. Turpault, S. Mair, Z. Meng, A. Hochet, F. Menguy-Vacheron (Bridgewater, US; Nottingham, GB; Chilly Mazarin, FR)
15:30 - 17:00 Biomarkers
Relapses influence prognosis in clinically isolated syndrome P 623
T. Kalincik, M. Vaneckova, M. Tyblova, J. Krasensky, Z. Seidl, E. Havrdova, D. Horakova (Melbourne, AU; Prague, CZ)
15:30 - 17:00 Clinical assessment tools
Technical feasibility of implementing multifocal VEP for multicentre clinical trials P 281
D. Cadavid, N. Levin, F. Costello, A. Rahilly, A. Klistorner (Cambridge, US; Jerusalem, IL; Calgary, CA; Sydney, AU)
15:30 - 17:00 Treatment of specific symptoms
Evaluation of the abuse potential of dalfampridine extended-release tablets P 565
M. Jara, D. Gauvin, A. Caggiano, B. Walter, T. Parry, H. Henney (Hawthorne, Mattawan, US)
15:30 - 17:00 Adaptative and Innate immunology
Interleukin-15 amplifies the pathogenic activity of CD4+CD28- T cells in multiple sclerosis patients P 348
B. Broux, B. Van Wijmeersch, P. Stinissen, N. Hellings (Diepenbeek, BE)
15:30 - 17:00 Immunomodulation
Further insights on immunomodulatory mechanisms of natalizumab in multiple sclerosis P 478
M. Ruggieri, P. Iaffaldano, M. Mastrapasqua, D. Paolicelli, M. Trojano (Bari, IT)
15:30 - 17:00 Epidemiology
Reversed causality might explain the association between reproductive history and MS: results from the Epidemiological Investigation of Multiple Sclerosis (EIMS) P 256
L. Alfredsson, A.K. Hedström, J. Hillert, T. Olsson (Stockholm, SE)
15:30 - 17:00 Neuroprotection
Olesoxime improves clinical score and promotes remyelination in MOG-induced experimental autoimmune encephalomyelitis P 512
T. Bordet, M. Cayre, C. Zimmer, K. Magalon, A. Viola, P. Durbec, R.M. Pruss (Marseille, FR)
15:30 - 17:00 Genetics / transcriptomics
Association of CD40 gene polymorphisms with the multiple sclerosis in population of Russian Federation P 341
E.A. Kudryavtseva, A.S. Rozhdestvenskii, A.V. Kakulya, E.V. Khanokh, N.A. Malkova, D.S. Korobko, F.A. Platonov, E.G. Aref'eva, N.N. Zagorskaya, V.M. Alifirova, M. Titova, V.P. Puzyrev, I.V. Smagina, S.A. El'chaninova, A.G. Zolovkina, E.Y. Tsareva, O.O. Favorova, A.N. Boiko, M.L. Filipenko (Novosibirsk, Omsk, Yakutsk, Kemerovo, Tomsk, Barnaul, Moscow, RU)
15:30 - 17:00 Others
The oldest multiple sclerosis patient living actively until age 97 P 561
M. Elian (London, GB)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prospective, case-control study of CCSVI with imaging-blinded assessments P 628
J. Wolinsky, L. Kramer, A. Barreto, A. Cohen, S. Brod, T.-T. Bui, P. Narayana, J. Jemelka, F. Nelson, J. Lindsey (Houston, US)
15:30 - 17:00 Experimental models
Glatiramer acetate does not interfere with CNS immune surveillance in an animal model of Toxoplasmosis gondii infection P 338
R. Hussain, L. Hayardeny, M. Raetz, F. Yarovinsky, O. Stuve (Dallas, US; Petah Tikva, IL)
15:30 - 17:00 Adaptative and Innate immunology
Prolactin modulates B cell responses in multiple sclerosis P 350
J. Correale, M. Farez, M. Ysrraelit (Buenos Aires, AR)
15:30 - 17:00 Clinical assessment tools
Improving the psychometric properties of the multiple sclerosis functional composite index: replacing the PASAT-3” with a brief measure of vigilant attention P 288
C. Edgar, J.E. Swartz, T. Feaster, K.A. Wesnes (Goring-on-Thames, GB; Wayne, US)
15:30 - 17:00 Immunomodulation
In-vivo response to interferon-alpha is preserved in multiple sclerosis patients with neutralising antibodies against interferon-beta P 487
M. Magyari, H Bach Sřndergaard, F. Sellebjerg, P. Soelberg Sřrensen (Copenhagen, DK)
15:30 - 17:00 Experimental models
Gene expression profile of brain cells in response to treatment with interferon-beta and C-phycocyanin in the experimental autoimmune encephalomyelitis model P 327
G. Penton-Rol, M. Nazabal-Galvez, N. Lagumersindez-Denis, L. Muzio, A. Bergami, J. Fernandez-Masso, A. Cintado-Benitez, N. Polentarutti, T. Veliz, G. Guillen-Nieto, R. Furlan, A. Mantovani, E. Penton-Arias (Havana, CU; Milan, IT)
15:30 - 17:00 Immunomodulation
A phase 1b, randomised, placebo-controlled, multiple-dose study of human placenta-derived cells (PDA-001) for the treatment of adults with multiple sclerosis P 456
F. Lublin, J. Bowen, J. Huddlestone, M. Kremenchutzky, A. Carpenter, J. Corboy, M. Freedman, L. Krupp, C. Paulo, R. Hariri, S. Fischkoff (New York, Seattle, Tacoma, US; London, CA; Minneapolis, Aurora, US; Ottawa, CA; Stony Brook, Warrren, US)
15:30 - 17:00 Environmental risk factors
Fatty fish intake decrease multiple sclerosis risk among people exposed to low levels of ultraviolet radiation P 371
M. Bäärnhielm, T. Olsson, L. Alfredsson (Stockholm, SE)
15:30 - 17:00 Imaging
A comparison of motor reorganisation between African-American and Caucasian-American patients with MS P 388
R. Teodorescu, W. Zaaraoui, J. Howard, H. Jaggi, J. Herbert, J. Ranjeva, M. Inglese (New York, US; Marseille, FR)
15:30 - 17:00 Devic’s NMO spectrum
Initial presentation of central nervous system demyelinating disease in Thai patients: retrospective study P 216
A. Nawa-Apisak, M. Apiwattanakul (Bangkok, TH)
15:30 - 17:00 MS symptoms
Physical exercise: a double-edged sword with benefits and risks on multiple sclerosis related fatigue. Identifying good and bad responders P 272
N. Téllez, M.J Neri, M. Archanco, A. Vázquez, M. Benito, V. García, M.F Muńoz, R. Fernández (Valladolid, ES)
15:30 - 17:00 Natural history
Follow-up study of patients with clinically isolated syndrome who did not develop multiple sclerosis when reaching the age of expected survival in the population P 231
L. Novakova, B. Skoog, O. Andersen (Gothenburg, SE)
15:30 - 17:00 Biomarkers
Increase of interleukin-6 levels is related with depressive phenomena in the acute (relapsing) phase of multiple sclerosis P 610
E. Koutsouraki, E. Hatzifilippou, D. Michmizos, C. Cotsavasiloglou, V. Costa, S. Baloyannis (Thessaloniki, GR)
15:30 - 17:00 Treatment of specific symptoms
Musculo-skeletal pain in multiple sclerosis: results of a prospective study in 52 patients treated with an interdisciplinary concept P 567
J. Bräuer, W. Pöllmann, M. Starck (Berg, DE)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Anatomical cadaver study of the internal jugular veins' configuration in non-MS persons P 631
M. Denislic, M. Zorc, Z. Milosevic, O. Mendiz, R. Zorc Pleskovic, D. Ravnik (Ljubljana, SI; Buenos Aires, AR)
15:30 - 17:00 Diagnosis and differential diagnosis
White matter lesions in Behcet's disease: neuro-Behcet's disease or multiple sclerosis? P 188
G. Akman-Demir, M. Mutlu, A. Kiyat-Atamer, E. Shugaiv, M. Kurtuncu, I. Tugal-Tutkun, E. Tuzun, M. Eraksoy, S. Bahar (Istanbul, TR)
15:30 - 17:00 Economic burden
Costs of multiple sclerosis in Latin America and the Caribbean: systematic review of the literature P 305
M. Romano, G. Machnicki, J.I. Rojas, N. Frider, J. Correale (Buenos Aires, AR)
15:30 - 17:00 MS and infections
The envelope protein of the human endogenous retrovirus type W family member multiple sclerosis-associated retrovirus is present in human chronic active MS lesions and inhibits oligodendroglial precursor cell differentiation via nitrosative stress P 366
D. Kremer, T. Schichel, M. Förster, C. Bernard, J. van Horssen, H.-P. Hartung, H. Perron, P. Küry (Düsseldorf, DE; Geneva, CH; Amsterdam, NL)
15:30 - 17:00 Others
Safety and pharmacokinetics of GNbAC1, a humanised monoclonal antibody against the multiple sclerosis retrovirus envelope protein P 558
F. Curtin, A.B Lang, H. Perron, T. Derfuss, P. Lalive, L. Kappos, H.-P. Hartung (Geneva, Basel, CH; Düsseldorf, DE)
15:30 - 17:00 Environmental risk factors
Month of birth is a latitude-dependent risk factor for multiple sclerosis in Norway P 370
N. Grytten Torkildsen, O. Torkildsen, J. Aarseth, E. Benjaminsen, E. Gulowsen Celius, O. Dahl, T. Holmoey, K. Loeken-Amsrud, R. Midgard, K.-M. Myhr, G. Risberg, A. Vatne, M. Kampman (Bergen, Bodř, Oslo, Namsos, Lillehammer, Molde, Kristiansand, Tromsř, NO)
15:30 - 17:00 Epidemiology
Association of changes in EDSS with confirmed MS relapses P 236
P. K. Coyle, H. Zwibel, T. Leist, M. Tullman, B. Cohen, M. Lage on behalf of the TOP MS Study Steering Committeee
15:30 - 17:00 Neuropsychology and fatigue
Influence of emotional valence in episodic memory in multiple sclerosis: neuropsychological and MRI study P 443
N. Derache, A. Mondou, F. Doidy, R. Makouri, P. Piolino, F. Eustache, G.L. Defer, B. Desgranges (Caen, Paris, FR)
15:30 - 17:00 Immunomodulation
Analysis of genetic models predicting the response to GA on two-year follow-up of relapsing-remitting multiple sclerosis patient data P 480
F. Martinelli Boneschi, A. Tchelet, F. Esposito, P. Manunta, J. Levy, S. Weiss, L. Citterio, G. Pavan, G. Liberatore, P. Brambilla, V. Martinelli, G. Comi (Milan, IT; Netanya, IL; London, GB)
15:30 - 17:00 Diagnosis and differential diagnosis
Neuromyelitis optica previously diagnosed as multiple sclerosis P 191
P. Zago Melo, F. Jorge, R. Faria Simm, S. Apóstolos Pereira, C. Galvăo, C. Hobi, L. Moraes, M. Fazzito, D. Sato, M. Lana-Peixoto, D. Callegaro (Săo Paulo, BR)
15:30 - 17:00 Neuroprotection
Brain reserve and cognitive reserve in MS patients. Lifetime maximal brain size and early life cognitive leisure independently protect against disease-related cognitive decline P 505
J.F. Sumowski, M.A. Rocca, V.M. Leavitt, G. Riccitelli, G. Comi, J. DeLuca, M. Filippi (West Orange, US; Milan, IT)
15:30 - 17:00 Immunomodulation
Therapeutic decision after JC virus testing in a cohort of patients treated with natalizumab P 496
J.C. Ongagna, S. Courtois, C. Gaultier, A. Kopf, M.C. Fleury, G. Ahle, N. Collongues, J.P. Chanson, C. Marcel, F. Blanc, J. De Seze (Strasbourg, Mulhouse, Colmar, Haguenau, FR)
15:30 - 17:00 Risk management for disease modifying treatments
Immunostimulatory effect of G-CSF is potentially beneficial in natalizumab-associated PML/IRIS P 528
D. Stefoski, M. Ko, R. Brillante, A. Javed, R. Balabanov (Chicago, US)
15:30 - 17:00 Neuropsychology and fatigue
Extensive neuropsychological assessment of cognitive impairment in multiple sclerosis patients P 451
S. Gebel, R. Luerding, S. Schwab-Malek, R. Weissert (Regensburg, DE)
15:30 - 17:00 Immunomodulation
Novel humanised antibody therapy in multiple sclerosis targeting immunopathogenic protein from endogenous retroviral element while preserving host’s immune system P 470
H. Perron, J.B. Bertrand, R. Faucard, C. Bernard, J. VanHorssen, R. Firouzi, J. Portoukalian, R. Germi, M. Garcia-Montojo, P. Morand, P. Marche, K. Sanhadji, J.-L. Touraine, A. Lang, F. Curtin (Plan les Ouates, CH; Lyon, FR; Amsterdam, NL; Grenoble, FR)
15:30 - 17:00 Imaging
Revised McDonald criteria for early multiple sclerosis diagnistics: applicability in Russian population P 413
I. Shalenkov, A. Belova, B. Shahov, D. Shakurova (N. Novgorod, RU)
15:30 - 17:00 Diagnosis and differential diagnosis
Aplication of the McDonald 2010 criteria for the diagnosis of multiple sclerosis in an Argentinian cohort of patients with clinically isolated syndromes P 193
L. Patrucco, J.I. Rojas, S. Tizio, E. Cristiano (Buenos Aires, AR)
15:30 - 17:00 Immunomodulation
Diffusion tensor imaging predicts development of natalizumab-associated progressive multifocal leukoencephalopathy P 458
D. Ontaneda, K. Sakaie, J. Lin, X. Wang, M. Lowe, M. Phillips, R. Fox (Cleveland, US)
15:30 - 17:00 Neuro-ophthalmology
Pattern of retinal neuronal loss in multiple sclerosis and neuromyelitis optica without optic neuritis measured by optical coherence tomography P 594
N. Kim, H.J. Kim, J.Y. Cho, K.S. Jeong, C.Y. Park (Goyang-si, KR)
15:30 - 17:00 Risk management for disease modifying treatments
Safety of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS II) P 545
E. Havrdova, D. L. Arnold, J. Cohen, A. J. Coles, C. Confavreux, E. J. Fox, H.-P. Hartung, K. Selmaj, H. Weiner, T. Miller, C.L. Twyman, S. L. Lake, D. H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Clinical assessment tools
Backward masking paradigm captures delays in speed of processing in multiple sclerosis on a millisecond scale P 286
J.H. Bacon, T.E. Bacon, I. Kister, Y. Strauchler, G. Tsikhanovski Bochner, M. Omari, A. Bochkanova, J. Herbert (New York, US)
15:30 - 17:00 Devic’s NMO spectrum
The spectrum of demyelinating diseases in a cohort of patients from Rio de Janeiro (Brazil) P 217
M. Papais-Alvarenga, R. Papais-Alvarenga, C. Vasconcelos, M. Alvarenga, S. Camargo, E. Batista, G. Santos (Rio de Janeiro, BR)
15:30 - 17:00 Immunomodulation
Efficacy of alemtuzumab in relapsing-remitting multiple sclerosis patients who relapsed on prior therapy (CARE-MS-II): subgroup analyses by previous DMT use P 483
M.S. Freedman, D.L. Arnold, J. Cohen, C. Confavreux, E.J. Fox, H.-P. Hartung, E. Havrdova, K. Selmaj, H. Weiner, T. Miller, C.L. Twyman, M. Vallee, D.H. Margolin, M. Panzara, D.A.S. Compston for the CARE-MS II investigators
15:30 - 17:00 Adaptative and Innate immunology
Effect of rituximab on white blood cell subtypes after single and multiple treatments in MS and NMO P 356
U. Vinayagasundaram, E.M. Mowry, I.R. Matthews, J. Marino, J. Cheng, E. Waubant (Cleveland, San Francisco, US)
15:30 - 17:00 MS Variants
High expression of HLA-DRB1*1501 variant and DRB5 gene associate with multiple sclerosis in a Caucasian population P 198
A. Alcina, M. Abad-Grau, M. Fedetz, G. Izquierdo, M. Lucas, O. Fernández, N. Dorothy, A. Catalá-Rabasa, C. Delgado, C. Arnál, F. Matesanz (Granada, Malaga, ES)
15:30 - 17:00 Neurophysiology
Correlations between auditory consonant trigram test, paced auditory serial addition test health-related quality of life during and after treatment of relapses in patients with clinically isolated syndrome P 430
S. Ozakbas, B. Piri Cinar, O. Ozturk, A. Gurkan, E. Idiman (Izmir, TR)
15:30 - 17:00 Neurophysiology
Optical coherence tomography and visual-evoked potentials: which is more sensitive in multiple sclerosis? P 425
G. Di Maggio, M. Bianco, L. Ferrari, S. Medaglini, M. Rodegher, B. Colombo, L. Moiola, V. Martinelli, G. Comi, L. Leocani (Milan, IT)
15:30 - 17:00 Databases and Pharmacoepidemiology
MS therapy adherence and relapse risk P 260
T. Leist, H. Zwibel, M. Schwartz, B. Cohen, M. Tullman, P. K. Coyle on behalf of the TOP MS Steering Committee
15:30 - 17:00 Risk management for disease modifying treatments
Initiating a low-dose class Ia anti-arrhythmic (dextromethorphan/quinidine) in fingolimod-treated patients may be safe and effective: the first case series P 529
D. Kantor (Ponte Vedra, US)
15:30 - 17:00 Tools for detecting therapeutic response
Rio Score and Modified Rio Score validation in an Italian cohort of relapsing-remitting multiple sclerosis patients P 549
M. Romeo, V. Martinelli, M. Rodegher, S. Maida, E. Perego, G. Comi (Milan, IT)
15:30 - 17:00 Neurophysiology
iSP study in multiple sclerosis relapsing-remitting during and after a motor relapse P 426
L. Straffi, R. Chieffo, E. Coppi, F. Spagnolo, A. Inuggi, A. Nuara, G. Di Maggio, G. Comi, L. Leocani (Milan, IT)
15:30 - 17:00 MS and infections
Long-term safety and efficacy of ocrelizumab in patients with relapsing-remitting multiple sclerosis: week 144 results of a phase II, randomised, multicentre trial P 362
L. Kappos, D. Li, P. Calabresi, P. O’Connor, A. Bar-Or, F. Barkhof, C. Wells, D. Leppert, D. Masterman, J. Tinbergen, S.L. Hauser (Basel, CH; Vancouver, CA; Baltimore, US; Toronto, Montreal, CA; Amsterdam, NL; Welwyn Garden City, GB; San Francisco, US)
15:30 - 17:00 Clinical assessment tools
Development of an objective testbattery for motor and cognitive fatigue in patients with relapsing-remitting and secondary progressive multiple sclerosis P 291
U. Hofstadt-van Oy, U. Menge, R. Weimer, J. Burschka, P. Oschmann (Bayreuth, DE)
15:30 - 17:00 MS symptoms
Early cognitive impairment in multiple sclerosis P 269
F. Gampourou, P. Clavelou (Clermont-Ferrand, FR)
15:30 - 17:00 MS symptoms
Central pain in patients with multiple sclerosis P 268
S. Feketová, I. Waczulíková, J. Mareš, P. Kukumberg (Bratislava, SK; Olomouc, CZ)
15:30 - 17:00 Imaging
Brain medullary veins visibility with susceptibility-weighted MR imaging in clinically isolated syndromes and relapsing-remitting multiple sclerosis P 399
A. Rovira, F. Aymerich, C. Auger, E. Huerga, R. Mitjana, M. Tintoré, J. Alonso, X. Montalban (Barcelona, ES)
15:30 - 17:00 Imaging
Brain lesion location and cognitive impairment in relapsing multiple sclerosis P 403
F. Rossi, A. Giorgio, M. Battaglini, M.L. Stromillo, E. Portaccio, B. Goretti, B. Hakiki, A. Federico, M.P. Amato, N. De Stefano (Siena, IT)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Intra and extra cranial arterial, venous and CSF analysis comparing MS patients and healthy controls P 630
S. El Sankari, O. Balédent, V. van Pesch, T. Duprez, C. Sindic (Bruxelles, BE; Amiens, FR)
15:30 - 17:00 Immunomodulation
MicroRNA-301a represents a promising therapeutic target for controlling of autoimmune demyelination P 485
M. Mycko, M. Cichalewska, A. Machlanska, H. Cwiklinska, K. Selmaj (Lodz, PL)
15:30 - 17:00 Neurobiology
Region specific protection of cuprizone-induced demyelination in CCL2/3 double deficient animals P 378
M. Rickert, K. Berger, T. Reiß, T. Clarner, C. Beyer, M. Kipp (Aachen, DE)
15:30 - 17:00 Imaging
A supervised approach to segment multiple sclerosis lesions using context-rich features and a boosting classifier P 398
M. Cabezas, A. Oliver, X. Lladó, Y. Díez, J. Freixenet, J.C. Vilanova, A. Quiles, G. Laguillo, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Grey matter damage in MS
Cerebellar cortical lesion load is related to clinical disability in multiple sclerosis patients P 322
A. Damasceno, B. Damasceno, F. Cendes (Campinas, BR)
15:30 - 17:00 Experimental models
Protection of oligodendroglia in experimental NMO lesions P 334
C. Wrzos, J. Bennett, W. Brück, S. Nessler, C. Stadelmann (Göttingen, DE; Denver, US)
15:30 - 17:00 Grey matter damage in MS
Cognitive deficit is associated with subcortical grey matter volume in relapsing-remitting multiple sclerosis patients P 321
A. Kalinowska-Lyszczarz, M. Pawlak, W. Paprzycki, W. Kozubski (Poznan, PL)
15:30 - 17:00 Experimental models
Recovery from motor deficit with ERbeta ligand Indazole-Cl in a mouse model of multiple sclerosis P 328
S. Moore, G. Hannsun, J. Yoon, T. Yoo, N. Yasui, J. Katzenellenbogen, S. Tiwari-Woodruff (Los Angeles, Urbana, US)
15:30 - 17:00 Biomarkers
Contactin 2 and contactin-associated protein 2 antibodies in patients with multiple sclerosis and clinically isolated syndrome P 618
P. Nytrova, P. Waters, D. Horakova, Y. Hacohen, T. Kalincik, P. Zbornikova, J. Dusankova Blahova, J. Krasensky, M. Vaneckova, E. Havrdova, K.P. Wandinger, A. Vincent (Oxford, GB; Prague, CZ; Lübeck, DE)
15:30 - 17:00 Biology of recovery
Laquinimod treatment reverses cortical and hippocampal pathology due to inflammatory demyelination in a chronic mouse model of multiple sclerosis P 380
R. Patel, G. Hannsun, T. McLaughlin, D. Ichwan, A. Khalaj, S. Moore, S. Tiwari-Woodruff (Los Angeles, US)
15:30 - 17:00 Neuroprotection
Copaxone treatment inhibits axon degeneration and myelination in the corpus callosum of mice with experimental autoimmune encephalomyelitis P 508
G. Hannsun, S. Moore, R. Patel, J. Yoon, S. Tiwari-Woodruff (Los Angeles, US)
15:30 - 17:00 Paediatric MS
Retinal nerve fibre layer thickness thresholds for visual function in paediatric demyelinating disease: further evidence of the RNFL tipping point P 223
Y.A. Reginald, F. Costello, J. O'Mahoney, J.R. Buncic, B. Banwell on behalf of the Canadian Pediatric Demyelinating Disease Study
15:30 - 17:00 Epidemiology
Demographic, clinical manifestations and course of multiple sclerosis: a retrospective study P 244
E.H. Ait Ben Haddou, K. El Alaoui Taoussi, N. Chtaou, Y. Hsaini, A. Satte, M. Alhyan, I. Derouich, J. Oumerzouk, J. Mounach, W. Regragui, Z. Souirti, R. Abouqal, O. Messouak, H. Ouhabi, A. Bourazza, F. Belahcen, A. Benomar, M. Yahyaoui (Rabat, Fes, MA)
15:30 - 17:00 Natural history
Modelling longitudinal change in multiple sclerosis P 233
S. Hum, Y. Lapierre, S.C. Scott, L.E. Finch, N.E. Mayo (Montreal, CA)
15:30 - 17:00 Devic’s NMO spectrum
Autologous haematopoietic stem cell transplant in patients with neuromyelitis optica P 199
J.M. Burton, J. Storek, P. Duggan, F. Costello, D. Genest, R. Bell, L. Metz (Calgary, CA)
15:30 - 17:00 Immunomodulation
Interferon-beta-1b treatment in clinical practice: final results of a large international observational study P 481
J. Kuhle, K. Beckmann, J.-P. Bugge, L. Kappos for the BEST Study Group
15:30 - 17:00 Tools for detecting therapeutic response
Antibody dissociation rates are predictive of neutralising antibody course: a comparison of interferon-beta-1b-treated patients with transient versus sustained NAbs P 551
E. Gibbs, J. Oger (Vancouver, CA)
15:30 - 17:00 Biomarkers
MicroRNA and dicer expression as a marker of MS dysimmunity and response to interferon therapy P 616
B. Weinstock-Guttman, W.J. Magner, M. Ramanathan, A. Khan, M. Dillon, K. McGowan, T. Tomasi (Buffalo, US)
15:30 - 17:00 Immunomodulation
Relapses requiring intravenous steroid use and MS-related hospitalisations: findings from the phase 3 DEFINE and CONFIRM studies P 490
E. Havrdova, R. Gold, R.J. Fox, L. Kappos, M. Kita, M. Yang, R. Zhang, K.T. Dawson, V. Viglietta, S.I. Sheikh, G. Giovannoni (Prague, CZ; Bochum, DE; Cleveland, US; Basel, CH; Seattle, Weston, US; London, GB)
15:30 - 17:00 Diagnosis and differential diagnosis
Diagnostic efficacy of the flow cytometric aquaporin-4 autoantibody assay: comparison with conventional cell-based assay P 195
H.R. Yang, S.M. Kim, Y.J. Kim, K.W. Lee, K.C. Jung, S.W. Ahn, K.K. Kim, S.Y. Pyun, J.E. Kim, K.S. Park (Gyeonggi-do, Seoul, KR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Cerebrospinal venous outflow in MS patients and fatigue/depression P 635
E.L.J. Hoogervorst, S.C. Tromp, S.T.F.M. Frequin (Nieuwegein, NL)
15:30 - 17:00 Neuropsychology and fatigue
Computerised cognitive training in MS: preliminary outcomes for working memory, information processing speed, and executive functioning P 435
L. Hancock, J. Bruce, J. Thelen, L. Fletcher, J. McGee, A. Ness, B. Baker, S. Lynch (Kansas City, US)
15:30 - 17:00 Quality of life
Effects of BG-12 on quality of life in patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study P 586
M. Kita, R.J. Fox, J.T. Phillips, M. Hutchinson, E. Havrdova, S.P. Sarda, J. Kong, V. Viglietta, S.I. Sheikh, K.T. Dawson (Seattle, Cleveland, Dallas, US; Dublin, IE; Prague, CZ; Weston, US)
15:30 - 17:00 Risk management for disease modifying treatments
Safety and tolerability of the first dose of fingolimod: first experience in a tertiary outpatient clinic P 537
P. Ng, S. Hum, N. Spinelli, Y. Lapierre (Montreal, CA)
15:30 - 17:00 Epidemiology
The relationship between body size and the risk of multiple sclerosis. The EnvIMS study P 253
K. Wesnes, T. Riise, K. Bjřrnevik, K.M. Myhr, S. Magalhaes, C. Wolfson, T. Holmřy, I. Casetta, J. Drulovic, E. Granieri, M. Kampman, A.M. Landtblom, K. Lauer, T. Pekmezovic, M. Pugliatti (Bergen, NO; Montreal, CA; Oslo, NO; Ferrara, IT; Belgrade, RS; Tromsř, NO; Linköping, SE; Darmstadt, DE; Sassari, IT)
15:30 - 17:00 Others
An association study on the R92Q mutation in the TNFRSF1A gene and symptoms compatible with a TNFRSF1A-associated periodic syndrome (TRAPS) in multiple sclerosis patients P 560
L.A. Gerdes, W. Igl, S. Schwenke, R. Sandbrink, B. Stemper, R. Hohlfeld, T. Kümpfel, C. Pohl (Munich, Berlin, DE)
15:30 - 17:00 Neuropsychology and fatigue
Correlation of hormonal status and cytokine profiles with fatigue in patients with multiple sclerosis: a case-control study P 439
D. Athanasopoulos, D. Kitsos, N. Protopapas, A. Liverezas, C.E. Karageorgiou (Athens, GR)
15:30 - 17:00 Experimental models
Unravelling an unexpected role for the proteoglycan NG2 in EAE P 324
A. Uccelli, S. Morando, F. Girolamo, S. Casazza, D. Virgintino, R. Furlan, R. Perris, C. Bendotti, G. Ferrara (Genoa, Bari, Milan, Parma, IT)
15:30 - 17:00 Devic’s NMO spectrum
Recurrent optic neuritis: the importance of the differential diagnosis P 215
I. Palmi-Cortes, V. Meca-Lallana, B. Canneti, F.J. Valenzuela-Rojas, J. Vivancos (Madrid, ES)
15:30 - 17:00 Immunomodulation
Robust induction of fibrotic responses in normal human lung fibroblasts by non-selective S1P receptor modulators, but not by the S1P1 receptor modulator ponesimod P 467
K. Sobel, K. Menyhart, B. Renault, N. Killer, R. Studer, Y. Bauer, O. Nayler, J. Gatfield (Allschwil, CH)
15:30 - 17:00 MS symptoms
Sustained improvement in urinary incontinence and quality of life with onabotulinumtoxin A regardless of baseline EDSS score in MS patients with neurogenic detrusor overactivity P 273
M. Tullman, P. Denys, B. Jenkins, AJ Joshi, J. Zhou, I. Yushmanova, C. Fowler (St. Louis, US; Garches, FR; Irvine, US; London, GB)
15:30 - 17:00 Biomarkers
20-kDa Nogo A: highly specific and sensitive biomarker for multiple sclerosis P 621
M. Matysiak, A. Jurewicz, I. Selmaj, L. Bartyzel, P. Kadrowicz, K. Selmaj (Lodz, PL)
15:30 - 17:00 Economic burden
Multiple sclerosis: employment and employability – patient reported perspectives P 301
M. Gudesblatt, R. Goldstein, J. Kalina, M. Zarif, B. Bumstead, L. Fafard, I. Topalli, M. Buhse (Patchogue, New York, Cambridge, Stony Brook, US)
15:30 - 17:00 Epidemiology
Early identification of aggressive multiple sclerosis using EDSS P 239
T. Scott, C. Hackett, C. Schramke (Pittsburgh, US)
15:30 - 17:00 Neuropsychology and fatigue
Neuroimaging, psychosocial, and demographic determinants of subjective and objective cognitive function in MS P 452
H.E. Hulst, K. Gehring, B.M.J. Uitdehaag, L.H. Visser, C.H. Polman, F. Barkhof, M.M. Sitskoorn, J.J.G. Geurts (Amsterdam, Tilburg, NL)
15:30 - 17:00 Neuroprotection
Neurogenic effects of fingolimod in mice P 501
P. Efstathopoulos, I. Charalampopoulos, A. Gravanis (Heraklion, GR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Endovascular treatment of chronic cerebro-spinal venous insufficiency in multiple sclerosis: a retrospective study P 629
R. Alroughani, S. Lamdhade (Kuwait, KW)
15:30 - 17:00 Paediatric MS
MRI pattern classification using cluster analysis for early prediction of multiple sclerosis in paediatric acquired demyelinating syndromes P 227
M. Absoud, M.J. Lim, K. Chong, C.G. De Goede, K. Foster, R. Gunny, C. Hemingway, P. Jardine, R. Kneen, M. Likeman, K.K. Nischal, M.G. Pike, N.A. Sibtain, W.P. Whitehouse, E. Wassmer, C. Cummins on behalf of the UK & Ireland Childhood CNS Inflammatory Demyelination Working Group
15:30 - 17:00 Experimental models
High resolution genetic mapping of the cytokine response in the rat heterogeneous stock P 325
S. Flytzani, P. Stridh, D. Ekman, M. Diez, J. Öckinger, A. Beyeen, A. Gillett, A. Ortlieb, N. Abdelmagid, M. Jagodic, T. Olsson (Stockholm, SE)
15:30 - 17:00 Experimental models
Partial deprivation of the DC-poietin FLT3L protects animals from experimental autoimmune encephalomyelitis P 336
P.H. Lalive, N.L. Tran, M. Benkhoucha, G. Schneiter, M.-L. Santiago-Raber (Geneva, CH)
15:30 - 17:00 Pregnancy and MS
Longitudinal optical coherence tomography study in MS patients during pregnancy and postpartum breastfeeding P 278
I. Ayzenberg, K. Hellwig, R. Gold, S. Schippling (Bochum, DE; Zurich, CH)
15:30 - 17:00 Neuroprotection
Laquinimod treatment reduces cuprizone-induced pathology in a dose-dependent manner P 510
R. Pförtner, N. Kramann, W. Brück, C. Wegner (Göttingen, DE)
15:30 - 17:00 Immunomodulation
Efficacy and safety of the S1P receptor agonist ONO-4641 in patients with relapsing-remitting multiple sclerosis: results of a 26-week, double-blind, placebo-controlled, phase II trial (DreaMS) P 482
F. Zipp, T.L. Vollmer, K.W. Selmaj, A. Bar-Or on behalf of the DreaMS Study Group
15:30 - 17:00 Treatment of specific symptoms
The effects of resistance training and physical activities in groups in comparison for the treatment of chronic fatigue in patients with multiple sclerosis P 570
L. Bernhardt, C. Jolk, R. Alcantara, P. Platen, M. Marziniak, K. Weßling (Münster, Bochum, DE)
15:30 - 17:00 MS symptoms
Impaired social cognition in multiple sclerosis occurs independently of neuropsychological deficits and depression P 262
J. Pöttgen, S. Moritz, S. Reh, I. Dziobek, C. Heesen, S. Gold (Hamburg, Berlin, DE)
15:30 - 17:00 Biomarkers
Proteomic analysis: identification of candidate protein biomarkers in the CSF and serum samples of patients with clinically different multiple sclerosis subtypes P 607
T. Avsar, U. Uygunoglu, M. Tütüncü, N.O. Demirci, S. Saip, A. Siva, E. Tahir Turanli (Istanbul, TR)
15:30 - 17:00 Neuroprotection
BG-12 is neuroprotective in the murine cuprizone/rapamycin model of demyelination and neurodegeneration P 504
R.H. Scannevin, B. Bai, R. Huang, S. Medicetty, B. Trapp, K.J. Rhodes (Weston, Cleveland, US)
15:30 - 17:00 Imaging
Evaluation of an albumin binding gadolinium contrast agent in multiple sclerosis P 409
A. Magnus, J. Lamy, J. de Sčze, J. Dietemann, J. Armspach, S. Kremer (Strasbourg, FR)
15:30 - 17:00 Economic burden
A cost-effectiveness analysis of subcutaneous interferon-beta-1a 44mcg three times a week versus no treatment for patients with a single demyelinating event in Sweden P 304
S. Fredrikson, E. McLeod, N. Henry, A. Pitcher, M. Cuche, L. Fajutrao, R. Perard, D. Bates, A. Chan (Stockholm, SE; London, GB; Geneva, CH; Solna, SE; Middlesex, Newcastle, GB; Bochum, DE)
15:30 - 17:00 Adaptative and Innate immunology
Maintenance of chronic/sterile inflammation in MS: induction of cytokine production in human monocytes by T-cell surface lipids P 353
D. Burger, L. Gruaz, I. Riezman, H. Riezman (Geneva, CH)
15:30 - 17:00 Imaging
Model-based meta-analysis of lesion count time dynamics in multiple sclerosis P 410
F. Mercier (Wintzenheim, FR)
15:30 - 17:00 Biomarkers
SIGLEC1 and SIGLEC7 expression in peripheral blood monocytes of patients with multiple sclerosis P 620
S. Malhotra, J. Castilló, M. Bustamante, Ŕ. Vidal-Jordana, X. Montalban, M. Comabella (Barcelona, ES)
15:30 - 17:00 Biomarkers
Ceruloplasmin system activation is representative of brain damage in relapsing-remitting multiple sclerosis P 611
D. Landi, S. Vollaro, R. Squitti, D. Lupoi, A. Coniglio, E. Falato, A. Ghazaryan, M. Corbetto, F. Vernieri, M.M. Filippi (Rome, IT)
15:30 - 17:00 Immunosuppression
Autologous Stem Cell Transplantation International Multiple Sclerosis (ASTIMS) trial: a randomised, phase II, controlled, multicentre trial P 498
G.L. Mancardi, M.P. Sormani, F. Gualandi, A. Saiz, E. Carreras, E. Merelli, A. Donelli, A. Lugaresi, P. Di Bartolomeo, A. Rambaldi, M. Rottoli, M.P. Amato, L. Massacesi, M. Di Gioia, L. Vuolo, D. Currň, L. Roccatagliata, E. Capello, A. Uccelli, P. Iacopino, U. Aguglia, M. Filippi, R. Saccardi (Genoa, Barcelona, Modena, Chieti, Bergamo, Florence, Reggio Calabria, Milan, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Characterisation of intra-cycle and long-term lymphocyte VLA-4 saturation dynamics in a natalizumab infusing population P 531
J. Foley, T. Hoyt, A. Christensen (Salt Lake City, US)
15:30 - 17:00 Economic burden
Cost-effectiveness of multiple sclerosis treatment in Latin America assessed by the Markov model based on long-term clinical data P 307
Y. Fragoso, A. Finkelsztejn, A. Gabbai, A. Carra, M. Macias-Islas, A. Tarulla, R. Arcega-Revilla, J. Duran-Quiroz, C. Carcamo-Rodriguez, J. Garcia-Bonitto, D. Vizcarra-Escobar, G. Orosco-Escobar, C. Oehninger-Gatti, V. Bedoya, P. Abad-Herrera (Santos, Porto Alegre, Săo Paulo, BR; Buenos Aires, AR; Guadalajara, MX; Puebla, MX; La Paz, BO; Santiago, CL; Bogota, CO; Lima, PE; Caracas, VE; Montevideo, UY; Assuncion, PY; Quito, EC)
15:30 - 17:00 Epidemiology
Temporal trends in hospital admissions in multiple sclerosis: findings from British Columbia, Canada P 243
C. Evans, E. Kingwell, F. Zhu, J. Oger, Y. Zhao, BC MS Clinic Neurologists, H. Tremlett (Vancouver, CA)
15:30 - 17:00 Risk management for disease modifying treatments
Natalizumab discontinuation and the role of corticosteroid treatment. An observational study P 542
Ŕ. Vidal-Jordana, M. Tintoré, C. Tur, F. Pérez-Miralles, A. Horga, J. Sastre-Garriga, C. Auger, J. Río, C. Nos, Í. Galán, J. Castilló, G. Arrambide, M.J. Vicente, A. Rovira, X. Montalban (Barcelona, ES)
15:30 - 17:00 Imaging
Investigation of the corticospinal tract integrity and cortical thickness in patients with multiple sclerosis P 408
M. Pawlitzki, J. Heidel, E. Stadler, J. Kaufmann, M. Sailer (Magdeburg, DE)
15:30 - 17:00 Imaging
Exploring the relationship between regional grey matter atrophy and cognitive impairment in paediatric multiple sclerosis P 400
M.A. Rocca, M. Absinta, M.P. Amato, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi, M. Filippi and the MS and Neuroimaging Study Groups of the Italian Neurological Society
15:30 - 17:00 Grey matter damage in MS
Gene expression profiling of cortical lesions in secondary progressive multiple sclerosis P 318
R. Magliozzi, E. Aricň, P. Durrenberger, O. Howell, F. Roncaroli, R. Nicholas, F. Aloisi, R. Reynolds (Rome, IT; London, GB)
15:30 - 17:00 Clinical assessment tools
Symbol digit modalities test and faces symbol test better reflect white matter damage than paced auditory serial addition test in relapsing-remitting multiple sclerosis P 292
A. Freing, M. Scheel, N. Weinges-Evers, L. Wieder, J. Dörr, F. Paul, A. U. Brandt, J. Würfel (Berlin, DE)
15:30 - 17:00 Grey matter damage in MS
Patterns of regional grey and white matter atrophy associated to PASAT and SDMT performances in relapsing-remitting multiple sclerosis patients P 320
G. Riccitelli, M.A. Rocca, E. Pagani, V. Martinelli, M. Radaelli, G. Comi, M. Filippi (Milan, IT)
15:30 - 17:00 Imaging
Cerebellar peduncles intrinsic damage in multiple sclerosis: association with clinical disabilty P 405
P. Preziosa, M.A. Rocca, S. Mesaros, E. Pagani, T. Stosic-Opincal, J. Drulovic, G. Comi, M. Filippi (Milan, IT; Belgrade, RS)
15:30 - 17:00 Paediatric MS
The use of modafinil and amantadine in the treatment of fatigue in paediatric MS P 221
J. O'Mahony, B. Banwell, S. Khan, E.A. Yeh (Toronto, CA)
15:30 - 17:00 Imaging
Diffusion tensor imaging evidence of abnormal white matter integrity in very early onset paediatric MS P 418
M. Sonkin, M.A. Rocca, E. Pagani, M. Copetti, M. Absinta, B. Banwell, J.G. Sled, D.L. Arnold, S. Narayanan, D.L. Collins, M. Filippi (Toronto, CA; Milan, Foggia, IT; Montreal, CA)
15:30 - 17:00 Neuro-ophthalmology
The relationship between OCT and H-MRS parameters in MS patients P 596
M. Davydovskaya, M. Cysar, V. Akopyan, A. Podoprigora, I. Pronin, V. Kornienko (Moscow, RU)
15:30 - 17:00 Imaging
Functional connectivity abnormalities and cognitive impairment in relapse-onset MS patients: a whole-brain functional network connectivity analysis P 404
M. Filippi, P. Valsasina, P. Preziosa, G. Riccitelli, V. Martinelli, G. Comi, M.A. Rocca (Milan, IT)
15:30 - 17:00 Adaptative and Innate immunology
Role of circulating CD4+CD8+ double positive T-cells in multiple sclerosis P 352
L. Sammet, S.D. Schröder, D.-H. Lee, R. Linker, A. Waschbisch (Erlangen, DE)
15:30 - 17:00 Tools for detecting therapeutic response
Effects of BG-12 on a marker of Nrf2 pathway activation: pharmacodynamic results from the phase 3 DEFINE and CONFIRM studies P 554
L. Amaravadi, S. Gopal, R. Gold, R.J. Fox, A. Mikulskis, M. Lukashev, J. Kong, M. Stephan, K.T. Dawson (Weston, US; Bochum, DE; Cleveland, US)
15:30 - 17:00 Devic’s NMO spectrum
Neuromyelitis optica IgG does not alter aquaporin-4 water permeability, plasma membrane M1/M23 isoform content or supramolecular assembly P 200
A. Rossi, J. Ratelade, M. Papadopoulos, J. Bennett, A. Verkman (San Francisco, US; London, GB; Denver, US)
15:30 - 17:00 Imaging
Longitudinal assessment of metabolic alterations in the brains of patients with secondary progressive multiple sclerosis P 386
P. Lee, S. Lynch, A. Hughes, D. Denney, I.-Y. Choi (Kansas City, Lawrence, US)
15:30 - 17:00 Neuropsychology and fatigue
Construction and pre-validation study of a cognitive-ergonomic questionnaire of work in multiple sclerosis P 449
G. Delrue, A. Monisse, A. Balvier, A.-S. Nyssen, P. Calay, S. Belachew (Ličge, BE)
15:30 - 17:00 Imaging
Assessing correlation of regional white and grey matter damage with motor and cognitive impairment in multiple sclerosis P 402
E. Sbardella, F. Tona, N. Petsas, L. Prosperini, E. Raz, C. Pozzilli, P. Pantano (Rome, IT)
15:30 - 17:00 Neuroprotection
Effects of BG-12 on magnetic resonance imaging and magnetisation transfer ratio outcomes in relapsing–remitting multiple sclerosis: findings from the phase 3 DEFINE study P 509
D.L. Arnold, R. Gold, L. Kappos, A. Bar-Or, G. Giovannoni, K. Selmaj, M. Yang, R. Zhang, M. Stephan, K.T. Dawson (Montreal, CA; Bochum, DE; Basel, CH; London, GB; Lodz, PL; Weston, US)
15:30 - 17:00 Imaging
An ImageJ-based automated method to quantify oligodendrocyte and microglia parameters in multiple sclerosis animal models P 406
T. Reiß, K. Berger, T. Clarner, C. Beyer, M. Kipp (Aachen, DE)
15:30 - 17:00 Neurobiology
17-beta estradiol differentially affects Cx43 and AQP4 expression in a model of astrocyte-microglia culture P 379
Z. Moinfar, H. Dambach, S. Sahin, D. Hinkerohe, R. Gold, P.M. Faustmann (Bochum, DE)
15:30 - 17:00 Imaging
Alteration in cerebral haemodynamics in multiple sclerosis P 396
D. Paling, E. Petersen, D. Tozer, C. Wheeler-Kingshott, R. Kapoor, D. Miller, X. Golay (London, GB; Utrecht, NL)
15:30 - 17:00 Neurophysiology
Comparison of multifocal and conventional visual-evoked potentials in assessing patients with multiple sclerosis P 428
K. Morris, A. Klistorner, C. Yiannikas (Sydney, AU)
15:30 - 17:00 Devic’s NMO spectrum
Factors associated with the aquaporin-4 antibodies positivity in patients with longitidunally extensive transverse myelitis: possible role of asymptomatic visual-evoked potential abnormality P 211
H.R. Yang, S.M. Kim, P. Waters, M. Woodhall, J.E. Kim, J.S. Kim, J.J. Sung, K.S. Park, S.W. Ahn, K.K. Kim, S.Y. Pyun, K.W. Lee (Gyeonggi-do, Seoul, KR; Oxford, GB)
15:30 - 17:00 Pathology
IL-7, IL-9 and IL-12 are associated with current aspects of disease, but do not predict disease course in multiple sclerosis P 311
K.E. Harding, M.D. Cossburn, P. Moore, T.P. Pickersgill, M. Wardle, N.P. Robertson (Cardiff, Poole, Liverpool, GB)
15:30 - 17:00 Biomarkers
CSF histamine levels in multiple sclerosis patients P 606
U. Kallweit, K. Aritake, C.L. Bassetti, S. Blumenthal, O. Hayaishi, M. Linnebank, Y. Urade, C.R. Baumann (Zurich, CH; Osaka, JP)
15:30 - 17:00 Economic burden
First interim results on treatment satisfaction and pharmaco-economic data comparing fingolimod and first-line therapies in multiple sclerosis patients in Germany (PANGAEA and PEARL) P 302
S. Ortler, T. Ziemssen, M. Meergans, F. Tracik, A. van Lokven (Nuremberg, Dresden, DE)
15:30 - 17:00 Immunomodulation
Reasons for switching first-line disease-modifying therapies in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC) P 455
D. Wynn, M. Cascione, N. Agashivala, K. McCague, L. Pestreich, L. Schofield, L. Barbato, E. Kim (Northbrook, Tampa, East Hanover, US)
15:30 - 17:00 Imaging
Longitudinal pre-processing decreases the required sample size for measurement of cortical atrophy in multicentre MS clinical trials P 419
K. Nakamura, S. Narayanan, D. Arnold (Montreal, CA)
15:30 - 17:00 Immunomodulation
Effect of BG-12 on magnetic resonance imaging activity in subgroups of patients with relapsing–remitting multiple sclerosis: findings from the CONFIRM study P 464
D.H. Miller, M. Hutchinson, R.J. Fox, J.T. Phillips, M. Kita, E. Havrdova, J. O’Gorman, M. Yang, V. Viglietta, K.T. Dawson (London, GB; Dublin, IE; Cleveland, Dallas, Seattle, US; Prague, CZ; Weston, US)
15:30 - 17:00 Imaging
Imbalance in multiple sclerosis: a result of cerebellum and spinal cord atrophy P 401
L. Prosperini, N. Petsas, D. Fortuna, E. Sbardella, E. Raz, F. Tona, C. Pozzilli, P. Pantano (Rome, IT)
15:30 - 17:00 Pathology
Increased cerebrospinal fluid bradykinin correlate with lesion load P 309
M. Degn, L.T. Jensen, J. Frederiksen (Glostrup, DK)
15:30 - 17:00 Treatment of specific symptoms
Office-based, single-shot bolus trial of intrathecal ziconotide in patients with painful myelopathy and neuropathy P 564
J. Nicholas, M. Bartoszek, C. O’Connell, B. Morgan-Followell, V. Lawson, D. Pitt, A. Boster (Columbus, US)
15:30 - 17:00 Experimental models
Selective oligodendrocyte loss associated with wide-spread mitochondrial dysfunction in the cuprizone-induced experimental demyelination P 337
S. Komoly, P. Acs, M. Selak, B. Kalman (Pecs, HU; Philadelphia, US; Munich, DE)
15:30 - 17:00 Immunomodulation
Efficacy and safety of fingolimod versus placebo: primary outcomes from the phase 3 FREEDOMS II study in patients with relapsing–remitting multiple sclerosis P 491
P.A. Calabresi, D. Goodin, D. Jeffery, L. Kappos, F.D. Lublin, K. Rammohan, A.T. Reder, T. Vollmer, M.A. Agius, L. Cappiello, T. Stites, B.B. Li, M. Malhotra, P. von Rosenstiel, E.-W. Radue (Baltimore, San Francisco, North Carolina, US; Basel, CH; New York, Miami, Chicago, Aurora, Davis, East Hanover, US)
15:30 - 17:00 Treatment of specific symptoms
The effects of telephone-based physical activity counselling on fatigue, pain, symptoms and quality of life in people with multiple sclerosis and major depression P 566
A.M. Verrall, H. Bombardier, M. Ehde, E. Gibbons, G.H. Kraft (Seattle, US)
15:30 - 17:00 Long-term treatment monitoring
IRF5 genotypes, relapses and progression in multiple sclerosis patients treated with interferon-beta P 527
F. Sellebjerg, H.B. Sřndergaard, N. Koch-Henriksen, P.S. Sřrensen, A.B. Oturai (Copenhagen, DK)
15:30 - 17:00 Clinical assessment tools
MS Curves: a new online tool for assessing MS severity using the MSBase Registry P 287
S.E. Hughes, T. Spelman, E. Bianchi, S. Méchati, H. Butzkueven on behalf of the MSBase investigators
15:30 - 17:00 Immunomodulation
Early therapy with IFNB-1b started at the first event suggestive of MS reduces the evolution of persistent T1 hypointensities on brain MRI P 488
F. Barkhof, G. Nagtegaal, M.P:. Wattjes, C.H. Polman, H.E. Hulst, M.S. Freedman, H.-P. Hartung, D.H. Miller, X. Montalbán, L. Kappos, G. Edan, D. Pleimes, K. Beckmann, C. Pohl, B. Stemper, R. Sandbrink (Amsterdam, NL; Ottawa, CA; Düsseldorf, DE; London, GB; Barcelona, ES; Basel, CH; Rennes, FR; Montville, US; Berlin, DE)
15:30 - 17:00 Experimental models
Induction of CD39+ Tregs in both murine EAE and human PBMC by a gut commensal derived polysaccharide antigen P 339
K. Telesford, Y. Wang, S. Begum-Haque, J. Ochoa-Repáraz, D.L. Kasper, L.H. Kasper (Lebanon, Boston, US)
15:30 - 17:00 Others
Clinically isolated syndromes and conversion to relapsing-remitting multiple sclerosis: a study on possible predictors, including cerebrospinal fluid oligoclonal IgM bands P 559
D. Ferraro, A.M. Simone, R. Bedin, V. Galli, F. Vitetta, L. Federzoni, R. D'Amico, P.F. Nichelli, P. Sola (Modena, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Fingolimod reduces the risk of recurrence of disease activity during the first 12 months after natalizumab discontinuation in multiple sclerosis P 536
J. Havla, B. Tackenberg, K. Hellwig, I. Meinl, M. Krumbholz, F. Seitz, C. Eienbröcker, R. Gold, R. Hohlfeld, I. Kleiter, T. Kümpfel (Munich, Marburg, Bochum, DE)
15:30 - 17:00 Comprehensive care and rehabilitation
Risk factors of reduced bone mass in patients with multiple sclerosis P 574
C. Boz, S. Zengin Karahan (Trabzon, TR)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Cine cerebrospinal fluid imaging changes in patients with multiple sclerosis after venous angioplasty. A 1-year follow-up study P 634
R. Zivadinov, C. Magnano, R. Galeotti, C. Schirda, B. Weinstock-Guttman, E. Menegatti, J. Hagemeier, A.M. Malagoni, D. Hojnacki, C. Kennedy, I. Bartolomei, C. Beggs, F. Salvi, P. Zamboni (Buffalo, US; Ferrara, IT; Bologna, IT; Bradford, GB)
15:30 - 17:00 Immunomodulation
Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients P 472
R. Pul, F. Morbiducci, J. Skuljec, T. Skripuletz, N. Garde, E.V. Voss, C. Trebst, M. Stangel (Hannover, DE)
15:30 - 17:00 Economic burden
Treatment experience, burden, and unmet needs (encoms) in multiple sclerosis study: the costs of MS patients in Argentina P 306
C. Ysrraelit, F. Caceres, A.M. Villa, M. Parada Marcilla, M. Melcon, M.M. Resk, J.I. Rojas, G. Kuperman, G. Seifer, G. Machnicki, J. Cúneo on behalf of the ENCOMS STUDY GROUP
15:30 - 17:00 MS symptoms
Onabotulinumtoxin A decreases urinary incontinence and improves quality of life in multiple sclerosis patients with neurogenic detrusor overactivity P 266
V. Keppenne, D. Ginsberg, W. Lam, C. Thompson, J. Heesakkers (Ličge, BE; Los Angeles, Irvine, US; Nijmegen, NL)
15:30 - 17:00 Comprehensive care and rehabilitation
Predictors of efficacy of a short-term intensive inpatient motor rehabilitation in patients affected with multiple sclerosis P 579
G. Liberatore, P. Rossi, D. Ungaro, A. Nuara, L. Saraceno, R. Gatti, M. Comola, G. Comi, F. Martinelli Boneschi (Milan, IT)
15:30 - 17:00 Neuropsychology and fatigue
Alexithymia and interhemispheric transfer in patients with clinically isolated syndrome P 442
C. Jougleux, R. Lopes, H. Zephir, C. Delmaire, C. Moroni, P. Vermersch (Lille, FR)
15:30 - 17:00 Clinical assessment tools
Longitudinal assessment of hand function in individuals with multiple sclerosis P 280
G. von Geldern, R. Marasigan, S. Newsome, P. Calabresi, K. Zackowski (Baltimore, US)
15:30 - 17:00 Grey matter damage in MS
Bi-monthly evolution of cortical atrophy in early relapsing-remitting multiple sclerosis over 2 years. A longitudinal study P 317
R. Zivadinov, C. Tekwe, N. Bergsland, O. Dolezal, E. Havrdova, J. Krasensky, M. Dwyer, Z. Seidl, D. Ramasamy, M. Vaneckova, D. Horakova (Buffalo, US; Prague, CZ)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Heart disease, overweight and cigarette smoking are associated with increased prevalence of extra-cranial venous abnormalities P 633
K. Dolic, B. Weinstock-Guttman, K. Marr, V. Valnarov, E. Carl, J. Hagemeier, C. Kennedy, C. Kilanowski, D. Hojnacki, M. Ramanathan, R. Zivadinov (Buffalo, US)
15:30 - 17:00 Risk management for disease modifying treatments
Remain vigilant after natalizumab discontinuation: three remarkable cases P 538
S. Roggerone, F. Durand-Dubief, F. Chenevier, S. Berroir, E. Creisson, A. Benoit, S. Boulogne, C. Laurencin, S. Vukusic, C. Confavreux (Bron, Annemasse, Thonon, FR)
15:30 - 17:00 Imaging
Sensitivity and specificity of SWI venography for detection of cerebral venous alterations in multiple sclerosis P 385
C. Beggs, S. Shepherd, M. Dwyer, P. Polak, C. Magnano, E. Carl, G. Poloni, B. Weinstock-Guttman, R. Zivadinov (Bradford, GB; Buffalo, US)
15:30 - 17:00 Immunomodulation
Clinical effects of BG-12 in subgroups of patients with relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies P 466
A. Bar-Or, R.J. Fox, R. Gold, G. Giovannoni, M. Kita, J. O’Gorman, M. Yang, S.I. Sheikh, V. Viglietta, K.T. Dawson, M. Hutchinson (Montreal, CA; Cleveland, US; Bochum, DE; London, GB; Seattle, Weston, US; Dublin, IE)
15:30 - 17:00 Immunomodulation
Safety and tolerability of BG-12 in patients with relapsing–remitting multiple sclerosis: an integrated analysis of the placebo-controlled studies P 484
K. Selmaj, R.J. Fox, R. Gold, E. Havrdova, L. Kappos, K. Raghupathi, H. Yuan, M. Novas, M.T. Sweetser, V. Viglietta, S.I. Sheikh, K.T. Dawson, J.T. Phillips (Lodz, PL; Cleveland, US; Bochum, DE; Prague, CZ; Basel, CH; Weston, Dallas, US)
15:30 - 17:00 Tools for detecting therapeutic response
Anti-phospholipid antibodies are associated with response to interferon-beta-1a treatment in MS: results from a 3-year longitudinal study P 556
R. Zivadinov, M. Ramanathan, J. Ambrus, S. Hussein, D. Ramasamy, M. Dwyer, N. Bergsland, A. Minagar, B. Weinstock-Guttman (Buffalo, US)
17:00 - 17:15 PML and IRIS (Forum 2 & 3)
The PML spectrum 97
D. Clifford (St. Louis, US)
17:00 - 17:15 Temporal changes in MS epidemiology (Auditorium Lumičre)
Overview 100
N. Koch-Henriksen (Aalborg, DK)
17:15 - 17:30 Temporal changes in MS epidemiology (Auditorium Lumičre)
The French OFSEP experience 101
T. Moreau (Dijon, FR)
17:15 - 17:30 Devic's neuromyelitis optica spectrum (Amphitheatre)
CRION/RION 95
D. Bichuetti (Sao Paulo, BR)
17:15 - 17:30 PML and IRIS (Forum 2 & 3)
Epidemiology of natalizumab-associated PML and IRIS in MS 98
P. Vermersch (Lille, FR)
17:30 - 17:45 Temporal changes in MS epidemiology (Auditorium Lumičre)
Increasing multiple sclerosis incidence in Tehran, Iran: a Joinpoint Trend Analysis 102
P. Heydarpour, K. Mohammad, M.S. Yekaninejad, J. Lotfi, M.A. Sahraian (Tehran, IR)
17:30 - 17:45 PML and IRIS (Forum 2 & 3)
Imaging findings for PML in natalizumab-treated MS patients 99
N. Richert, G. Bloomgren, D. Cadavid, T. Dong-Si, S. Richman, B. Ticho (Weston, US)
17:30 - 17:45 Devic's neuromyelitis optica spectrum (Amphitheatre)
Clinical and MR features of paediatric aquaporin-4-IgG seropositive neuromyelitis optica spectrum disorders 96
S. Tenembaum, S. Pittock, J. Princich, V. Lennon, M. Segura (Buenos Aires, AR; Rochester, US)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
MS spasticity daily management, retrospective data from EU 103
T. Berger (Innsbruck, AT)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
Endocannabinoid system modulator use in the everyday clinical practice in UK and Spain 104
J.A. Garcia Merino (Madrid, ES)
18:00 - 19:00 Almirall:
MS spasticity symptoms management.
Endocannabinoid system modulator data beyond clinical trials (Auditorium Lumičre)
A new MS spasticity treatment option effect in everyday clinical practice and cost-effectiveness in Germany 105
P. Flachenecker (Bad Wilbad, DE)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
MS pathology: from focal to diffuse damage 107
W. Brück (Göttingen, DE)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
Peripheral and central immunomodulation - new insights of glatiramer acetate 106
O. Khan (Detroit, US)
19:15 - 20:15 Teva Pharmaceutical Industries: New concepts in MS pathology shed light on MS treatment approaches (Amphitheatre)
Laquinimod: a new MS therapy with evidence for CNS direct effect 108
G. Comi (Milan, IT)

Friday, October 12, 2012

09:15 - 09:30 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Computer-assisted rehabilitation of attention in patients with multiple sclerosis: results of a randomised double-blind trial 117
M.P. Amato, B. Goretti, E. Portaccio, R.G. Viterbo, P. Iaffaldano, M. Trojano (Florence, Bari, IT)
09:15 - 09:30 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
EDSS changes and progression in the CombiRx randomised clinical trial: 3-year results 109
G. Cutter, S. Cofield, T. Gustafson, R. Conwit, J. Wolinsky, F. Lublin for the The CombiRx Investigators
09:15 - 09:30 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Predicting clinical conversion to multiple sclerosis in patients with clinically isolated syndrome using machine learning techniques 113
O. Ciccarelli, P.P. Kwok, V. Wottschel, D. Chard, M.L. Stromillo, N. De Stefano, A.J. Thompson, D.H. Miller, D.H. Alexander (London, GB; Lübeck, DE; Siena, IT)
09:30 - 09:45 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Magnetic resonance phase predicts acute multiple sclerosis lesions 114
A. Rauscher, V. Wiggermann, E. Hernández Torres, I. Vavasour, C. Laule, W. Moore, D. Li, A. Traboulsee, A. MacKay (Vancouver, CA)
09:30 - 09:45 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Eosinophil pathogenicity in neuromyelitis optica by ADCC and CDCC mechanisms: Potential therapeutic efficacy of over-the-counter eosinophil stabilizing drugs 110
H. Zhang, J. Ratelade, A.S. Verkman (San Francisco, US)
09:30 - 09:45 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Fatigue in multiple sclerosis: relation to quantitative neurologic and visual outcomes 118
S. Chahin, D. Miller, R. Sakai, J. Wilson, A. Green, P. Calabresi, E. Frohman, S. Galetta, L. Balcer (Philadelphia, Cleveland, San Francisco, Baltimore, Dallas, US)
09:45 - 10:00 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
Topographic analysis of visual-evoked potentials improves sensitivity for previous optic neuritis 115
M. Hardmeier, F. Hatz, Y. Naegelin, C. Schindler, L. Kappos, M. Seeck, P. Fuhr, C. Michel (Basel, Geneva, CH)
09:45 - 10:00 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Relationship between cognition and working hours in people with clinically isolated syndrome and early relapsing-remitting multiple sclerosis 119
P. Jongen, K. Wesnes, B. Van Geel, P. Pop, E. Sanders, H. Schrijver, L. Visser, J. Gilhuis, O. Sinnige, A. Brands (Nijmegen, NL; Goring, GB; Alkmaar, Venray, Breda, Hoorn, Tilburg, Delft, Leeuwarden, Utrecht, NL)
09:45 - 10:00 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Statistical properties of time to first relapse as an endpoint in multiple sclerosis clinical trials 111
A. Signori, P. Siri, M.P. Sormani (Genoa, Turin, IT)
10:00 - 10:15 Platform presentation of selected abstracts on MS disease evolution (Forum 2 & 3)
It’s time to change the way we measure change: demonstration, explanation, recommendations 116
J.C. Hobart, S.J. Cano, A.J. Thompson, D. Andrich (Plymouth, GB; Perth, AU)
10:00 - 10:15 Platform presentation of selected abstracts on therapy and clinical trials (Amphitheatre)
Endovascular treatment of CCSVI in patients with multiple sclerosis: clinical outcome of an Italian cohort of 462 cases 112
A. Ghezzi, P.O. Annovazzi, M.P. Amato, R. Balgera, P. Banfi, M. L. Bartolozzi, R. Bergamaschi, A. Bertolotto, A. Bianchi, A Bosco, E. Capello, M. Capobianco, R. Capra, P. Cavalla, R. Clerici, G. Coarelli, E. Cocco, N. De Rossi, C. Di Tillio, M.T. Ferrň, A. Gallo, P. Gallo, L. Lamantia, A. Lugaresi, G. Lus, S. Malucchi, L. Moiola, L. Provinciali, F. Patti, P. Perini, P. Perrone, A. Protti, M.E. Rodegher, P. Rossi, M. Rottoli, M. Rovaris, G. Salemi, M. Salvetti, I. Simone, M.R. Tola, M. Trojano, F. Vitetta, M.G. Marrosu, G. Comi and MS Study Group, Italian Society of Neurology
10:00 - 10:15 Platform presentation of selected abstracts on fatigue and cognition (Auditorium Lumičre)
Grey matter damage predicts the accumulation of disability and cognitive impairment 13 years later in patients with multiple sclerosis 120
M. Filippi, P. Preziosa, M. Copetti, G. Riccitelli, M.A. Horsfield, V. Martinelli, G. Comi, M.A. Rocca (Milan, San Giovanni Rotondo (FG), IT; Leicester, GB)
10:45 - 11:05 Beyond clinical monitoring of progression in MS (Amphitheatre)
Biological markers 121
A. Petzold (Amsterdam, NL)
10:45 - 11:05 From natural to treated history (Forum 2 & 3)
Standpoint of the neurologist 126
C. Confavreux (Lyon, FR)
10:45 - 11:05 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
Pharmaco-epidemiology: methodological aspects 131
G. Tognoni (Santa Maria Imbaro (Chieti), IT)
11:05 - 11:25 Beyond clinical monitoring of progression in MS (Amphitheatre)
MR and OCT markers 122
D. Miller (London, GB)
11:05 - 11:25 From natural to treated history (Forum 2 & 3)
From natural to treated history - standpoint of the methodologist 127
M.P. Sormani (Genoa, IT)
11:25 - 11:40 Beyond clinical monitoring of progression in MS (Amphitheatre)
Retinal atrophy and brain damage in MS: a model for trans-synaptic neuronal degeneration? 123
I. Gabilondo, A. Saiz, E. Martinez, E. Fraga, S. Llufriu, S. Ortiz, C. Falcon, J. Berenguer, N. Sola, M. Sepulveda, Y. Blanco, F. Graus, B. Sanchez-Dalmau, P. Villoslada (Barcelona, ES)
11:25 - 11:40 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
Comparison of natalizumab and interferon-beta/glatiramer efficacy using propensity-matched registry data 133
T. Spelman, F. Pellegrini, A. Zhang, R. Hyde, A. Pace, R. Arnold, M. Trojano, H. Wiendl, L. Kappos, S. Belachew, F. Verheul, F. Grand'Maison, G. Izquierdo, H. Butzkueven on behalf of the MSCOMET Investigators (an MSBase Substudy) and the TOP investigators
11:25 - 11:40 From natural to treated history (Forum 2 & 3)
Do all patients with multiple sclerosis ultimately develop progressive MS? 128
M. Tutuncu, J. Tang, N. Abou Zeid, N. Kale, D. Crusan, E. Atkinson, A. Siva, S. Pittock, I. Pirko, M. Keegan, C. Lucchinetti, J. Noseworthy, M. Rodriguez, B. Weinshenker, O. Kantarci (Istanbul, TR; Minneapolis, US; Beirut, LB; Rochester, US)
11:40 - 11:55 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
The SURVIMUS study, a large multicentre study on long-term mortality of multiple sclerosis patients in France 134
E. Leray, S. Vukusic, C. Confavreux, M. Debouverie, M. Clanet, B. Brochet, J. de Sčze, H. Zéphir, P. Vermersch, C. Lebrun-Frenay, G. Defer, T. Moreau, P. Clavelou, J. Pelletier, L. Rumbach, P. Cabre, J.P. Camdessanché, J. Yaouanq, E. Le Page, G. Edan (Rennes, Lyon, Nancy, Toulouse, Bordeaux, Strasbourg, Lille, Nice, Caen, Dijon, Clermont-Ferrand, Marseille, Besançon, Fort de France, Saint-Etienne, FR)
11:40 - 11:55 From natural to treated history (Forum 2 & 3)
Relation of long-term exposure to subcutaneous interferon-beta-1a with clinical outcomes in patients with relapsing-remitting multiple sclerosis: exploratory analyses from the PRISMS-15 study 129
L. Kappos, P. Cornelisse, L. Lehr, J. Kuhle, B. Uitdehaag (Basel, Geneva, CH; Amsterdam, NL)
11:40 - 11:55 Beyond clinical monitoring of progression in MS (Amphitheatre)
Mechanisms of disability in relapse onset multiple sclerosis of long disease duration 124
H. Kearney, M.A. Rocca, L. Balk, J. Sastre-Garriga, J. Reinhardt, S. Ruggieri, A. Rovira, L. Kappos, M. Rovaris, C. Gasperini, X. Montalban, J.J.G. Geurts, F. Barkhof, M. Filippi, D.R. Altmann, O. Ciccarelli, D.H. Miller, D.T. Chard on behalf of the MAGNIMS collaborative group
11:55 - 12:10 Beyond clinical monitoring of progression in MS (Amphitheatre)
Probing the clinico-radiological paradox of the spinal cord in multiple sclerosis with quantitative MRI 125
J. Oh, S. Saidha, M. Chen, S. Smith, J. Prince, C. Jones, P. van Zijl, D. Reich, P. Calabresi (Baltimore, US)
11:55 - 12:10 From natural to treated history (Forum 2 & 3)
Cognitive issues in childhood and juvenile multiple sclerosis patients: five-year results 130
M.P. Amato, B. Goretti, A. Ghezzi, S. Lori, B. Hakiki, M. Giannini, L. Pastň, L. Razzolini, L. Moiola, M. Falautano, R.G. Viterbo, F. Patti, S. Cilia, C. Pozzilli, V. Bianchi, M. Roscio, V. Martinelli, G. Comi, E. Portaccio, M. Trojano on behalf of the MS Study Group of the Italian Neurological Society
11:55 - 12:10 From databases and cohorts to pharmaco-epidemiology (Auditorium Lumičre)
The natural history of aggressive multiple sclerosis: findings from British Columbia, Canada 135
S. Menon, F. Zhu, A. Shirani, J. Oger, A. Traboulsee, M. Freedman, BC. MS Clinic Neurologists, H. Tremlett (Vancouver, Ottawa, CA)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
Novel measures broadening our understanding of treatment benefits and risks 137
X. Montalban (Barcelona, ES)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
Historical measures of response and outcomes 136
T. Ziemssen (Dresden, DE)
12:45 - 13:45 Bayer HealthCare: Novel performance measures for early and long-term gains (Forum 2 & 3)
The ultimate long-term measure - survival 138
A. Reder (Chicago, US)
14:00 - 14:20 Pregnancy (Auditorium Lumičre)
Prognosis- pregnancy 139
M.P. Amato (Florence, IT)
14:00 - 14:20 Imaging (Forum 2 & 3)
Demyelination and remyelination 144
F. Barkhof (Amsterdam, NL)
14:00 - 14:20 Disease-modifying treatments (Amphitheatre)
Oral treatments: past, present, future 149
C.H. Polman (Amsterdam, NL)
14:20 - 14:40 Imaging (Forum 2 & 3)
Positron emission tomography (PET) and molecular imaging for multiple sclerosis 145
B. Stankoff, L. Freeman, B. Bodini, L. Bottin, A. Chardain, C. Lubetzki, M. Bottlaender (Paris, Orsay, FR)
14:20 - 14:40 Pregnancy (Auditorium Lumičre)
MS treatments during pregnancy 140
E. Waubant (San Francisco, US)
14:40 - 14:55 Pregnancy (Auditorium Lumičre)
Pregnancy outcomes from fingolimod clinical trials and post-marketing experience and the need for a multinational Gilenya™ (fingolimod) Pregnancy Exposure Registry in multiple sclerosis 141
Y. Geissbühler, H. Butzkueven, S. Hernández-Diaz, K. Hellwig, G. Koren, T. MacDonald, H. Tilson, K. Starzyk, E. Plana, M. Cremer, P. von Rosenstiel, D. Anand, V. Dong, R. Schlosshauer, G. Karlsson, X. Zhang (Basel, CH; Parkville, AU; Boston, US; Bochum, DE; Toronto, CA; Dundee, GB; Chapel Hill, Cambridge, US; Barcelona, ES; East Hanover, US)
14:40 - 14:55 Disease-modifying treatments (Amphitheatre)
Clinical efficacy of BG-12 in relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies 151
R. Gold, D. H. Miller, J. T. Phillips, D. L. Arnold, K. Selmaj, M. Yang, R. Zhang, K. T. Dawson, V. Viglietta, S. I. Sheikh, R. J. Fox (Bochum, DE; London, GB; Dallas, US; Montreal, CA; Lodz, PL; Weston, Cleveland, US)
14:40 - 14:55 Imaging (Forum 2 & 3)
Improved detection of cortical lesions using 7T magnetisation transfer imaging in patients with multiple sclerosis 146
R. Abdel-Fahim, N. Mistry, O. Mougin, A. Blazejewska, P. Gowland, N. Evangelou (Nottingham, GB)
14:55 - 15:10 Imaging (Forum 2 & 3)
Resting state functional connectivity abnormalities are associated with cognitive impairment in patients with paediatric multiple sclerosis 147
M. Filippi, M.A. Rocca, P. Valsasina, M.P. Amato, M. Absinta, A. Ghezzi, L. Moiola, A. Fiorino, P. Veggiotti, G. Comi and the MS and Neuroimaging Study Groups of the Italian Neurological Society
14:55 - 15:10 Disease-modifying treatments (Amphitheatre)
Efficacy and safety of ponesimod, an oral, selective sphingosine 1-phosphate receptor-1 modulator, in patients with relapsing-remitting multiple sclerosis: results from a phase IIb, randomised, double-blind, placebo-controlled trial 152
T. Olsson, A. Boster, O. Fernandez, M.S. Freedman, C. Pozzilli, D. Bach, O. Berkani, M. Mueller, T. Sidorenko, M. Melanson (Stockholm, SE; Columbus, US; Malaga, ES; Ottawa, CA; Rome, IT; Allschwil, CH; Cincinnati, US)
14:55 - 15:10 Pregnancy (Auditorium Lumičre)
The impact of pregnancy on progression of relapsing-remitting multiple sclerosis 142
I. Karp, A. Manganas, M.-P. Sylvestre, E. Roger, A. Ho, P. Duquette (Montreal, CA)
15:10 - 15:25 Disease-modifying treatments (Amphitheatre)
The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo-controlled study 153
L. Kappos, G. Comi, C. Confavreux, M.S. Freedman, A.E. Miller, T. Olsson, J.S. Wolinsky, T. Bagulho, J.-L. Delhay, Y. Zheng, P. Truffinet, P.W. O'Connor (Basel, CH; Milan, IT; Lyon, FR; Ottawa, CA; New York, US; Stockholm, SE; Houston, Bridgewater, US; Chilly Mazarin, FR; Toronto, CA)
15:10 - 15:25 Pregnancy (Auditorium Lumičre)
The POPARTMUS French-Italian multicentric trial of Post Partum Progestin and Estriol in Multiple Sclerosis: final results 143
S. Vukusic, M. El-Etr, I. Ionescu, F. Cotton, H. Merle, C. Cornu, B. Frangoulis, L. Remontet, N. Bossard, L. Durelli, E.E. Baulieu, C. Confavreux on behalf of the POPARTMUS Investigators group
15:10 - 15:25 Imaging (Forum 2 & 3)
Dynamic changes in grey matter volume over 5 years in primary progressive multiple sclerosis: a tensor-based morphometry study 148
A. Eshaghi, B. Bodini, G. Ridgway, D. García-Lorenzo, D. Tozer, M.A. Sahraian, A.J. Thompson, O. Ciccarelli (London, GB; Paris, FR; Tehran, IR)
15:30 - 17:00 Neuropsychology and fatigue
HYPNOSEP : Brief Hypnotherapy Treating Chronic Fatigue for Multiple Sclerosis Patients P 898
R. Devy, P. Cormier, O. Anne, I. Devy-Gourdon, G. Chedeau, G. Edan (Saumur, Laval, La Rochelle, FR; Geneva, CH; Rennes, FR)
15:30 - 17:00 Adaptative and Innate immunology
Non-classical and intermediate monocytes in relapsing-remitting multiple sclerosis P 809
S.D. Schröder, D.H. Lee, S. Pfeifenbring, C. Stadelmann, R.A. Linker, A. Waschbisch (Erlangen, Göttingen, DE)
15:30 - 17:00 Neurophysiology
The response of the blink reflex test in a group of Brazilian patients with multiple sclerosis P 883
J.B.B. Brooks, Y.D. Fragoso, C.L.S. Oliveira, M.R. Kai, C.A.C. Silva (Santos, Săo Paulo, BR)
15:30 - 17:00 Imaging
Inter-rater variability of new T2 determination in the clinic has implications for MS diagnosis and monitoring P 874
C. Elliott, J. Maranzano, D. Cadavid, N. Richert, P. Duda, E. Fisher, S. Narayanan, D.L. Collins, T. Arbel, D.L. Arnold (Montreal, CA; Cambridge, Cleveland, US)
15:30 - 17:00 Grey matter damage in MS
Imaging cortical lesions in multiple sclerosis brains – a combined post-mortem 7 Tesla MRI and histopathological study P 778
S. Hametner, B. Yao, P. van Gelderen, H. Merkle, H. Lassmann, F.K. Cantor, C. Chen, J. Duyn, F. Bagnato (Vienna, AT; Bethesda, US)
15:30 - 17:00 Grey matter damage in MS
The relative contribution of cortical versus white matter lesions to cognitive dysfunction in MS: evidence from an MRI study with double inversion recovery imaging P 775
A. Papadopoulou, N. Müller-Lenke, Y. Nägelin, G. Kalt, K. Bendfeldt, P. Kuster, A. Gass, T. Sprenger, E.-W. Radue, L. Kappos, I.K. Penner (Basel, CH; Mannheim, DE)
15:30 - 17:00 Imaging
Longitudinal prediction of cognition in multiple sclerosis P 845
M.M. Schoonheim, V. Popescu, H. Vrenken, C.H. Polman, J.J.G. Geurts, F. Barkhof (Amsterdam, NL)
15:30 - 17:00 Grey matter damage in MS
Deficits in memory and spatial cognition correlate with regional hippocampal atrophy in multiple sclerosis P 777
M.A. Rocca, G. Longoni, E. Pagani, G. Riccitelli, B. Colombo, M. Rodegher, G. Comi, M. Filippi (Milan, IT)
15:30 - 17:00 Devic’s NMO spectrum
Ultra-high-field (7T) magnetic resonance imaging of brain lesions of neuromyelitis optica spectrum disorders and multiple sclerosis: a case-control study P 661
I. Kister, J. Herbert, Y. Zhou, Y. Ge (New York, US)
15:30 - 17:00 Immunosuppression
Prolonged remission with cyclophosphamide in a patient with CLIPPERS complicating MS P 957
M.R. Ortega, S. Delgado, J. Maldonado, L. Tornes, W. Sheremata, K.W. Rammohan (Miami, US)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
A prospective follow-up of the venous haemodynamics in patients with MS: the fluctuating natural course of CCSVI P 1092
L.H. Visser, L. van den Berg, A. van der Zande, G. van den Berg, B. Westerhuis (Tilburg, Maassluis, NL)
15:30 - 17:00 Biomarkers
Role of serum amyloid A in multiple sclerosis and neuromyelitis optica P 1080
H. Yokote, Y. Yagi, T. Amino, T. Kamata (Musashino, JP)
15:30 - 17:00 Experimental models
DMF treatment prevents cellular infiltration and reduces the frequency of IFN[gamma]-positive CD4-T-lymphocytes in EAE spinal cords P 797
B.T. Wipke*, P. Bista*, A. Thomas, W. Zeng, K. Fu, M.N. Shackett, D. Huss, R.H. Scannevin, M. Lukashev (Weston, US)
15:30 - 17:00 Imaging
A Voxel-based assessment of cervical cord damage in MS patients P 859
M.A. Rocca, P. Valsasina, D. Damjanovic, S. Mesaros, M.A. Horsfield, T. Stosic-Opincal, J. Drulovic, G. Comi, M. Filippi (Milan, IT; Belgrade, RS; Leicester, GB)
15:30 - 17:00 Experimental models
Intranasal HHV-6A infection accelerates EAE in the common marmoset P 786
E. Leibovitch, P. Maggi, S. Cummings Macri, G. Brunetto, K. Motanic, J. Wohler, S. Westmoreland, A. Silva, D. Reich, S. Jacobson (Bethesda, Southborough, US)
15:30 - 17:00 Pregnancy and MS
Neuromyelitis optica in pregnancy: treatment with intravenous immunoglobulin P 735
M. Houtchens, K.H. Vo, L. Stazzone, H. Weiner (Boston, US)
15:30 - 17:00 Paediatric MS
Retinal nerve fibre layer thickness in paediatric demyelinating disease: the Canadian Paediatric Disease Study Group P 679
Y.A. Reginald, F. Costello, J. O'Mahoney, J.R. Buncic, B. Banwell on behalf of The Canadian Pediatric Demyelinating Disease Study
15:30 - 17:00 Epidemiology
Prevalence of multiple sclerosis in Verona, Italy: an epidemiologic and genetic study P 707
A. Gajofatto, A. Stefani, M. Turatti, M.R. Bianchi, M. Gomez Lira, A. Salviati, M.D. Benedetti (Verona, IT)
15:30 - 17:00 Tools for detecting therapeutic response
Predicting the response status to natalizumab in relapsing-remitting multiple sclerosis P 1012
L. Prosperini, C.R. Mancinelli, C. Gianně, V. Barletta, F. Fubelli, G. Borriello, C. Pozzilli (Rome, IT)
15:30 - 17:00 Immunomodulation
Clinical efficacy of anti-IL-6 receptor monoclonal antibody tocilizumab in three patients with neuromyelitis optica P 918
M. Araki, T. Aranami, T. Matsuoka, M. Nakamura, T. Okamoto, M. Murata, S. Miyake, T. Yamamura (Kodaira, Tokyo, JP)
15:30 - 17:00 Databases and Pharmacoepidemiology
Propensity score matching in large observational databases: a virtual trial comparing two doses of interferon-beta-1a SC in MSBase P 720
T. Kalincik, T. Spelman, H. Butzkueven on behalf of the MSBase Investigators
15:30 - 17:00 Pathology
Fractalkine its receptor (CX3CR1) expression in the spinal cord associated with MS-induced neuropathic pain P 768
M.P. Namaka, W. Zhu, C.M.R. Acosta, B. MacNeil, E.E. Frost (Winnipeg, CA)
15:30 - 17:00 Imaging
Deformation based MRI analysis of deep grey matter structures in MS P 872
S. Magon, M. Chakravarty, M. Amann, K. Weier, Y. Naegelin, M. Andelova, E.-W. Radue, C. Stippich, J. Lerch, L. Kappos, T. Sprenger (Basel, CH; Toronto, CA)
15:30 - 17:00 Immunomodulation
Correlation between EDSS and MSFC in the FREEDOMS study P 917
R.A. Rudick, R. Hashmonay, X. Meng, P. Chin, G. Cutter (Cleveland, East Hanover, Birmingham, US)
15:30 - 17:00 Paediatric MS
Evaluation of vitamin D-related parameters in a multinational paediatric multiple sclerosis case-control study P 676
H.E. Hanwell, B. Bhan, M.R. Bardini, A. Belman, A. Boiko, O. Bykova, M.-E. Dilenge, K. Farrell, M. Freedman, J. Hahn, M. Iivanainen, J. Kennedy, M. Kremenchutzky, L. Krupp, J.K. Mah, J. Ness, M. Rensel, M. Ruggieri, M. Sevon, C. Stoian, E. Waubant, B. Weinstock-Guttman, S. Tenembaum, E.A. Yeh, R. Vieth, R.A. Marrie, A. Bar-Or, B. Banwell on behalf of the Wadsworth Pediatric Multiple Sclerosis Study Group
15:30 - 17:00 Imaging
Regional changes in tissue sodium concentration in relapsing-remitting and secondary progressive MS P 851
D. Paling, B. Solanky, F. Riemer, C. Wheeler-Kingshott, X. Golay, R. Kapoor, D. Miller (London, GB)
15:30 - 17:00 Genetics / transcriptomics
Conventional and non-conventional MRI characteristics of familial and sporadic multiple sclerosis patients P 801
A. Tipirneni, B. Weinstock-Guttman, M. Ramanathan, N. Abdelrahman, S. Hussein, J. Hagemeier, J. Durfee, B. Teter, D. Hojnacki, M. Dwyer, F. Munschauer, R. Zivadinov (Buffalo, US)
15:30 - 17:00 Epidemiology
Aquaporin-4 antibodies in Korean patients with idiopathic inflammatory demyelinating diseases of the central nervous system P 715
H.R. Yang, S.M. Kim, P. Waters, M. Woodhall, S.W. Ahn, K.K. Kim, S.Y. Pyun, J.E. Kim, J.S. Kim, J.J. Sung, K.S. Park, K.W. Lee (Gyeonggi-do, Seoul, KR; Oxford, GB)
15:30 - 17:00 Treatment of specific symptoms
Lisdexamfetamine dimesylate improves processing speed and memory in cognitively impaired MS patients: a phase II study P 1024
S.A. Morrow, A Smerbeck, K. Patrick, D. Cookfair, B. Weinstock-Guttman, R.H.B. Benedict (London, CA; Buffalo, US)
15:30 - 17:00 Immunomodulation
Effect of switching from intramuscular interferon beta-1a to fingolimod on time to relapse in patients with relapsing-remitting multiple sclerosis enrolled in a 1-year extension of TRANSFORMS P 909
G. Cutter, X. Meng, P. Chin, R. Hashmonay, M.Z. Islam (Birmingham, East Hanover, US)
15:30 - 17:00 Risk management for disease modifying treatments
Low immunogenicity but reduced bioavailability of an interferon-beta-1a biosimilar: results of MATRIX, a cross-sectional, multicentre phase 4 study P 1006
C. Cuevas, F. Deisenhammer, X. You, M. Scolnik, R. Buffels, B. Sperling on behalf of the MATRIX study group
15:30 - 17:00 Quality of life
Summary scores for patient-reported outcome measures in multiple sclerosis. Baseline data from the trial to Evaluate Patient OutComes, safety and tolerability of fingolimod (EPOC) P 1052
M. Cascione, D. Wynn, N. Agashivala, K. McCague, L. Pestreich, L. Schofield, E. Kim, L. Barbato (Tampa, Northbrook, East Hanover, US)
15:30 - 17:00 Immunomodulation
Bioequivalence of BG-12 administered as a single 240 mg capsule and two 120 mg capsules: findings from a randomised, two-period crossover study P 913
K.T. Dawson, I. Nestorov, R. Manchanda, D. Goldman, J. O'Gorman, H. Russell, M.A. Matson, M. Tighe, S.I. Sheikh (Weston, Cambridge, St Paul, US)
15:30 - 17:00 Comprehensive care and rehabilitation
Evaluating the effects of functional electrical stimulation on ambulation in individuals with secondary progressive multiple sclerosis P 1043
S. Newsome, K. Zackowski, P. Calabresi, D. Becker (Baltimore, US)
15:30 - 17:00 Clinical assessment tools
Does OCT predict conversion to MS? A longitudinal study P 751
C. Oreja-Guevara, S. Noval, A. Royo, B. Chamorro, J. Moreno, J. Alvarez-Linera (Madrid, ES)
15:30 - 17:00 Clinical assessment tools
The effect of standardised EDSS re-training on the performance of EDSS raters P 757
M. D`Souza, O. Yaldizli, E. Lucassen, E. Kornyeyeva, L. Kappos (Basel, CH; East Hanover, US)
15:30 - 17:00 Environmental risk factors
Vitamin A not associated with exacerbations in multiple sclerosis P 826
T.F. Runia, W.C.J. Hop, Y.B. De Rijke, D. Buljevac, R.Q. Hintzen (Rotterdam, NL)
15:30 - 17:00 Devic’s NMO spectrum
Seasonal pattern of variation in neuromyelitis optica relapses P 664
L. Elsone, S. Luppe, J. Kitley, P. Chater-Lea, K. Harding, K. Mutch, M.I. Leite, J. Palace, N. Robertson, A. Jacob (Liverpool, Cardiff, Oxford, GB)
15:30 - 17:00 Imaging
Perfusion and permeability MR imaging in differentiating tumefactive demyelinating lesions from high-grade gliomas P 855
A. Rovira, S. Cavalletto, P. Alcaide, C. Auger, J. Sastre-Garriga, E. Huerga, X. Montalban (Barcelona, ES)
15:30 - 17:00 Imaging
Cortical-juxtacortical lesions in clinically isolated syndromes: distribution and diagnostic value P 854
D. Pareto, C. Auger, A. Pla, R. Mitjana, M. Tintoré, J.F. Corral, X. Montalban, A. Rovira (Barcelona, ES)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
No evidence for impairment in venous haemodynamics in children or young adults with paediatric-onset multiple sclerosis P 1087
B. Banwell, S. Laughlin, J. Traubici, S. Khan, K.Y. Chan, R.A. Marrie, C.K. Macgowan (Toronto, Winnipeg, CA)
15:30 - 17:00 Immunosuppression
Mycophenolate mofetil – an underestimated MS rescue treatment? P 955
I. Marques, S. Batista, J. Sargento-Freitas, C. Macário, F. Matias, L. Sousa (Coimbra, PT)
15:30 - 17:00 Clinical assessment tools
Do motor impairments detected on onset of multiple sclerosis suggest an early second attack? P 741
A. Kalron, Z. Dvir, A. Achiron (Tel-Hashomer, Tel-Aviv, IL)
15:30 - 17:00 Imaging
Regional hippocampal involvement differs across multiple sclerosis clinical phenotypes: evidences from a radial mapping MR-based study P 860
M. Filippi, M.A. Rocca, G. Longoni, E. Pagani, B. Colombo, M. Rodegher, G. Comi (Milan, IT)
15:30 - 17:00 Immunomodulation
Analysis of lymph node dendritic cells induced in multiple sclerosis patients after transdermal immunisation with myelin peptides P 944
M. Jurynczyk, A. Jurewicz, A. Walczak, K. Wodz, K. Selmaj (Lodz, PL)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prevalence, sensitivity and specificity of chronic cerebrospinal venous insufficiency in other neurologic diseases. A case-control study P 1089
R. Zivadinov, K. Marr, V. Valnarov, C. Kilanowski, C. Kennedy, T. Guttuso, D. Lichter, N. Silvestri, L. Fugoso, E.A. Yeh, M. Ramanathan, R. Benedict, E. Carl, D. Hojnacki, B. Weinstock-Guttman (Buffalo, US)
15:30 - 17:00 Imaging
Quantification of independent cervical spinal cord atrophy measures correlate to motor and sensory deficits in MS P 869
E. Garde, H. Lundell, A.-M. Dogonowski, S. Gude, H. Schmidt, P. Soelberg Sorensen, M. Blinkenberg, H.R. Siebner (Hvidovre, Copenhagen, DK)
15:30 - 17:00 Epidemiology
Causes of death in US patients with multiple sclerosis P 697
S. Reshef, H. Golub, D. Goodin, G. Cutter, D. Kaufman, D. Pleimes, M. Corwin (Montville, Boston, San Francisco, Birmingham, US)
15:30 - 17:00 Genetics / transcriptomics
Study of the TNFRSF1A polymorphisms rs4149584 and rs1800693 in patients with multiple sclerosis P 802
M. Comabella, A.B. Caminero, S. Malhotra, L. Agulló, F. Reverter, K. Vandenbroeck, O. Fernández, F. Matesanz, G. Izquierdo, A. López-Larios, E. Urcelay, A. Sánchez, A. Rodríguez-Antigüedad, S. Otero, M. Tintoré, X. Montalban (Barcelona, Leioa, Málaga, Granada, Sevilla, Madrid, Bilbao, ES)
15:30 - 17:00 Imaging
Registration of serial brain MRI scans from multiple sclerosis patients. Analysis of 3D intensity-based methods P 852
Y. Díez, X. Lladó, A. Oliver, R. Martí, E. Roura, M. Cabezas, O. Ganiler, J. Freixenet, J.C. Vilanova, L. Valls, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Diagnosis and differential diagnosis
Proteomic investigations on differential post-translational modifications of transthyretin in multiple sclerosis P 640
D. Pieragostino, P. Del Boccio, M. di Ioia, L. Pieroni, V. Greco, G. De Luca, C. Di Ilio, D. Centonze, P. Sacchetta, A. Lugaresi, A. Urbani (Chieti, Rome, IT)
15:30 - 17:00 Imaging
Detecting evolving white matter MS lesions in serial brain MRI studies: analysis of a subtraction approach P 853
O. Ganiler, X. Lladó, A. Oliver, Y. Díez, J. Freixenet, J.C. Vilanova, A. Quiles, G. Laguillo, L. Ramió-Torrentŕ, D. Pareto, A. Rovira (Girona, Barcelona, ES)
15:30 - 17:00 Imaging
Reproducibility of surface-based laminar measures of T2* relaxation decay in the cortex at 7 Tesla MRI P 838
S.T. Govindarajan, M.P. Sormani, J. Cohen-Adad, C. Mainero (Charlestown, US; Genoa, IT)
15:30 - 17:00 Risk management for disease modifying treatments
How does risk tolerance to MS therapies change with time: survey results from the NARCOMS registry P 986
R. Fox, J. Alster, N. Dawson, M. Kattan, D. Miller, S. Ramesh, A. Salter, T. Tyry, B. Wells, G. Cutter (Cleveland, Birmingham, Phoenix, US)
15:30 - 17:00 Immunomodulation
Effects of inhibitors of the renin-angiotensin-system on clinical and MRI outcomes in patients with multiple sclerosis receiving interferon-beta-1b or glatiramer acetate. A post-hoc-analysis of the BEYOND study P 942
M. Doerner, K. Beckmann, V. Knappertz, V. Limmroth and the BEYOND Steering Committee
15:30 - 17:00 Risk management for disease modifying treatments
TYSTART: monitoring and management of MS patients starting natalizumab treatment in Germany P 994
B. Kallmann, R. Hoffmann, U. Walter, C. Wernsdörfer, V. Zingler, A. Chan (Bamberg, Berlin, Fulda, Ismaning, Bochum, DE)
15:30 - 17:00 Epidemiology
Evidence for sub-clinical malnutrition in Kuwaiti patients with multiple sclerosis: relationship with clinical phenotypes, disease activity and outcome P 711
S. Al-Shammri, A. Bhattacharya, R. Mathew, M. Girgis, C. Madala, A. Akanji (Kuwait, KW)
15:30 - 17:00 Genetics / transcriptomics
A weighted genetic risk score to predict neutralising antibodies to interferon-beta in multiple sclerosis patients P 803
B. Hemmer, W. Igl, D. Buck, M. Mühlau, S. Schwenke, B. Müller-Myhsok, R. Sandbrink, C. Pohl (Munich, Berlin, DE)
15:30 - 17:00 Imaging
Brain distribution of BZM055, an analog of fingolimod (FTY720), in human P 839
G. Tamagnan, A. Tavares, O. Barret, D. Alagille, J. Seibyl, K. Marek, P.R Maguire, E. Briard, R. Schmouder, R. Behrje, D. Jennings (New Haven, US; Basel, CH)
15:30 - 17:00 Treatment of specific symptoms
Extensive semi-automated gait analysis by Zebris FDM during treatment of multiple Sclerosis associated gait disturbancies with fampridine-SR P 1034
G. Wewerka, B. Holl, H. Bartsch, M. Malisa, C. Illhardt, G. Wewerka, G. Pilz, P. Wipfler, E. Trinka, B. Iglseder, J. Kraus (Salzburg, AT)
15:30 - 17:00 Economic burden
Assessing prognostic factors of severe relapse requiring hospitalisation and/or IV methylprednisolone in RRMS treated with placebo or laquinimod: pooled analysis from the ALLEGRO and BRAVO trials P 762
C.A. Carroll, P. Lindgren, A. Lang on behalf of the Allegro & BRAVO Study Group
15:30 - 17:00 Immunomodulation
EARLIMS Study methodology: open-label, non-randomised trial to assess the efficacy of fingolimod in treatment-naďve patients with RRMS vs. fingolimod in patients previously treated with interferons or glatiramer acetate, based on the presence of relapses P 953
X. Montalbán, O. Fernández, H. Butzkueven, M.H. Barnett, A. Gobartt, D. Silva on behalf of the EARLIMS Study Investigators
15:30 - 17:00 Biomarkers
Pharmacogenomic study in multiple sclerosis patients responders and non-responders to interferon-beta P 1083
M. Bustamante, C. Morcillo-Suárez, S. Malhotra, D. Brassat, R. Goertsches, J. Lechner-Scott, E. Urcelay, Ó. Fernández, J. Drulovic, A. García-Merino, F. Martinelli-Boneschi, A. Chan, K. Vandenbroeck, A. Navarro, J. Río, D. Akkad, G. Giacalone, A. Sánchez, L. Leyva, R. Álvarez-Lafuente, U. Zettl, A. Rodríguez-Antigüedad, J. Killestein, J. Oksenberg, X. Montalban, M. Comabella (Barcelona, ES; Toulouse, FR; Rostock, DE; Madrid, Málaga, ES; Belgrade, RS; Milan, IT; Bochum, DE; Leioa, ES; Bilbao, ES; Amsterdam, NL; San Francisco, US)
15:30 - 17:00 Genetics / transcriptomics
Gene variants in interferon regulatory factor 5 regulate the endogenous type 1 interferon-response in multiple sclerosis P 800
H.B. Sřndergaard, A.B. Oturai, P. Soelberg Sřrensen, F. Sellebjerg (Copenhagen, DK)
15:30 - 17:00 Risk management for disease modifying treatments
Management of natalizumab-related PML: a different approach P 998
C. Cordioli, C. Costanzi, N. De Rossi, S. Rasia, R. Capra (Brescia, IT)
15:30 - 17:00 Pregnancy and MS
Use of glatiramer acetate during pregnancy: offering women a choice P 733
A.E. Miller, S. Rustgi, C. Farrell (New York, US)
15:30 - 17:00 Treatment of specific symptoms
Comparison of different endurance trainings in advanced multiple sclerosis patients: a randomised, controlled pilot study P 1031
S. Briken, S. Gold, K. Schulz, D. Harbs, S. Patra, G. Ketels, C. Heesen (Hamburg, DE)
15:30 - 17:00 Neurophysiology
Clinical disability in MS correlates with resting-state oscillatory brain activity: an MEG source-space study P 882
M.L. vd Meer, P. Tewarie, M.M. Schoonheim, L. Douw, F. Barkhof, C.H. Polman, C.J. Stam, A. Hillebrand (Amsterdam, NL)
15:30 - 17:00 Imaging
Short-term evolution of spinal cord damage in multiple sclerosis: a diffusion tensor MRI study P 866
M. Théaudin, G. Saliou, B. Ducot, C. Denier, K. Deiva, D. Adams, D. Ducreux (Kremlin-Bicętre, FR)
15:30 - 17:00 Imaging
Ganglion cells loss in non-optic neuritis eyes of MS patients P 846
P. Sriram, N. Saakova, C. Wang, H. Arvind, S. Graham, C. Yiannikus, R. Garrick, M.H. Barnett, J. Parratt, A. Klistorner (Sydney, AU)
15:30 - 17:00 Paediatric MS
Quality of life in paediatric and juvenile multiple sclerosis and its clinical correlations P 688
R. Lanzillo, V. Magri, A. Napolitano, R. Liuzzi, G. Vacca, M. Ottobre, A. Filla, P. Valerio, A. Chiodi, V. Brescia Morra (Naples, IT)
15:30 - 17:00 Risk management for disease modifying treatments
Treatment-associated risk acceptance in natalizumab-treated MS patients P 1002
C. Tur, M. Tintoré, Ŕ. Vidal-Jordana, D. Bichuetti, P. Nieto, M.J. Arévalo, G. Arrambide, E. Anglada, Í. Galán, J. Castilló, C. Nos, J. Río, I. Martín, M. Comabella, J. Sastre-Garriga, X. Montalban (Barcelona, ES)
15:30 - 17:00 Environmental risk factors
Serum 25-hydroxyvitamin D concentrations among patients in BENEFIT predicts conversion to multiple sclerosis, MRI lesions, and brain volume loss P 831
A. Ascherio, K. Munger, C. Simon, L. Kappos, C.H. Polman, M.S. Freedman, H.-P. Hartung, D.H. Miller, X. Montalbán, G. Edan, F. Barkhof, R. White, R. Sandbrink, C. Pohl (Cambridge, US; Basel, CH; Amsterdam, NL; Ottawa, CA; Düsseldorf, DE; London, GB; Barcelona, ES; Rennes, FR; Vancouver, CA; Berlin, DE)
15:30 - 17:00 Adaptative and Innate immunology
Peripheral blood depletion-kinetics after S1P-receptor blockade allow better understanding of lymph node access-hierarchy and homing-frequency of human T-cells in MS P 810
M. Mehling, V. Brinkmann, A.-V. Burgener, P. Gubser, L. Kappos, C. Hess (Basel, CH)
15:30 - 17:00 Neuroprotection
Mesenchymal stem cells exert their therapeutic effect by inducing microglia to acquire a neuroprotective phenotype P 959
A. Uccelli, B. Parodi, C. Usai, L. Vergani, S. Bruzzone, G. Mancardi, D. Giunti (Genoa, IT)
15:30 - 17:00 Diagnosis and differential diagnosis
Application of the revised version of the 2010 McDonald diagnostic criteria: retrospective comparison using the BENEFIT clinical study dataset P 648
X. Montalbán, L. Kappos, M.S. Freedman, H.-P. Hartung, G. Edan, D.H. Miller, C.H. Polman, F. Barkhof, B. Stemper, J. Herrmann, C. Stolz, R. Sandbrink, C. Pohl, D. Pleimes (Barcelona, ES; Basel, CH; Ottawa, CA; Düsseldorf, DE; Rennes, FR; London, GB; Amsterdam, NL; Berlin, DE; Montville, US)
15:30 - 17:00 Chronic cerebro-spinal venous insufficiency (CCVI)
Prevalence, sensitivity and specificity of chronic cerebrospinal venous insufficiency in paediatric multiple sclerosis P 1090
R. Zivadinov, E.A. Yeh, K. Marr, V. Valnarov, C. Kilanowski, M. Karpinski, E. Carl, C. Kennedy, B. Weinstock-Guttman (Buffalo, US)
15:30 - 17:00 Treatment of specific symptoms
Office-based single-bolus intrathecal Baclofen trials in MS patients: a call to action P 1025
J. Nicholas, M. Bartoszek, C. O’Connell, B. Morgan-Followell, D. Pitt, A. Boster (Columbus, US)
15:30 - 17:00 Experimental models
The regulatory function of B-cells in protection against EAE by a human commensal bacteria polysaccharide P 796
Y. Wang, K. Telesford, S. Begum-Haque, J. Ochoa-Repáraz, D.L. Kasper, L.H. Kasper (Lebanon, Boston, US)
15:30 - 17:00 Immunomodulation
Effects of BG-12 on magnetic resonance imaging outcomes in relapsing–remitting multiple sclerosis: an integrated analysis of the phase 3 DEFINE and CONFIRM studies P 920
D. H. Miller, R. Gold, R. J. Fox, D. MacManus, T. Yousry, A. Bar-Or, R. Zhang, V. Viglietta, M. Stephan, K. T. Dawson, D. L. Arnold (London, GB; Bochum, DE; Cleveland, US; Montreal, CA; Weston, US)
15:30 - 17:00 Neuro-ophthalmology
Correlation between structural and functional measures of optic nerve myelination P 1057
C. Yiannikas, A. Van Der Walt, P. Mitchell, Y. Wang, S. Kolbe, T. Kilpatrick, H. Butzkueven, G. Egan, H. Arvind, S. Graham, M. Paine, A. Klistorner (Sydney, Melbourne, AU)
15:30 - 17:00 Clinical assessment tools
Early diagnosis of cognitive disorders in multiple sclerosis: the HV3 score P 744
M. Laffon, G. Malandain, M. Cohen, C. Lebrun (Nice, Sophia Antipolis, FR)
15:30 - 17:00 Databases and Pharmacoepidemiology
The clinical outcomes associated with adherence to and discontinuation of disease-modifying treatments P 716
J. Burks, E. Malangone, M. Jhaveri, S. Zhou, L. Stern, S. Bhurke, R. Casciano (Cherry Hill, New York, Bridgewater, US)
15:30 - 17:00 Imaging
Assessing brain connectivity at rest is clinically relevant in early multiple sclerosis P 867
A. Faivre, A. Rico, W. Zaaraoui, L. Crespy, F. Reuter, D. Wybrecht, E. Soulier, I. Malikova, S. Confort-Gouny, P.J. Cozzone, J. Pelletier, J.-P. Ranjeva, B. Audoin (Marseille, FR)
15:30 - 17:00 Imaging
MTR analysis of inner and outer cortical bands in multiple sclerosis P 850
R.S. Samson, M.J. Cardoso, N. Muhlert, V. Sethi, C.A.M. Wheeler-Kingshott, S. Ourselin, T. Yousry, M. Ron, D.H. Miller, D.T. Chard (London, GB)
15:30 - 17:00 Experimental models
BNN27, a neuroprotective neurosteroid derivative, induces IL-10-producing regulatory T-cells and treats established experimental autoimmune encephalomyelitis P 794
M. Aggelakopoulou, E. Kourepini, I. Lazarides, D.C.M. Simoes, N. Paschalidis, D. Kalavrizioti, I. Pediaditakis, A. Mouzaki, I. Charalampopoulos, A. Gravanis, V. Panoutsakopoulou (Athens, Heraklion, Patras, GR)
15:30 - 17:00 Devic’s NMO spectrum
Interleukin-6 receptor blockade in neuromyelitis optica resistant to anti-CD20 therapy P 667
I. Kleiter, I. Ayzenberg, A. Schröder, K. Hellwig, A. Chan, R. Gold (Bochum, DE)
15:30 - 17:00 Neurobiology
Functional genomic analysis of cuprizone-induced demyelination reveals the importance of oligodendrocytes for MS lesion formation P 836
K. Berger, B. Krauspe, W. Baumgartner, M. Rickert, T. Clarner, J.-P. Buschmann, C. Beutner, B. Linnartz, H. Neumann, L. Valliéres, C. Beyer, M. Kipp (Aachen, Bonn, DE; Quebec, CA)
15:30 - 17:00 MS and infections
Ex vivo and in vitro expression of the neuroinflammatory endogenous protein MSRV-Env (Envelope protein of Multiple Sclerosis Associated Retrovirus) from human endogenous type W elements and interaction with Epstein-Barr virus in multiple sclerosis P 825
N. Morel, R. Germi, O. Casez, O. Epaulard, L. Grossi, L. Morand, M. Zaccaria, H. Perron, P. Morand (Grenoble, FR; Geneva, CH)
15:30 - 17:00 Diagnosis and differential diagnosis
A sound localisation test discriminates between controls and multiple sclerosis patients with no measurable disability P 638
J.H. Bacon, T.E. Bacon, I. Kister, Y. Strauchler, G. Tsikhanovski Bochner, M. Omari, A. Bochkanova, J. Herbert (New York, US)
15:30 - 17:00 Devic’s NMO spectrum
In-vivo identification of a novel retinal pathology in neuromyelitis optica P 657
E.S. Sotirchos, S. Saidha, G. Byraiah, M.A. Mealy, M.A. Ibrahim, Y.J. Sepah, S.D. Newsome, J.N. Ratchford, E.M. Frohman, L.J. Balcer, Q.D. Nguyen, M. Levy, P.A. Calabresi (Baltimore, Dallas, Philadelphia, US)
15:30 - 17:00 Risk management for disease modifying treatments
Body mass and natalizumab concentration as potential risk stratification markers for drug-related PML P 987
J. Foley, A. Christensen, T. Hoyt (Salt Lake City, US)
15:30 - 17:00 Risk management for disease modifying treatments
Dynamics of the peripheral blood CD4 cell counts of JCV Ab positive patients at the different phases of natalizumab treatment P 989
R. Berkovich, D. Togasaki, D. Subhani, L. Steinman (Los Angeles, Stanford, US)
15:30 - 17:00 Neuro-ophthalmology
The retinal nerve fibre layer of patients with neuromyelitis optica and chronic relapsing optic neuritis are more severely affected than patients with multiple sclerosis: an exploratory study P 1067
D.B. Bichuetti, A.S. Camargo, A.B. Falcăo, I.M. Tavares, A.A. Gabbai, E.M.L. Oliveira (Săo Paulo, BR)
15:30 - 17:00 Neuro-ophthalmology
The role of vitamin D status in optic neuritis P 1058
J.M. Burton, J. Trufyn, C. Tung, M. Eliasziw, F. Costello (Calgary, CA; Boston, US)
15:30 - 17:00 Immunomodulation
Effect of fingolimod on severe relapses, healthcare utilisation and relapse recovery in patients with relapsing–remitting multiple sclerosis: results from the phase 3 FREEDOMS II study